Category Archive Health

Cerebral Hemiplegia; Symptoms, Diagnosis, Treatment

Cerebral Hemiplegia occurs when hemiplegia is caused by cerebral palsy (or other conditions affecting the brain), it can be referred to as cerebral hemiplegia. Cerebral hemiplegia symptoms are often similar to other forms of hemiplegia but may vary in severity and duration depending on the condition causing the paralysis.

Hemiplegia is a neurological condition that affects paralysis is on one vertical half of the body. Its most obvious result is a varying degree of weakness and lack of control on one side of the body. It affects everyone differently but its most obvious result is a varying degree of weakness and lack of control in one side of the body. You may be reading this because your child or someone you know has hemiplegia.

Hemiplegia, paralysis of the muscles of the lower face, arm, and leg on one side of the body. The most common cause of hemiplegia is a stroke, which damages the corticospinal tracts in one hemisphere of the brain. The corticospinal tracts extend from the lower spinal cord to the cerebral cortex. They decussate, or cross, in the brainstem; therefore, damage to the right cerebral hemisphere results in paralysis of the left side of the body. Damage to the left hemisphere of a right-handed person may also result in aphasia. Other causes of hemiplegia include trauma, such as spinal cord injury; brain tumors; and brain infections.

Hemiplegia is a condition where half of the body is paralyzed due to damage to the parts of the brain responsible for movement. Hemiparesis and hemiplegia can be caused by different medical conditions, including congenital causes, trauma, tumors, or stroke, etc.

Types of Hemiplegia

  • Alternate hemiplegia –  paralysis of one side of the face and the opposite side of the body.
  • Cerebral hemiplegia –  that due to a brain lesion.
  • Crossed hemiplegia – alternate hemiplegia. It affects the alter side of the body instated of the affected side.
  • Facial hemiplegia paralysis – of one side of the face.
  • Spastic hemiplegia – with spasticity of the affected muscles and increased tendon reflexes.
  • Spinal hemiplegia – due to a lesion of the spinal cord.

While hemiplegia is typically characterized as paralysis on one side of the body, there are multiple types of hemiplegia—some of which may be more limited in scope than others. A few different types of hemiplegia include:

  • Facial Hemiplegia – Also referred to as partial facial paralysis, this is a form of partial hemiplegia where the muscles on one side of the face are paralyzed. Often caused by a stroke or similar brain injury. This may or may not be associated with complete/incomplete hemiplegia in other areas of the body.
  • Cerebral Hemiplegia  – When hemiplegia is caused by cerebral palsy (or other conditions affecting the brain), it can be referred to as cerebral hemiplegia. Cerebral hemiplegia symptoms are often similar to other forms of hemiplegia but may vary in severity and duration depending on the condition causing the paralysis.
  • Spastic Hemiplegia – A variation of hemiplegia where the muscles on one side of the body are in a state of constant contraction. This type of hemiplegia may result in muscle pain, deformities in affected limbs (in extreme cases), and difficulty walking or maintaining motor control. Closely linked to cerebral palsy, and the severity (as well as the duration) of spastic hemiplegia symptoms may vary from case to case.
  • Spinal Hemiplegia – Often the result of an incomplete injury to the spinal cord or lesions on spinal nerves (especially at the C6 vertebra or higher). Spinal cord injury hemiplegia is often a long-term condition.

Causes of Cerebral Hemiplegia

Though the arms, legs, and possibly torso are the regions of the body most obviously affected by hemiplegia, in most cases of hemiplegia these body regions are actually perfectly healthy. Instead, the problem resides in the brain, which is unable to produce, send, or interpret signals due to disease or trauma-related damage. Less frequently, hemiplegia results from damage to one side of the spinal cord, but these sorts of injuries more typically produce global problems, not just paralysis on one side of the body.

  • Traumatic brain injuries to one side of the brain only. These may be caused by car accidents, falls, acts of violence, and other factors.
  • Cardiovascular problems, particularly aneurysms and hemorrhages in the brain.
  • Strokes and transient ischemic attacks (better known as TIA or mini-strokes).
  • Infections, particularly encephalitis and meningitis. Some serious infections, particularly sepsis and abscesses in the neck, may spread to the brain if left untreated.
  • Conditions that cause demyelination of the brain, including multiple sclerosis and some other autoimmune diseases.
  • Traumatic brain injuries to one side of the brain only. These may be caused by car accidents, falls, acts of violence, and other factors.
  • Cardiovascular problems, particularly aneurysms and hemorrhages in the brain.
  • Strokes and transient ischemic attacks (better known as TIA or mini-strokes).
  • Infections, particularly encephalitis and meningitis. Some serious infections, particularly sepsis and abscesses in the neck, may spread to the brain if left untreated.
  • Conditions that cause demyelination of the brain, including multiple sclerosis and some other autoimmune diseases.
  • Reactions to surgery, medication, or anesthesia.
  • Loss of oxygen to the brain due to choking or anaphylactic shock.
  • Brain cancers.
  • Lesions in the brain, even if non-cancerous, since these lesions can impede function on one side of the brain.
  • Congenital abnormalities, including cerebral palsy and neonatal-onset multi-inflammatory disease.
  • Rarely, psychological causes; some states of catatonia can cause hemiplegia, and people with parasomnia—a sleep disorder leading to unusual nighttime behavior—may experience nighttime episodes of hemiplegia.
  • Reactions to surgery, medication, or anesthesia.
  • Loss of oxygen to the brain due to choking or anaphylactic shock.
  • Brain cancers.
  • Lesions in the brain, even if non-cancerous, since these lesions can impede function on one side of the brain.
  • Congenital abnormalities, including cerebral palsy and neonatal-onset multi-inflammatory disease.
  • Rarely, psychological causes; some states of catatonia can cause hemiplegia, and people with parasomnia—a sleep disorder leading to unusual nighttime behavior—may experience nighttime episodes of hemiplegia.
Cerebral Hemiplegia

Rx

Some common causes of hemiplegia include

Stroke is the commonest cause of hemiplegia. Insufficient blood supply to the brain leads to loss of brain functions. The stroke may be caused by:

  • A clot formed within the blood vessel blocking the blood supply -> a thrombus
  • A thrombus breaks away from its site of origin and forms a block elsewhere in the circulation -> an emboli
  • A bleed from a blood vessel supplying the brain -> a hemorrhage
  • A thrombus breaks away from its site of origin and forms a block elsewhere in the circulation. -> an emboli
  • A bleed from a blood vessel supplying the brain -> a hemorrhage
  • Traumatic brain injuries to one side of the brain only. These may be caused by car accidents, falls, acts of violence, and other factors.
  • Cardiovascular problems, particularly aneurysms and hemorrhages in the brain.
  • Infections, particularly encephalitis and meningitis. Some serious infections, particularly sepsis and abscesses in the neck, may spread to the brain if left untreated.
  • Migraine syndrome -> recurrent headaches of severe intensity occasionally accompanied by sensations of numbness and tingling in one half of the body.
  • Conditions that cause demyelination of the brain, including multiple sclerosis and some other autoimmune diseases.
  • Reactions to surgery, medication, or anesthesia.
  • Loss of oxygen to the brain due to choking or anaphylactic shock.
  • Brain cancers.
  • Lesions in the brain, even if non-cancerous, since these lesions can impede function on one side of the brain.
  • Congenital abnormalities, including cerebral palsy and neonatal-onset multi-inflammatory disease.
  • Rarely, psychological causes; some states of catatonia can cause hemiplegia, and people with parasomnia—a sleep disorder leading to unusual nighttime behavior—may experience nighttime episodes of hemiplegia.
  • Head injury
  • Diabetes
  • Brain tumor
  • Infections –> meningitis, encephalitis, meningitis, brain abscess
  • Migraine syndrome -> recurrent headaches of severe intensity occasionally accompanied by sensations of numbness and tingling in one half of the body.
  • Inflammation of the blood vessels -> vasculitis
  • Diseases affecting the nerves -> like Multiple Sclerosis; acute necrotizing myelitis.
  • Conditions presenting from birth -> cerebral palsy. Lack of blood supply damages nerve cells in the brain. Birth trauma, difficult labor, perinatal strokes in infants within 3 days of birth can all cause cerebral palsy.
  • Hereditary diseases –> leukodystrophies. This is a rare disorder affecting the myelin sheath which covers and protects nerve cells in the brain. The condition usually appears in infancy or childhood.
  • Vascular – cerebral hemorrhage
  • Neoplastic – glioma-meningioma
  • Demyelination – disseminated sclerosis, lesions to the internal capsule
  • Traumatic – cerebral lacerations, subdural hematoma rare cause of hemiplegia is due to local anesthetic injections given intra-arterially rapidly, instead of given in a nerve branch.
  • Congenitalcerebral palsy, Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
  • Disseminated – multiple sclerosis
  • Psychological – parasomnia (nocturnal hemiplegia)
  • Severe headache
  • Impairment or loss of vision
  • Memory loss
  • Confusion
  • Loss of balance or co-ordination
  • Poor balance and dizziness
  • Sudden numbness, paralysis or weakness of an arm, leg or side of the face.
  • Slurred or abnormal speech
  • Loss of consciousness
  • Incontinence

Symptoms of Cerebral Hemiplegia

What Is Hemiplegia?

Rx

The main symptom of hemiplegia is weakness or paralysis on one side of the child’s body. The condition can vary in severity and affects each child differently. It will only affect one side of the child’s body. General symptoms include

  • Total or partial loss of sensation on just one side.
  • Changes in cognition, mood, or perception.
  • Difficulty speaking.
  • Changes on the other side of the body, since those muscles, may begin to atrophy or become painful due to chronic muscle spasms.
  • Spastic attacks during which the muscles move without your conscious control.
  • Seizures.
  • Pusher syndrome – With this symptom, hemiplegics shift their weight to the paralyzed side of the body, resulting in significant loss of motor control.
  • Severe, throbbing pain, often on one side of your head
  • A pins-and-needles feeling, often moving from your hand up your arm
  • Numbness on one side of your body, which can include your arm, leg, and half of your face
  • Weakness or paralysis on one side of your body
  • Loss of balance and coordination
  • Dizziness or vertigo
  • Nausea and vomiting

You may also have problems with your senses, communication, and drowsiness

  • Seeing zigzag lines, double vision, or blind spots
  • Extreme sensitivity to light, sound, and smell
  • Language difficulties, such as mixing words or trouble remembering a word
  • Slurred speech
  • Confusion
  • Loss of consciousness or coma
  • Difficulty walking
  • Poor balance
  • Little or no use of one hand or leg
  • Speech problems
  • Visual problems
  • Behavioral problems
  • Learning difficulties
  • Epilepsy
  • Developmental delay, for example learning to walk later than other children

amzn_assoc_placement = “adunit0”;
amzn_assoc_search_bar = “false”;
amzn_assoc_tracking_id = “raharun-20”;
amzn_assoc_ad_mode = “search”;
amzn_assoc_ad_type = “smart”;
amzn_assoc_marketplace = “amazon”;
amzn_assoc_region = “US”;
amzn_assoc_title = “Shop Related Products”;
amzn_assoc_default_search_phrase = “stroke home machine “;
amzn_assoc_default_category = “All”;
amzn_assoc_linkid = “8bd8f033dd014012f0966d32f581235c”;

Diagnosis of Cerebral Hemiplegia

To diagnose a stroke doctor hemiplegia will usually make an assessment using several of the following

Treatment of Cerebral Hemiplegia

Some potential hemiplegia exercises to consider include

  • Strength Training Exercises – Some strength training exercises can prove to be beneficial for hemiplegics. The training recommended may vary depending on the type of hemiplegia, but common exercises include knee rolling, single-leg dropouts, and single-leg bridges, among others. In some cerebral hemiplegia patients, this can help improve range of motion and functionality in the affected limbs—though this isn’t certain.
  • Muscle Stretches – Stretching specific muscle groups helps hemiplegics stave off some of the side effects of hemiplegia, such as joint/muscle pain from not moving limbs for too long and muscular atrophy. Spastic hemiplegics may need assistance in safely moving their contracted muscles without injury.
  • Seated Aerobics – Seated aerobics provide a relatively safe way to burn calories and improve health from virtually anywhere. This form of exercise is recommended for hemiplegics recovering from a spinal cord injury.
  • Water Aerobics – This hemiplegia exercise allows hemiplegics to relax their muscles and support the full weight of their bodies relatively easily as they stretch and work on their range of motion. Some rehabilitation programs use water aerobics as a chance to help people with paralysis to get out of the chair and experience some freedom of movement as they work muscles that are often neglected during in-chair exercises.
  • Muscle relaxant – that help to increase muscle strength. It can be done either by any drugs or manually applying heat and electromagnetic radiation.
  • Physical therapy – designed to help the brain work around the injuries. Physical therapy can also strengthen the unaffected side and help you reduce the loss of muscle control and tone.
  • Support groups – family education, and advocacy by family support, friend circle, etc.
  • Psychotherapy – to help you deal with the psychological effects of the disease.
  • Exercise therapy – to help you remain healthy in spite of your disability.

Initial Treatment of Hemiplegia

Immediate treatment is aimed at limiting the size of the stroke and preventing further stroke. Acute stroke therapies try to stop a stroke while it is happening by quickly dissolving the blood clot causing an ischaemic stroke or by stopping the bleeding of a hemorrhagic stroke.  This will involve administering medications and may involve surgery in some cases.

Medications

Cerebral Hemiplegia

RX

  • Thrombolytic therapy – These medications dissolve blood clots allowing blood flow to be re-established
  • Anticoagulants (eg: heparin) or aspirin These medications help to prevent blot clots from getting bigger and prevent new blood clots from forming
  • Antihypertensives  In cases of hemorrhagic stroke these medications may be prescribed to help lower high blood pressure
  • Medications– to reduce swelling in the brain and medications to treat underlying causes for the stroke eg: heart rhythm disorders may also be given.
  • Blood thinners – to reduce cardiovascular blockages and decrease the chances of future strokes.
  • Antibiotics usually delivered intravenously, to combat brain infections.
  • Muscle relaxant drugs – Tolperisone or eperisone hcl
  • Surgery to address secondary issues-particularly involuntary muscle contractions, spinal damage, or damage to the ligaments or tendons on the unaffected side of the body.
  • Physical therapy – designed to help the brain work around the injuries. Physical therapy can also strengthen the unaffected side and help you reduce the loss of muscle control and tone.
  • Support groups – family education, and advocacy.
  • Psychotherapy to help you deal with the psychological effects of the disease.
  • Exercise therapy to help you remain healthy in spite of your disability.

amzn_assoc_placement = “adunit0”;
amzn_assoc_search_bar = “false”;
amzn_assoc_tracking_id = “raharun-20”;
amzn_assoc_ad_mode = “search”;
amzn_assoc_ad_type = “smart”;
amzn_assoc_marketplace = “amazon”;
amzn_assoc_region = “US”;
amzn_assoc_title = “Shop Related Products”;
amzn_assoc_default_search_phrase = “stroke rehab equipment”;
amzn_assoc_default_category = “All”;
amzn_assoc_linkid = “a38e31d09cae256cbcced58ec6497a3a”;

Treatment of Cerebral Hemiplegia

Brain cells do not generally regenerate. Following a stroke, surviving brain cells can take over the function of areas that are dead or damaged, but only to a certain degree. The adaptive ability of the brain requires the relearning of various skills. As each person who suffers a stroke is affected differently, individual rehabilitation plans are developed in conjunction with the patient, family, and healthcare team. These aim to teach skills and maximize function so that the person can achieve maximum independence.

Physiotherapy

Treatment of hemiplegia requires coordination of several health professionals. A physiotherapist, occupational therapist, a physician, a surgeon and support from family, etc.

  • Treatment is focused – to find the causative factor and check its further progression. Secondly, after a few days, rehabilitation therapy helps to minimize disability.
  • Several medicines – are prescribed to control the primary cause such as antihypertensive, anti-thrombolytic agents to dissolve the clot, drugs to control cerebral edema, etc.
  • Intensive physical therapy – is begun after a few days. Activities such as walking, standing are done repeatedly under the guidance of a physiotherapist. It helps to improve the muscular functions which have become rigid. It is aimed to make the patient self-sufficient to perform his daily activities.
  • The patient is taught – to move his affected arm with his strong arm. With exercise, it is possible to maintain the flexibility of joints and it also prevents tightening and shortening of muscles. Speech therapy is simultaneously begun to improve communication and speaking skills.
  • Speech therapy – to improve communication
  • Occupational therapy to improve daily functions such as eating, cooking, toileting, and washing.
Recovery can take months and it may be several days or weeks after the stroke before doctors are able to give an accurate prediction for recovery.

Occupational therapy

  • Occupational therapy – Occupational Therapists may specifically help with hemiplegia with tasks such as improving hand function, strengthening the hand, shoulder, and torso, and participating in activities of daily living (ADLs), such as eating and dressing.
  • Therapists – may also recommend a hand splint for active use or for stretching at night. Some therapists actually make the splint; others may measure your child’s hand and order a splint. OTs educate patients and family on compensatory techniques to continue participating in daily living, fostering independence for the individual – which may include, environmental modification, use of adaptive equipment, sensory integration, etc.

Rehabilitation & Therapy for Hemiplegia

1. Improving motor control

a. Neurofacilitatory Techniques

In Stroke Physical Therapy these therapeutic interventions use sensory stimuli (e.g. quick stretch, brushing, reflex stimulation, and associated reactions), which are based on neurological theories, to facilitate movement in patients following stroke. The following are the different approaches

  • Bobath Concept- Berta & Karel Bobath’s approach focuses to control responses from the damaged postural reflex mechanisms. Emphasis is placed on affected inputs facilitation and normal movement patterns (Bobath, 1990).
  • ii.Brunnstrom – Brunnstrom approach is one form of neurological exercise therapy in the rehabilitation of stroke patients. The relative effectiveness of Neuro-developmental treatment versus the Brunnstrom method was studied by Wagenaar and colleagues from the perspective of the functional recovery of stroke patients. The result of this study showed no clear differences in the effectiveness of the two methods within the framework of functional recovery.
  • iii.Rood – Emphasise the use of activities in developmental sequences, sensation stimulation, and muscle work classification. Cutaneous stimuli such as icing, tapping, and brushing are employed to facilitate activities.
  • iv. Proprioceptive neuromuscular facilitation (PNF) – Developed by Knott and Voss, they advocated the use of peripheral inputs as stretch and resisted movement to reinforce existing motor response. Total patterns of movement are used in the treatment and are followed in a developmental sequence.

b. Learning theory approach

  • i. Conductive education – In Stroke Physical Therapy, Conductive education is one of the methods in treating neurological conditions including hemiplegic patients. Cotton and Kinsman (1984) demonstrated a neuropsychological approach using the concept of CE for adult hemiplegia. The patient is taught how to guide his movements towards each task-part of the task by using his own speech – rhythmical intention.
  • ii. Motor relearning theory – Carr & Shepherd, both are Australian physiotherapists, developed this approach in 1980. It emphasizes the practice of functional tasks and the importance of relearning real-life activities for patients. Principles of learning and biomechanical analysis of movements and tasks are important. There is no evidence adequately supporting the superiority of one type of exercise approach over another. However, the aim of the therapeutic approach is to increase physical independence and to facilitate the motor control of skill acquisition and there is strong evidence to support the effect of rehabilitation in terms of improved functional independence and reduced mortality.

c. Functional electrical stimulation (FES) 

  • FES is a modality that applied a short burst of electrical current to the hemiplegic muscle or nerve. In Stroke Physical Therapy, FES has been demonstrated to be beneficial to restore motor control, spasticity, and reduction of hemiplegic shoulder pain and subluxation.  A recent meta-analysis of the randomized controlled trial study showed that FES improves motor strength. A study by Faghri has identified that FES can significantly improve arm function, electromyographic activity of posterior deltoid, the range of motion and reduction of severity of subluxation and pain of the hemiplegic shoulder.

d. Biofeedback

  • Biofeedback is a modality that facilitates the cognizant of electromyographic activity in selected muscle or awareness of joint position sense via visual or auditory cues. In Stroke Physical Therapy the result of studies in biofeedback is controversial. A meta-analysis of 8 randomized controlled trials of biofeedback therapy demonstrated that electromyographic biofeedback could improve motor function in stroke patients.
  • A conflicting meta-analysis study by showing that biofeedback was not efficacious in improving the range of motion in the ankle and shoulder in a stroke patient. Moreland conducted another meta-analysis that concluded that EMG biofeedback alone or with conventional therapy did not superior to conventional physical therapy in improving upper- extremity function in the adult stroke patient.

2. Hemiplegic shoulder management

Shoulder subluxation and pain of the affected arm is not uncommon in at least 30% of all patient after stroke, whereas subluxation is found in 80% of stroke patients. It is associated with the severity of the disability and is common in patients in rehabilitation settings. Suggested interventions are as follows:

  • a. Exercise – Active weight-bearing exercise can be used as a means of improving motor control of the affected arm; introducing and grading tactile, proprioceptive, and kinesthetic stimulation; and preventing edema and pain. In Stroke Physical Therapy, Upper extremity weight bearing can be used to lengthen or inhibit tight or spastic muscles while simultaneously facilitating muscles that are not active (Donatelli, 1991). According to Robert (1992), the amount of shoulder pain in hemiplegia was related most to loss of motion. He advocated that the provision of ROM exercise (caution to avoid improvement) as treatment as early as possible.
  • b. Functional electrical stimulation – Functional electrical stimulation (FES) is an increasingly popular treatment for hemiplegic stroke patients. It has been applied in stroke physical therapy for the treatment of shoulder subluxation spasticity and functionally, for the restoration of function in the upper and lower limb. In Stroke Physical Therapy, Electrical stimulation is effective in reducing pain and severity of subluxation, and possibly in facilitating recovery of arm function c. Positioning & proper handling – In Stroke Physical Therapy, proper positioning and handling of the hemiplegic shoulder, whenever in bed, sitting and standing or during lifting, can prevent shoulder injury is recommended in the AHCPR & SIGN guidelines for stroke rehabilitation. In Stroke Physical Therapy, positioning can be therapeutic for tone control and neuro-facilitation of stroke patients (Davies, 1991). Braus et al 94 found shoulder hand syndrome reduced from 27% to 8% by the instruction to everyone including family on handling technique.
  • d. Neuro-facilitation
  • e. Passive limb physiotherapy – Maintenance of a full pain-free range of movement without traumatizing the joint and the structures can be carried out. In Stroke Physical Therapy, at no time should pain in or around the shoulder joint be produced during treatment.
  • f. Pain relief physiotherapy – Passive mobilization as described by Maitland can be useful in gaining relief of pain and range of movement. In Stroke Physical Therapy other treatment modalities such as thermal, electrical, cryotherapy, etc. can be applied for shoulder pains or musculoskeletal in nature.
  • g. Reciprocal pulley – The use of reciprocal pulley appears to increase the risk of developing shoulder pain in stroke patients. It is not related to the presence of subluxation or to muscle strength.
  • h. Sling – In Stroke Physical Therapy the use of a sling is controversial. No shoulder support will correct a glenohumeral joint subluxation. However, it may prevent the flaccid arm from hanging against the body during functional activities, thus decreasing shoulder joint pain. They also help to relieve downward traction on the shoulder capsule caused by the weight of the arm.

3. Limb physiotherapy

  • Limb physiotherapy/Stroke Physical Therapy includes passive, assisted-active and active range-of-motion exercise for the hemiplegic limbs. This can be effective management for the prevention of limb contractures and spasticity and is recommended within AHCPR. Self-assisted limb exercise is effective for reducing spasticity and shoulder protection. Adams and coworkers recommended passive full-range-of-motion exercise for a paralyzed limb for potential reduction of complication for stroke patients

4. Chest physiotherapy

  • In Stroke Physical Therapy, evidence shows that both cough and forced expiratory technique (FET) can eliminate induced radio aerosol particles in the lung field. Directed coughing and FET can be used as a technique for bronchial hygiene clearance in stroke patients.

5. Positioning

  • In Stroke, Physical Therapy consistent “reflex-inhibitory” patterns of posture in resting is encouraged to discourage physical complication of stroke and to improve recovery (Bobath, 1990).
  • Meanwhile, therapeutic positioning is a widely advocated strategy to discourage the development of abnormal tone, contractures, pain, and respiratory complications. It is an important element in maximizing the patient’s functional gains and quality of life.

6. Tone management

  • A goal of Stroke Physical Therapy interventions has been to “normalize tone to normalize movement.” Therapy modalities for reducing tone include stretching, prolonged stretching, passive manipulation by therapists, weight-bearing, ice, contraction of muscles antagonistic to spastic muscles, splinting, and casting.
  • Research on tone-reducing techniques has been hampered by the inadequacies of methods to measure spasticity and the uncertainty about the relationship between spasticity and volitional motor control.
  • The manual stretch of finger muscles, pressure splints, and dantrolene sodium do not produce apparent long-term improvement in motor control. Dorsal resting hand splints reduced spasticity more than volar splints, but the effect on motor control is uncertain while TENS stimulation showed improvement for chronic spasticity of lower extremities.

7. Sensory re-education

  • Bobath and other therapy approaches recommend the use of sensory stimulation to promote the sensory recovery of stroke patients.

8. Balance retraining

  • Re-establishment of balance function in patients following stroke has been advocated as an essential component in the practice of stroke physical therapy. Some studies of patients with hemiparesis revealed that these patients have a greater amount of postural sway, the asymmetry with greater weight on the non-paretic leg, and a decreased ability to move within a weight-bearing posture. Meanwhile, research has demonstrated moderate relationships between balance function and parameters such as gait speed, independence, wheelchair mobility, reaching, as well as dressing. Some tenable support on the effectiveness of treatment of disturbed balance can be found in studies comparing the effects of balance retraining plus physiotherapy treatment and physiotherapy treatment alone.

9. Fall prevention

  • In Stroke Physical Therapy, falls are one of the most frequent complications and the consequences of which are likely to have a negative effect on the rehabilitation process and its outcome.
  • According to the systematic review of the Cochrane Library, which evaluated the effectiveness of several fall prevention interventions in the elderly, there was significant protection against falling from interventions that targeted multiple, identified, risk factors in individual patients. The same is true for interventions which focused on behavioral interventions targeting environmental hazards plus other risk factors

10. Gait re-education

  • Recovery of independent mobility is an important goal for the immobile patient, and much therapy is devoted to gait-reeducation. Bobath assumes abnormal postural reflex activity is caused by dysfunction so gait training involved tone normalization and preparatory activity for gait activity.
  • In contrast, Carr and Shepherd advocate task-related training with methods to increase strength, coordination and flexible MS system to develop skill in walking while Treadmill training combined with the use of a suspension tube. Some patient’s body weight can effective in regaining walking ability when used as an adjunct to convention therapy 3 months after active training.

11. Functional Mobility Training

  • To handle the functional limitations of stroke patients, functional tasks are taught to them based on movement analysis principles. In Stroke Physical Therapy these tasks include bridging, rolling to sit to stand and vice versa, transfer skills, walking and staring, etc.
  • Published studies report that many patients improve during rehabilitation. The strongest evidence of benefit is from studies that have enrolled patients with chronic deficits or have included a no-treatment control group.
  • Meanwhile, early mobilization helps prevent compilations e.g. DVT, skin breakdown contracture and pneumonia. Evidence has shown better orthostatic tolerance and earlier ambulation.

12. Upper limb training

By 3 months poststroke, approximately 37% of the individuals continue to have decreased upper extremities (UE) function. Recovery of UE function lags behind that of the lower extremities because of the more complex motor skill required of the UE in daily life tasks. That means many individuals who have a stroke are at risk for a lowered quality of life. Many approaches to the physical rehabilitation of adults post-stroke exist that attempt to maximize motor skill recovery. However, the literature does not support the efficacy of any single approach. The followings are the current approaches to motor rehabilitation of the UE.

  • a. Facilitation models – They are the most common methods of intervention for the deficits in UE motor skills including Bobath, proprioceptive neuromuscular facilitation, Brunnstrom’s movement therapy, and Rood’s sensorimotor approach. There is some evidence that practice based on the facilitation models can result in improved motor control of UE. However, an intervention based on the facilitation models has not been effective in restoring the fine hand coordination required for the performance of actions.
  • b. Functional electric stimulation – In Stroke Physical Therapy, Functional electric stimulation (FES) can be effective in increasing the electric activity of muscles or increased active range of motion in individuals with stroke. Some evidence showed that FES may be more effective than facilitation approaches.
  • c. Electromyographic biofeedback – In Stroke Physical Therapy, biofeedback can contribute to improvements in motor control at the neuromuscular and movement levels. Some studies have shown improvements in the ability to perform actions during post-testing after biofeedback training. However, the ability to generalize these skills and incorporate them into daily life is not measured.
  • d. Constraint-induced therapy – Constraint-Induced (CI) therapy was designed to overcome the learned nonuse of the affected UE. In the most extreme form of CI therapy, individual post-stroke is prevented from using the less affected UE by keeping it in a splint and sling for at least 90% of their waking hours. Studies have found that the most extreme of CI therapy can effect rapid improvement in UE motor skill and that is retained for at least as long as 2 years. However, CI therapy currently is effective only in those with distal voluntary movement.

13. Mobility appliances and equipment

  • Small changes in an individual’s local ‘environment’ can greatly increase independence, use of a wheelchair or walking stick. However, little research has been done for these ‘treatments’. It is acknowledged that walking aids and mobility appliances may benefit selected patients.

14. Acupuncture 

  • The World Health Organisation (WHO) has listed acupuncture as a possible treatment for pariesis after stroke. Studies had sown its beneficial effects on stroke rehabilitation.
  • Hua had reported a significant difference in changes of neurological score between the acupuncture group and the control group after 4 weeks of treatment in an RCT and no adverse effects were observed in patients treated with acupuncture.

15. Vasomotor training 

  • Early stimulation of the muscle pump can reduce the venous stasis and enhance the general circulation of the body. It then hastens the recovery process.

16. Edema management

  • Use of intermittent pneumatic pump, elastic stocking or bandages and massage can facilitate the venous return of the oedematous limbs. Therefore, the elasticity and flexibility of the musculoskeletal system can be maintained and enhance the recovery process and prevent complications like pressure ulcers.

Homeopathic Medicines for Hemiplegia

Homeopathic medicines cannot cure hemiplegia. However, the medicines can be administered to improve the state of paralysis, improve blood circulation, help control loss of power, improve the power of muscles to come extent and improve the overall health of the patient.

Some common medicines for hemiplegia and such states of paralysis are:

  • Plumbum Metallicum – This medicine is sourced by processing and potentizing the metal lead. It helps the neuro-muscular system of the body. It is administered with the intention to improve some muscle power. Plumbum met, as it is called, may be indicated all kinds of paralysis such as hemiplegia, paraplegia, and quadriplegia. As said earlier, it cannot cure paralysis as such.
  • Causticum Similar to the above medicine, Causticum is also a friend to all paralysis patients. It is aimed at improving some muscle power and not cure it.
  • Nux vomicaThis herbal medicine helps in the early stages of hemiplegia and not after some months or years.
  • Lathyrus sativus – This is another example of a toxin transformed into medicine. It is safe, There are some spasticity and stiffness in some muscles, in the cases of hemiplegia, where Lathyrus may be called for.
  • GelsemiumThis plant remedy is useful for early cases of paralysis including hemiplegia. It is supposed to improve muscle strength in the cases of paralysis.

amzn_assoc_placement = “adunit0”;
amzn_assoc_search_bar = “false”;
amzn_assoc_tracking_id = “raharun-20”;
amzn_assoc_ad_mode = “search”;
amzn_assoc_ad_type = “smart”;
amzn_assoc_marketplace = “amazon”;
amzn_assoc_region = “US”;
amzn_assoc_title = “Shop Related Products”;
amzn_assoc_default_search_phrase = “stroke recovery machine”;
amzn_assoc_default_category = “All”;
amzn_assoc_linkid = “a38e31d09cae256cbcced58ec6497a3a”;

Prevention

Reducing the number of controllable risk factors is the best way to prevent a stroke.  This can include:

  • Stopping smoking
  • Losing weight
  • Eating a balanced diet low in sodium and saturated and trans fat
  • Moderating alcohol intake (no more than 2 small drinks per day)
  • Exercising regularly in order to stay physically fit
  • Maintaining good control of existing medical conditions such as diabetes, high blood pressure and high cholesterol.

Referances

Cerebral Hemiplegia

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

What Is Spastic Hemiplegia; Causes, Symptoms

What Is Spastic Hemiplegia/Spastic Hemiplegia a variation of hemiplegia where the muscles on one side of the body are in a state of constant contraction. This type of hemiplegia may result in muscle pain, deformities in affected limbs (in extreme cases), and difficulty walking or maintaining motor control. Closely linked to cerebral palsy, and the severity (as well as the duration) of spastic hemiplegia symptoms may vary from case to case.

Hemiplegia is a neurological condition that affects paralysis is on one vertical half of the body. Its most obvious result is a varying degree of weakness and lack of control on one side of the body. It affects everyone differently but its most obvious result is a varying degree of weakness and lack of control in one side of the body. You may be reading this because your child or someone you know has hemiplegia.

Hemiplegia, paralysis of the muscles of the lower face, arm, and leg on one side of the body. The most common cause of hemiplegia is a stroke, which damages the corticospinal tracts in one hemisphere of the brain. The corticospinal tracts extend from the lower spinal cord to the cerebral cortex. They decussate, or cross, in the brainstem; therefore, damage to the right cerebral hemisphere results in paralysis of the left side of the body. Damage to the left hemisphere of a right-handed person may also result in aphasia. Other causes of hemiplegia include trauma, such as spinal cord injury; brain tumors; and brain infections.

Hemiplegia is a condition where half of the body is paralyzed due to damage to the parts of the brain responsible for movement. Hemiparesis and hemiplegia can be caused by different medical conditions, including congenital causes, trauma, tumors, or stroke, etc.

Types of Hemiplegia

  • Alternate hemiplegia –  paralysis of one side of the face and the opposite side of the body.
  • Cerebral hemiplegia –  that due to a brain lesion.
  • Crossed hemiplegia – alternate hemiplegia. It affects the alter side of the body instated of the affected side.
  • Facial hemiplegia paralysis – of one side of the face.
  • Spastic hemiplegia – with spasticity of the affected muscles and increased tendon reflexes.
  • Spinal hemiplegia – due to a lesion of the spinal cord.

While hemiplegia is typically characterized as paralysis on one side of the body, there are multiple types of hemiplegia—some of which may be more limited in scope than others. A few different types of hemiplegia include:

  • Facial Hemiplegia – Also referred to as partial facial paralysis, this is a form of partial hemiplegia where the muscles on one side of the face are paralyzed. Often caused by a stroke or similar brain injury. This may or may not be associated with complete/incomplete hemiplegia in other areas of the body.
  • Cerebral Hemiplegia  – When hemiplegia is caused by cerebral palsy (or other conditions affecting the brain), it can be referred to as cerebral hemiplegia. Cerebral hemiplegia symptoms are often similar to other forms of hemiplegia but may vary in severity and duration depending on the condition causing the paralysis.
  • Spastic Hemiplegia – A variation of hemiplegia where the muscles on one side of the body are in a state of constant contraction. This type of hemiplegia may result in muscle pain, deformities in affected limbs (in extreme cases), and difficulty walking or maintaining motor control. Closely linked to cerebral palsy, and the severity (as well as the duration) of spastic hemiplegia symptoms may vary from case to case.
  • Spinal Hemiplegia – Often the result of an incomplete injury to the spinal cord or lesions on spinal nerves (especially at the C6 vertebra or higher). Spinal cord injury hemiplegia is often a long-term condition.

Causes of Spastic Hemiplegia

Though the arms, legs, and possibly torso are the regions of the body most obviously affected by hemiplegia, in most cases of hemiplegia these body regions are actually perfectly healthy. Instead, the problem resides in the brain, which is unable to produce, send, or interpret signals due to disease or trauma-related damage. Less frequently, hemiplegia results from damage to one side of the spinal cord, but these sorts of injuries more typically produce global problems, not just paralysis on one side of the body.

  • Traumatic brain injuries to one side of the brain only. These may be caused by car accidents, falls, acts of violence, and other factors.
  • Cardiovascular problems, particularly aneurysms and hemorrhages in the brain.
  • Strokes and transient ischemic attacks (better known as TIA or mini-strokes).
  • Infections, particularly encephalitis and meningitis. Some serious infections, particularly sepsis and abscesses in the neck, may spread to the brain if left untreated.
  • Conditions that cause demyelination of the brain, including multiple sclerosis and some other autoimmune diseases.
  • Traumatic brain injuries to one side of the brain only. These may be caused by car accidents, falls, acts of violence, and other factors.
  • Cardiovascular problems, particularly aneurysms and hemorrhages in the brain.
  • Strokes and transient ischemic attacks (better known as TIA or mini-strokes).
  • Infections, particularly encephalitis and meningitis. Some serious infections, particularly sepsis and abscesses in the neck, may spread to the brain if left untreated.
  • Conditions that cause demyelination of the brain, including multiple sclerosis and some other autoimmune diseases.
  • Reactions to surgery, medication, or anesthesia.
  • Loss of oxygen to the brain due to choking or anaphylactic shock.
  • Brain cancers.
  • Lesions in the brain, even if non-cancerous, since these lesions can impede function on one side of the brain.
  • Congenital abnormalities, including cerebral palsy and neonatal-onset multi-inflammatory disease.
  • Rarely, psychological causes; some states of catatonia can cause hemiplegia, and people with parasomnia—a sleep disorder leading to unusual nighttime behavior—may experience nighttime episodes of hemiplegia.
  • Reactions to surgery, medication, or anesthesia.
  • Loss of oxygen to the brain due to choking or anaphylactic shock.
  • Brain cancers.
  • Lesions in the brain, even if non-cancerous, since these lesions can impede function on one side of the brain.
  • Congenital abnormalities, including cerebral palsy and neonatal-onset multi-inflammatory disease.
  • Rarely, psychological causes; some states of catatonia can cause hemiplegia, and people with parasomnia—a sleep disorder leading to unusual nighttime behavior—may experience nighttime episodes of hemiplegia.
What Is Spastic Hemiplegia

Rx

Some common causes of hemiplegia include

Stroke is the commonest cause of hemiplegia. Insufficient blood supply to the brain leads to loss of brain functions. The stroke may be caused by:

  • A clot formed within the blood vessel blocking the blood supply -> a thrombus
  • A thrombus breaks away from its site of origin and forms a block elsewhere in the circulation -> an emboli
  • A bleed from a blood vessel supplying the brain -> a hemorrhage
  • A thrombus breaks away from its site of origin and forms a block elsewhere in the circulation. -> an emboli
  • A bleed from a blood vessel supplying the brain -> a hemorrhage
  • Traumatic brain injuries to one side of the brain only. These may be caused by car accidents, falls, acts of violence, and other factors.
  • Cardiovascular problems, particularly aneurysms and hemorrhages in the brain.
  • Infections, particularly encephalitis and meningitis. Some serious infections, particularly sepsis and abscesses in the neck, may spread to the brain if left untreated.
  • Migraine syndrome -> recurrent headaches of severe intensity occasionally accompanied by sensations of numbness and tingling in one half of the body.
  • Conditions that cause demyelination of the brain, including multiple sclerosis and some other autoimmune diseases.
  • Reactions to surgery, medication, or anesthesia.
  • Loss of oxygen to the brain due to choking or anaphylactic shock.
  • Brain cancers.
  • Lesions in the brain, even if non-cancerous, since these lesions can impede function on one side of the brain.
  • Congenital abnormalities, including cerebral palsy and neonatal-onset multi-inflammatory disease.
  • Rarely, psychological causes; some states of catatonia can cause hemiplegia, and people with parasomnia—a sleep disorder leading to unusual nighttime behavior—may experience nighttime episodes of hemiplegia.
  • Head injury
  • Diabetes
  • Brain tumor
  • Infections –> meningitis, encephalitis, meningitis, brain abscess
  • Migraine syndrome -> recurrent headaches of severe intensity occasionally accompanied by sensations of numbness and tingling in one half of the body.
  • Inflammation of the blood vessels -> vasculitis
  • Diseases affecting the nerves -> like Multiple Sclerosis; acute necrotizing myelitis.
  • Conditions presenting from birth -> cerebral palsy. Lack of blood supply damages nerve cells in the brain. Birth trauma, difficult labor, perinatal strokes in infants within 3 days of birth can all cause cerebral palsy.
  • Hereditary diseases –> leukodystrophies. This is a rare disorder affecting the myelin sheath which covers and protects nerve cells in the brain. The condition usually appears in infancy or childhood.
  • Vascular – cerebral hemorrhage
  • Neoplastic – glioma-meningioma
  • Demyelination – disseminated sclerosis, lesions to the internal capsule
  • Traumatic – cerebral lacerations, subdural hematoma rare cause of hemiplegia is due to local anesthetic injections given intra-arterially rapidly, instead of given in a nerve branch.
  • Congenitalcerebral palsy, Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
  • Disseminated – multiple sclerosis
  • Psychological – parasomnia (nocturnal hemiplegia)
  • Severe headache
  • Impairment or loss of vision
  • Memory loss
  • Confusion
  • Loss of balance or co-ordination
  • Poor balance and dizziness
  • Sudden numbness, paralysis or weakness of an arm, leg or side of the face.
  • Slurred or abnormal speech
  • Loss of consciousness
  • Incontinence

Symptoms of Spastic Hemiplegia

What Is Hemiplegia?

Rx

The main symptom of hemiplegia is weakness or paralysis on one side of the child’s body. The condition can vary in severity and affects each child differently. It will only affect one side of the child’s body. General symptoms include

  • Total or partial loss of sensation on just one side.
  • Changes in cognition, mood, or perception.
  • Difficulty speaking.
  • Changes on the other side of the body, since those muscles, may begin to atrophy or become painful due to chronic muscle spasms.
  • Spastic attacks during which the muscles move without your conscious control.
  • Seizures.
  • Pusher syndrome – With this symptom, hemiplegics shift their weight to the paralyzed side of the body, resulting in significant loss of motor control.
  • Severe, throbbing pain, often on one side of your head
  • A pins-and-needles feeling, often moving from your hand up your arm
  • Numbness on one side of your body, which can include your arm, leg, and half of your face
  • Weakness or paralysis on one side of your body
  • Loss of balance and coordination
  • Dizziness or vertigo
  • Nausea and vomiting

You may also have problems with your senses, communication, and drowsiness

  • Seeing zigzag lines, double vision, or blind spots
  • Extreme sensitivity to light, sound, and smell
  • Language difficulties, such as mixing words or trouble remembering a word
  • Slurred speech
  • Confusion
  • Loss of consciousness or coma
  • Difficulty walking
  • Poor balance
  • Little or no use of one hand or leg
  • Speech problems
  • Visual problems
  • Behavioral problems
  • Learning difficulties
  • Epilepsy
  • Developmental delay, for example learning to walk later than other children

amzn_assoc_placement = “adunit0”;
amzn_assoc_search_bar = “false”;
amzn_assoc_tracking_id = “raharun-20”;
amzn_assoc_ad_mode = “search”;
amzn_assoc_ad_type = “smart”;
amzn_assoc_marketplace = “amazon”;
amzn_assoc_region = “US”;
amzn_assoc_title = “Shop Related Products”;
amzn_assoc_default_search_phrase = “stroke home machine “;
amzn_assoc_default_category = “All”;
amzn_assoc_linkid = “8bd8f033dd014012f0966d32f581235c”;

Diagnosis of Spastic Hemiplegia

To diagnose a stroke doctor hemiplegia will usually make an assessment using several of the following

Treatment of Spastic Hemiplegia

Some potential hemiplegia exercises to consider include

  • Strength Training Exercises – Some strength training exercises can prove to be beneficial for hemiplegics. The training recommended may vary depending on the type of hemiplegia, but common exercises include knee rolling, single-leg dropouts, and single-leg bridges, among others. In some cerebral hemiplegia patients, this can help improve range of motion and functionality in the affected limbs—though this isn’t certain.
  • Muscle Stretches – Stretching specific muscle groups helps hemiplegics stave off some of the side effects of hemiplegia, such as joint/muscle pain from not moving limbs for too long and muscular atrophy. Spastic hemiplegics may need assistance in safely moving their contracted muscles without injury.
  • Seated Aerobics – Seated aerobics provide a relatively safe way to burn calories and improve health from virtually anywhere. This form of exercise is recommended for hemiplegics recovering from a spinal cord injury.
  • Water Aerobics – This hemiplegia exercise allows hemiplegics to relax their muscles and support the full weight of their bodies relatively easily as they stretch and work on their range of motion. Some rehabilitation programs use water aerobics as a chance to help people with paralysis to get out of the chair and experience some freedom of movement as they work muscles that are often neglected during in-chair exercises.
  • Muscle relaxant – that help to increase muscle strength. It can be done either by any drugs or manually applying heat and electromagnetic radiation.
  • Physical therapy – designed to help the brain work around the injuries. Physical therapy can also strengthen the unaffected side and help you reduce the loss of muscle control and tone.
  • Support groups – family education, and advocacy by family support, friend circle, etc.
  • Psychotherapy – to help you deal with the psychological effects of the disease.
  • Exercise therapy – to help you remain healthy in spite of your disability.

Initial Treatment of Hemiplegia

Immediate treatment is aimed at limiting the size of the stroke and preventing further stroke. Acute stroke therapies try to stop a stroke while it is happening by quickly dissolving the blood clot causing an ischaemic stroke or by stopping the bleeding of a hemorrhagic stroke.  This will involve administering medications and may involve surgery in some cases.

Medications

Spastic Hemiplegia

RX

  • Thrombolytic therapy – These medications dissolve blood clots allowing blood flow to be re-established
  • Anticoagulants (eg: heparin) or aspirin These medications help to prevent blot clots from getting bigger and prevent new blood clots from forming
  • Antihypertensives  In cases of hemorrhagic stroke these medications may be prescribed to help lower high blood pressure
  • Medications– to reduce swelling in the brain and medications to treat underlying causes for the stroke eg: heart rhythm disorders may also be given.
  • Blood thinners – to reduce cardiovascular blockages and decrease the chances of future strokes.
  • Antibiotics usually delivered intravenously, to combat brain infections.
  • Muscle relaxant drugs – Tolperisone or eperisone hcl
  • Surgery to address secondary issues-particularly involuntary muscle contractions, spinal damage, or damage to the ligaments or tendons on the unaffected side of the body.
  • Physical therapy – designed to help the brain work around the injuries. Physical therapy can also strengthen the unaffected side and help you reduce the loss of muscle control and tone.
  • Support groups – family education, and advocacy.
  • Psychotherapy to help you deal with the psychological effects of the disease.
  • Exercise therapy to help you remain healthy in spite of your disability.

amzn_assoc_placement = “adunit0”;
amzn_assoc_search_bar = “false”;
amzn_assoc_tracking_id = “raharun-20”;
amzn_assoc_ad_mode = “search”;
amzn_assoc_ad_type = “smart”;
amzn_assoc_marketplace = “amazon”;
amzn_assoc_region = “US”;
amzn_assoc_title = “Shop Related Products”;
amzn_assoc_default_search_phrase = “stroke rehab equipment”;
amzn_assoc_default_category = “All”;
amzn_assoc_linkid = “a38e31d09cae256cbcced58ec6497a3a”;

Treatment of Spastic Hemiplegia

Brain cells do not generally regenerate. Following a stroke, surviving brain cells can take over the function of areas that are dead or damaged, but only to a certain degree. The adaptive ability of the brain requires the relearning of various skills. As each person who suffers a stroke is affected differently, individual rehabilitation plans are developed in conjunction with the patient, family, and healthcare team. These aim to teach skills and maximize function so that the person can achieve maximum independence.

Physiotherapy

Treatment of hemiplegia requires coordination of several health professionals. A physiotherapist, occupational therapist, a physician, a surgeon and support from family, etc.

  • Treatment is focused – to find the causative factor and check its further progression. Secondly, after a few days, rehabilitation therapy helps to minimize disability.
  • Several medicines – are prescribed to control the primary cause such as antihypertensive, anti-thrombolytic agents to dissolve the clot, drugs to control cerebral edema, etc.
  • Intensive physical therapy – is begun after a few days. Activities such as walking, standing are done repeatedly under the guidance of a physiotherapist. It helps to improve the muscular functions which have become rigid. It is aimed to make the patient self-sufficient to perform his daily activities.
  • The patient is taught – to move his affected arm with his strong arm. With exercise, it is possible to maintain the flexibility of joints and it also prevents tightening and shortening of muscles. Speech therapy is simultaneously begun to improve communication and speaking skills.
  • Speech therapy – to improve communication
  • Occupational therapy to improve daily functions such as eating, cooking, toileting, and washing.
Recovery can take months and it may be several days or weeks after the stroke before doctors are able to give an accurate prediction for recovery.

Occupational therapy

  • Occupational therapy – Occupational Therapists may specifically help with hemiplegia with tasks such as improving hand function, strengthening the hand, shoulder, and torso, and participating in activities of daily living (ADLs), such as eating and dressing.
  • Therapists – may also recommend a hand splint for active use or for stretching at night. Some therapists actually make the splint; others may measure your child’s hand and order a splint. OTs educate patients and family on compensatory techniques to continue participating in daily living, fostering independence for the individual – which may include, environmental modification, use of adaptive equipment, sensory integration, etc.

Rehabilitation & Therapy for Hemiplegia

1. Improving motor control

a. Neurofacilitatory Techniques

In Stroke Physical Therapy these therapeutic interventions use sensory stimuli (e.g. quick stretch, brushing, reflex stimulation, and associated reactions), which are based on neurological theories, to facilitate movement in patients following stroke. The following are the different approaches

  • Bobath Concept- Berta & Karel Bobath’s approach focuses to control responses from the damaged postural reflex mechanisms. Emphasis is placed on affected inputs facilitation and normal movement patterns (Bobath, 1990).
  • ii.Brunnstrom – Brunnstrom approach is one form of neurological exercise therapy in the rehabilitation of stroke patients. The relative effectiveness of Neuro-developmental treatment versus the Brunnstrom method was studied by Wagenaar and colleagues from the perspective of the functional recovery of stroke patients. The result of this study showed no clear differences in the effectiveness of the two methods within the framework of functional recovery.
  • iii.Rood – Emphasise the use of activities in developmental sequences, sensation stimulation, and muscle work classification. Cutaneous stimuli such as icing, tapping, and brushing are employed to facilitate activities.
  • iv. Proprioceptive neuromuscular facilitation (PNF) – Developed by Knott and Voss, they advocated the use of peripheral inputs as stretch and resisted movement to reinforce existing motor response. Total patterns of movement are used in the treatment and are followed in a developmental sequence.

b. Learning theory approach

  • i. Conductive education – In Stroke Physical Therapy, Conductive education is one of the methods in treating neurological conditions including hemiplegic patients. Cotton and Kinsman (1984) demonstrated a neuropsychological approach using the concept of CE for adult hemiplegia. The patient is taught how to guide his movements towards each task-part of the task by using his own speech – rhythmical intention.
  • ii. Motor relearning theory – Carr & Shepherd, both are Australian physiotherapists, developed this approach in 1980. It emphasizes the practice of functional tasks and the importance of relearning real-life activities for patients. Principles of learning and biomechanical analysis of movements and tasks are important. There is no evidence adequately supporting the superiority of one type of exercise approach over another. However, the aim of the therapeutic approach is to increase physical independence and to facilitate the motor control of skill acquisition and there is strong evidence to support the effect of rehabilitation in terms of improved functional independence and reduced mortality.

c. Functional electrical stimulation (FES) 

  • FES is a modality that applied a short burst of electrical current to the hemiplegic muscle or nerve. In Stroke Physical Therapy, FES has been demonstrated to be beneficial to restore motor control, spasticity, and reduction of hemiplegic shoulder pain and subluxation.  A recent meta-analysis of the randomized controlled trial study showed that FES improves motor strength. A study by Faghri has identified that FES can significantly improve arm function, electromyographic activity of posterior deltoid, the range of motion and reduction of severity of subluxation and pain of the hemiplegic shoulder.

d. Biofeedback

  • Biofeedback is a modality that facilitates the cognizant of electromyographic activity in selected muscle or awareness of joint position sense via visual or auditory cues. In Stroke Physical Therapy the result of studies in biofeedback is controversial. A meta-analysis of 8 randomized controlled trials of biofeedback therapy demonstrated that electromyographic biofeedback could improve motor function in stroke patients.
  • A conflicting meta-analysis study by showing that biofeedback was not efficacious in improving the range of motion in the ankle and shoulder in a stroke patient. Moreland conducted another meta-analysis that concluded that EMG biofeedback alone or with conventional therapy did not superior to conventional physical therapy in improving upper- extremity function in the adult stroke patient.

2. Hemiplegic shoulder management

Shoulder subluxation and pain of the affected arm is not uncommon in at least 30% of all patient after stroke, whereas subluxation is found in 80% of stroke patients. It is associated with the severity of the disability and is common in patients in rehabilitation settings. Suggested interventions are as follows:

  • a. Exercise – Active weight-bearing exercise can be used as a means of improving motor control of the affected arm; introducing and grading tactile, proprioceptive, and kinesthetic stimulation; and preventing edema and pain. In Stroke Physical Therapy, Upper extremity weight bearing can be used to lengthen or inhibit tight or spastic muscles while simultaneously facilitating muscles that are not active (Donatelli, 1991). According to Robert (1992), the amount of shoulder pain in hemiplegia was related most to loss of motion. He advocated that the provision of ROM exercise (caution to avoid improvement) as treatment as early as possible.
  • b. Functional electrical stimulation – Functional electrical stimulation (FES) is an increasingly popular treatment for hemiplegic stroke patients. It has been applied in stroke physical therapy for the treatment of shoulder subluxation spasticity and functionally, for the restoration of function in the upper and lower limb. In Stroke Physical Therapy, Electrical stimulation is effective in reducing pain and severity of subluxation, and possibly in facilitating recovery of arm function c. Positioning & proper handling – In Stroke Physical Therapy, proper positioning and handling of the hemiplegic shoulder, whenever in bed, sitting and standing or during lifting, can prevent shoulder injury is recommended in the AHCPR & SIGN guidelines for stroke rehabilitation. In Stroke Physical Therapy, positioning can be therapeutic for tone control and neuro-facilitation of stroke patients (Davies, 1991). Braus et al 94 found shoulder hand syndrome reduced from 27% to 8% by the instruction to everyone including family on handling technique.
  • d. Neuro-facilitation
  • e. Passive limb physiotherapy – Maintenance of a full pain-free range of movement without traumatizing the joint and the structures can be carried out. In Stroke Physical Therapy, at no time should pain in or around the shoulder joint be produced during treatment.
  • f. Pain relief physiotherapy – Passive mobilization as described by Maitland can be useful in gaining relief of pain and range of movement. In Stroke Physical Therapy other treatment modalities such as thermal, electrical, cryotherapy, etc. can be applied for shoulder pains or musculoskeletal in nature.
  • g. Reciprocal pulley – The use of reciprocal pulley appears to increase the risk of developing shoulder pain in stroke patients. It is not related to the presence of subluxation or to muscle strength.
  • h. Sling – In Stroke Physical Therapy the use of a sling is controversial. No shoulder support will correct a glenohumeral joint subluxation. However, it may prevent the flaccid arm from hanging against the body during functional activities, thus decreasing shoulder joint pain. They also help to relieve downward traction on the shoulder capsule caused by the weight of the arm.

3. Limb physiotherapy

  • Limb physiotherapy/Stroke Physical Therapy includes passive, assisted-active and active range-of-motion exercise for the hemiplegic limbs. This can be effective management for the prevention of limb contractures and spasticity and is recommended within AHCPR. Self-assisted limb exercise is effective for reducing spasticity and shoulder protection. Adams and coworkers recommended passive full-range-of-motion exercise for a paralyzed limb for potential reduction of complication for stroke patients

4. Chest physiotherapy

  • In Stroke Physical Therapy, evidence shows that both cough and forced expiratory technique (FET) can eliminate induced radio aerosol particles in the lung field. Directed coughing and FET can be used as a technique for bronchial hygiene clearance in stroke patients.

5. Positioning

  • In Stroke, Physical Therapy consistent “reflex-inhibitory” patterns of posture in resting is encouraged to discourage physical complication of stroke and to improve recovery (Bobath, 1990).
  • Meanwhile, therapeutic positioning is a widely advocated strategy to discourage the development of abnormal tone, contractures, pain, and respiratory complications. It is an important element in maximizing the patient’s functional gains and quality of life.

6. Tone management

  • A goal of Stroke Physical Therapy interventions has been to “normalize tone to normalize movement.” Therapy modalities for reducing tone include stretching, prolonged stretching, passive manipulation by therapists, weight-bearing, ice, contraction of muscles antagonistic to spastic muscles, splinting, and casting.
  • Research on tone-reducing techniques has been hampered by the inadequacies of methods to measure spasticity and the uncertainty about the relationship between spasticity and volitional motor control.
  • The manual stretch of finger muscles, pressure splints, and dantrolene sodium do not produce apparent long-term improvement in motor control. Dorsal resting hand splints reduced spasticity more than volar splints, but the effect on motor control is uncertain while TENS stimulation showed improvement for chronic spasticity of lower extremities.

7. Sensory re-education

  • Bobath and other therapy approaches recommend the use of sensory stimulation to promote the sensory recovery of stroke patients.

8. Balance retraining

  • Re-establishment of balance function in patients following stroke has been advocated as an essential component in the practice of stroke physical therapy. Some studies of patients with hemiparesis revealed that these patients have a greater amount of postural sway, the asymmetry with greater weight on the non-paretic leg, and a decreased ability to move within a weight-bearing posture. Meanwhile, research has demonstrated moderate relationships between balance function and parameters such as gait speed, independence, wheelchair mobility, reaching, as well as dressing. Some tenable support on the effectiveness of treatment of disturbed balance can be found in studies comparing the effects of balance retraining plus physiotherapy treatment and physiotherapy treatment alone.

9. Fall prevention

  • In Stroke Physical Therapy, falls are one of the most frequent complications and the consequences of which are likely to have a negative effect on the rehabilitation process and its outcome.
  • According to the systematic review of the Cochrane Library, which evaluated the effectiveness of several fall prevention interventions in the elderly, there was significant protection against falling from interventions that targeted multiple, identified, risk factors in individual patients. The same is true for interventions which focused on behavioral interventions targeting environmental hazards plus other risk factors

10. Gait re-education

  • Recovery of independent mobility is an important goal for the immobile patient, and much therapy is devoted to gait-reeducation. Bobath assumes abnormal postural reflex activity is caused by dysfunction so gait training involved tone normalization and preparatory activity for gait activity.
  • In contrast, Carr and Shepherd advocate task-related training with methods to increase strength, coordination and flexible MS system to develop skill in walking while Treadmill training combined with the use of a suspension tube. Some patient’s body weight can effective in regaining walking ability when used as an adjunct to convention therapy 3 months after active training.

11. Functional Mobility Training

  • To handle the functional limitations of stroke patients, functional tasks are taught to them based on movement analysis principles. In Stroke Physical Therapy these tasks include bridging, rolling to sit to stand and vice versa, transfer skills, walking and staring, etc.
  • Published studies report that many patients improve during rehabilitation. The strongest evidence of benefit is from studies that have enrolled patients with chronic deficits or have included a no-treatment control group.
  • Meanwhile, early mobilization helps prevent compilations e.g. DVT, skin breakdown contracture and pneumonia. Evidence has shown better orthostatic tolerance and earlier ambulation.

12. Upper limb training

By 3 months poststroke, approximately 37% of the individuals continue to have decreased upper extremities (UE) function. Recovery of UE function lags behind that of the lower extremities because of the more complex motor skill required of the UE in daily life tasks. That means many individuals who have a stroke are at risk for a lowered quality of life. Many approaches to the physical rehabilitation of adults post-stroke exist that attempt to maximize motor skill recovery. However, the literature does not support the efficacy of any single approach. The followings are the current approaches to motor rehabilitation of the UE.

  • a. Facilitation models – They are the most common methods of intervention for the deficits in UE motor skills including Bobath, proprioceptive neuromuscular facilitation, Brunnstrom’s movement therapy, and Rood’s sensorimotor approach. There is some evidence that practice based on the facilitation models can result in improved motor control of UE. However, an intervention based on the facilitation models has not been effective in restoring the fine hand coordination required for the performance of actions.
  • b. Functional electric stimulation – In Stroke Physical Therapy, Functional electric stimulation (FES) can be effective in increasing the electric activity of muscles or increased active range of motion in individuals with stroke. Some evidence showed that FES may be more effective than facilitation approaches.
  • c. Electromyographic biofeedback – In Stroke Physical Therapy, biofeedback can contribute to improvements in motor control at the neuromuscular and movement levels. Some studies have shown improvements in the ability to perform actions during post-testing after biofeedback training. However, the ability to generalize these skills and incorporate them into daily life is not measured.
  • d. Constraint-induced therapy – Constraint-Induced (CI) therapy was designed to overcome the learned nonuse of the affected UE. In the most extreme form of CI therapy, individual post-stroke is prevented from using the less affected UE by keeping it in a splint and sling for at least 90% of their waking hours. Studies have found that the most extreme of CI therapy can effect rapid improvement in UE motor skill and that is retained for at least as long as 2 years. However, CI therapy currently is effective only in those with distal voluntary movement.

13. Mobility appliances and equipment

  • Small changes in an individual’s local ‘environment’ can greatly increase independence, use of a wheelchair or walking stick. However, little research has been done for these ‘treatments’. It is acknowledged that walking aids and mobility appliances may benefit selected patients.

14. Acupuncture 

  • The World Health Organisation (WHO) has listed acupuncture as a possible treatment for pariesis after stroke. Studies had sown its beneficial effects on stroke rehabilitation.
  • Hua had reported a significant difference in changes of neurological score between the acupuncture group and the control group after 4 weeks of treatment in an RCT and no adverse effects were observed in patients treated with acupuncture.

15. Vasomotor training 

  • Early stimulation of the muscle pump can reduce the venous stasis and enhance the general circulation of the body. It then hastens the recovery process.

16. Edema management

  • Use of intermittent pneumatic pump, elastic stocking or bandages and massage can facilitate the venous return of the oedematous limbs. Therefore, the elasticity and flexibility of the musculoskeletal system can be maintained and enhance the recovery process and prevent complications like pressure ulcers.

Homeopathic Medicines for Hemiplegia

Homeopathic medicines cannot cure hemiplegia. However, the medicines can be administered to improve the state of paralysis, improve blood circulation, help control loss of power, improve the power of muscles to come extent and improve the overall health of the patient.

Some common medicines for hemiplegia and such states of paralysis are:

  • Plumbum Metallicum – This medicine is sourced by processing and potentizing the metal lead. It helps the neuro-muscular system of the body. It is administered with the intention to improve some muscle power. Plumbum met, as it is called, may be indicated all kinds of paralysis such as hemiplegia, paraplegia, and quadriplegia. As said earlier, it cannot cure paralysis as such.
  • Causticum Similar to the above medicine, Causticum is also a friend to all paralysis patients. It is aimed at improving some muscle power and not cure it.
  • Nux vomicaThis herbal medicine helps in the early stages of hemiplegia and not after some months or years.
  • Lathyrus sativus – This is another example of a toxin transformed into medicine. It is safe, There are some spasticity and stiffness in some muscles, in the cases of hemiplegia, where Lathyrus may be called for.
  • GelsemiumThis plant remedy is useful for early cases of paralysis including hemiplegia. It is supposed to improve muscle strength in the cases of paralysis.

amzn_assoc_placement = “adunit0”;
amzn_assoc_search_bar = “false”;
amzn_assoc_tracking_id = “raharun-20”;
amzn_assoc_ad_mode = “search”;
amzn_assoc_ad_type = “smart”;
amzn_assoc_marketplace = “amazon”;
amzn_assoc_region = “US”;
amzn_assoc_title = “Shop Related Products”;
amzn_assoc_default_search_phrase = “stroke recovery machine”;
amzn_assoc_default_category = “All”;
amzn_assoc_linkid = “a38e31d09cae256cbcced58ec6497a3a”;

Prevention

Reducing the number of controllable risk factors is the best way to prevent a stroke.  This can include:

  • Stopping smoking
  • Losing weight
  • Eating a balanced diet low in sodium and saturated and trans fat
  • Moderating alcohol intake (no more than 2 small drinks per day)
  • Exercising regularly in order to stay physically fit
  • Maintaining good control of existing medical conditions such as diabetes, high blood pressure and high cholesterol.

Referances

What Is Spastic Hemiplegia

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

How Do I Treat Dry Gangrene? Causes

How Do I Treat Dry Gangrene/Dry gangrene is a form of coagulative necrosis that develops in ischemic tissue, where the blood supply is inadequate to keep tissue viable. It is not a disease itself, but a symptom of other diseases.[10] Dry gangrene is often due to peripheral artery disease but can be due to acute limb ischemia. As a result, people with arteriosclerosis, high cholesterol, diabetes, and smoking commonly have dry gangrene.

Gangrene localized death of animal soft tissue, caused by prolonged interruption of the blood supply that may result from injury or infection. Diseases in which gangrene is prone to occur include arteriosclerosis, diabetes, Raynaud’s disease, thromboangiitis obliterans (Buerger’s disease), and typhus. It also may occur after severe burns, freezing, or prolonged bed rest (bed sores).

Gangrene is a rapidly progressive life-threatening infection of skeletal muscle caused by clostridia (principally Clostridium perfringens). It is due to wound contamination in the setting of severe tissue trauma, inadequate surgical débridement, immunosuppression, and impaired blood supply. Rarely, nontraumatic gas gangrene caused by Clostridium septicum may occur in patients with occult gastrointestinal malignancies and lead to transient bacteremia.

Gangrene is a type of tissue death caused by a lack of blood supply.[rx] Symptoms may include a change in skin color to red or black, numbness, swelling, pain, skin breakdown, and coolness.[rx] The feet and hands are most commonly affected.[rx] Certain types may present with a fever or sepsis.[rx]

Types of Gangrene

How Do I Treat Dry Gangrene

Dry gangrene

  • Dry gangrene is a form of coagulative necrosis that develops in ischemic tissue, where the blood supply is inadequate to keep tissue viable. It is not a disease itself, but a symptom of other diseases.[10] Dry gangrene is often due to peripheral artery disease but can be due to acute limb ischemia. As a result, people with arteriosclerosis, high cholesterol, diabetes, and smoking commonly have dry gangrene.[11] 
  • The affected area becomes cold and numb.
  • Initially, the affected area becomes red.
  • Then, it develops a brown discoloration.
  • Finally, it becomes black and shriveled.

Wet gangrene

  • Wet or infected, gangrene is characterized by thriving bacteria and has a poor prognosis (compared to dry gangrene) due to sepsis resulting from the free communication between infected fluid and circulatory fluid. In wet gangrene, the tissue is infected by saprogenic microorganisms (Clostridium perfringens or Bacillus fusiformis, for example), which cause the tissue to swell and emit a bad smell. Wet gangrene usually develops rapidly due to blockage of venous (mainly) or arterial blood flow.[rx] The affected part is saturated with stagnant blood, which promotes the rapid growth of bacteria.
  • The affected area becomes swollen and decays.
  • It is extremely painful.
  • Local oozing occurs.
  • It produces a foul-smelling odor.
  • It becomes black.
  • The affected person develops a fever.

Gas gangrene

  • Gas gangrene is a bacterial infection that produces gas within tissues. It can be caused by Clostridium, most commonly alpha toxin-producing C. perfringens, or various nonclostridial species.[rx][rx] The infection spreads rapidly as the gases produced by the bacteria expand and infiltrate healthy tissue in the vicinity. Because of its ability to quickly spread to surrounding tissues, gas gangrene should be treated as a medical emergency.
  • A brown-red or bloody discharge may ooze from the affected tissues.
  • The gas produced by Clostridia may produce a crackling sensation when the affected area is pressed.
  • It becomes swollen, and blisters may develop.
  • Pain in the affected area is severe.
  • The affected person develops fever, increased heart rate, and rapid breathing if the toxins spread into the bloodstream.

Clinical consideration when gas gangrene is present.

(I) Clostridial myonecrosis (true gas gangrene)
  •  (A) Localized – crepitant or noncrepitant
  • (B) Diffuse – crepitant or noncrepitant together with toxemia
(II) Clostridial cellulitis – anaerobic or crepitant
(III) Nonclostridial
  • (A) Bacterial – aerobic androgenic infections; Staphylococcal
    fasciitis; anaerobic streptococcal infections
  • (B) Nonbacterial – mechanical trauma; infiltration from air-hose
    injury.

Internal gangrene

  • Gangrene that affects one or more of your organs, such as your intestines, gallbladder or appendix, is called internal gangrene. This type of gangrene occurs when blood flow to an internal organ is blocked — for example, when your intestines bulge through a weakened area of muscle in your abdomen (hernia) and become twisted. Internal gangrene may cause fever and severe pain. Left untreated, internal gangrene can be fatal.

Fournier’s gangrene

  • Fournier’s gangrene involves genital organs. Men are more often affected, but women can develop this type of gangrene as well. Fournier’s gangrene usually arises due to an infection in the genital area or urinary tract and causes genital pain, tenderness, redness, and swelling.

Progressive bacterial synergistic gangrene (Meleney’s gangrene)

  • This rare type of gangrene typically occurs after an operation, with painful skin lesions developing one to two weeks after surgery.

Other Types

  • Necrotizing fasciitis, also known as hemolytic streptococcal gangrene, is an infection that spreads deep into the body along tissue planes. It is characterized by infection with S.pyogenes, a gram-positive cocci bacteria.[rx]
  • Noma is a gangrene of the face.
  • Fournier gangrene is a type of necrotizing fasciitis that usually affects the genitals and groin.[rx]
  • Venous limb gangrene may be caused by heparin-induced thrombocytopenia and thrombosis.[rx]
  • Severe mesenteric ischemia may result in gangrene of the small intestine.
  • Severe ischemic colitis may result in gangrene of the large intestine.

How Do I Treat Dry Gangrene

Causes of Gangrene

All forms of gangrene happen because of a loss of blood supply to a certain area. This deprives tissue of oxygen and nutrients, causing the tissue to die.

Dry forms can also result from:

  • Vascular problems – Most commonly due to the poor health of arteries and veins in the legs and toes. This usually develops over time due to conditions such as diabetes, peripheral arterial disease, and high blood pressure.
  • Severe burns, scalds, and cold – Heat, chemical agents, and extreme cold, including frostbite, can all lead to dry gangrene. Wet gangrene may develop later.
  • Raynaud’s disease – There is impaired circulation to the ends of fingers and toes, especially in cold weather. Raynaud’s is implicated in some cases of gangrene.
  • Diabetes – Imbalanced blood sugar levels can damage blood vessels and nerves, reducing the oxygen supply to extremities.
  • Injury – Deep, crushing, or penetrating wounds that are sustained in conditions that allow bacterial infection can lead to gangrene. Examples are war zones and railway, machinery, and street accidents if lacerated and bruised tissues are contaminated.
  • Dry gangrene – If the area is infected with bacteria.
  • Embolism – The sudden blockage of an artery can lead to dry gangrene, but it also increases the risk of infection, and therefore wet gangrene.
  • Immune deficiency – If an immune system is weakened, for example by HIV, diabetes, long-time alcohol or drug abuse, or recent chemotherapy or radiotherapy, minor infections escalate more quickly and can become gangrenous.

Anorectal Causes

  • Trauma
  • Ischiorectal, perirectal, or perianal abscesses, appendicitis,
  • diverticulitis, colonic perforations
  • Perianal fistulotomy, perianal biopsy, rectal biopsy, hemorrhoidectomy, anal fissures excision
  • Steroid enemas for radiation proctitis
  • Rectal cancer

Genitourinary Causes

  • Trauma
  • Urethral strictures with urinary extravasation
  • Urethral catheterization or instrumentation, penile implants insertion, prostatic biopsy, vasectomy, hydrocele aspiration, genital piercing, intracavernosal cocaine injection
  • Periurethral infection; chronic urinary tract infections
  • Epididymitis or orchitis
  • Penile artificial implant, foreign body
  • Hemipelvectomy
  • Cancer invasion to the external genitalia
  • Diabetes,
  • Peripheral arterial disease,
  • Smoking, major trauma,
  • Alcoholism, HIV/AIDS, frostbite, and Raynaud’s syndrome.[rx][rx]

Symptoms of Gangrene

  • Coldness and numbness in the affected area
  • Pain in or beyond the affected area
  • Redness and swelling around a wound (this is often present when wet gangrene develops)
  • Sores that keep cropping up in the same place
  • Initial redness and swelling 
  • Either a loss of sensation or severe pain in the affected area
  • Sores or blisters that bleed or release a dirty-looking or foul-smelling discharge (if the gangrene is caused by an infection)
  • The skin becomes cold and pale
  • Persistent, unexplained fever, with a temperature higher than 100.4°F (38°C)
  • A bad-smelling wound
  • Striking discoloration of the skin, with shades of greenish-black, blue, red, or bronze
  • Pus or discharge from a wound
  • Blisters and a crackling feeling under the skin
  • Confusion, pain, fever, and low blood pressure, especially if the gangrene is internal
  • Shock

[stextbox id=’custom’]

Differences in features of dry gangrene, wet gangrene, and gas gangrene

Feature Dry gangrene Wet gangrene Gas gangrene
Site Commonly limbs More common in bowel Limbs
Mechanism Arterial occlusion More commonly venous obstruction Gases produced by Clostridium bacteria
Macroscopy Organ dry, shrunken, and black Part moist, soft, swollen, rotten, and dark Organ red, cold, pale, numb, shriveled up, and auto-amputation
Putrefaction Limited due to very little blood supply Marked due to congestion of organ with blood Marked due to bacteria and infiltration of gases produced by them in tissues
Line of demarcation Present at the junction between healthy and gangrenous parts No clear-cut line of demarcation No clear-cut line of demarcation
Bacteria Bacteria fail to survive Numerous present Major cause
Prognosis Generally better due to little septicemia Generally poor due to profound toxemia Generally poor due to quickly spread to the surrounding tissues

Note: Data from NHP.gov.in.

[/stextbox]

Diagnosis of Gangrene

How Do I Treat Dry Gangrene

Laboratory Studies

The following studies are indicated in patients Fournier gangrene.

  • CBC with the differential count.
  • Electrolytes, BUN, creatinine, blood glucose levels: acidosis with hyperglycemia or hypoglycemia may be present. Dehydration occurs as the disease progresses.
  • ABG sampling to provide a more accurate assessment of acid/base disturbance.
  • Blood and urine cultures.
  • Disseminated intravascular coagulation (DIC) panel (coagulation studies, fibrinogen/fibrin degradation product levels) to find evidence of severe sepsis.
  • Cultures of any open wound or abscess.
  • Fluid or tissue culture – where a small tissue or fluid sample from the affected area is tested to find out which bacteria are responsible for the condition and determine the most effective antibiotic to treat it with
  • Blood cultures – where a sample of blood is taken and put into special culture bottles and placed in a warm environment (incubated) to encourage the growth of bacteria so they can be examined further
  • Imaging tests – a range of imaging tests, such as X-rays, magnetic resonance imaging (MRI) scans or computerized tomography (CT) scans can be used to confirm the presence and spread of gangrene; these tests can also be used to study blood vessels so any blockages can be identified
  • Ankle-brachial index test – This test helps in determining arterial blood circulation and blood pressure in the lower extremities.
  • Carotid duplex test – This test is done to know the rate of blood flow through carotid arteries. It helps in exploring the presence of any plaques that may cause carotid artery disease.
  • Computed angiography and magnetic resonance angiography – These are the computerized imaging tests that are useful in studying in the blood vessels. These techniques help the vascular surgeons to know the severity of the disease.
  • Duplex ultrasound Duplex ultrasound is used to assess the blood flow status in blood vessels. With this technique, vascular surgeons easily explore the existence of an occlusion or clot and plan the treatment.
  • Skin perfusion pressure (SPP) and skin vascular resistance – SPP and skin vascular resistance measurements also help in distinguishing the patients who require vascular reconstruction or major amputation and the patients who only require foot care or require minor amputation [rx]. A prospective, double-blinded study by Castronuovo et al concluded that in ~80% cases, SPP helps in diagnosing the critical limb ischemia accurately.,
  • Ultrasonography A US finding in Fournier gangrene is a thickened wall containing hyperechoic foci that demonstrate reverberation artifacts, causing “dirty” shadowing that represents gas within the scrotal wall. Evidence of gas within the scrotal wall may be seen prior to clinical crepitus. Reactive unilateral or bilateral hydroceles may also be present. If testicular involvement occurs, there is likely an intraabdominal or retroperitoneal source of infection. US is also useful in differentiating Fournier gangrene from an inguinoscrotal incarcerated hernia; in the latter condition, gas is observed in the obstructed bowel lumen, away from the scrotal wall [].
  • Computed Tomography The CT features of Fournier gangrene include soft-tissue thickening and inflammation. CT can demonstrate asymmetric fascial thickening, any coexisting fluid collection or abscess, fat stranding around the involved structures, and subcutaneous emphysema secondary to gas-forming bacteria. The underlying cause of the Fournier gangrene, such as a perianal abscess, a fistulous tract, or an intraabdominal or retroperitoneal infectious process, may also be demonstrated at CT. In early Fournier gangrene, CT can depict progressive soft-tissue infiltration, possibly with no evidence of subcutaneous emphysema. Because the infection progresses rapidly, the early stage with lack of subcutaneous emphysema is brief and is rarely seen at CT [].

Treatment of Gangrene


Broad-Spectrum Antibiotics Coverage

  • Empiric broad-spectrum antibiotic therapy should be instituted as soon as possible until the culture results could make adjusted the therapy. The antibiotic regimen chosen must have a high degree of effectiveness against staphylococcal and streptococcal bacteria, gram-negative, coliforms, pseudomonas, Bacteroides, and clostridium.
  • Classically Triple therapy is usually recommended. Third generation cefalosporins or aminoglycosides, plus penicillin and metronidazole.
  • Clindamycin may be used as it is shown to suppress toxin production and modulate cytokine production; also use of linezolid, daptomycin, and tigecycline is warranted in cases of previous hospitalizations with prolonged antibiotic therapy which may lead to resistant Bacteroides [].

[stextbox id=’custom’]

Pharmacologic approaches for gangrene management

Pharmacologic approach Drugs class examples Mechanism of action
Pain management Opioids and opioid-like analgesics Morphine, oxycodone, dextromethorphan, tapentadol, tramadol Mimic the actions of endogenous opioid peptides by interacting with mu, delta, or kappa opioid receptors
Topical medications: capsaicin, lidocaine Provide local action on the skin to relieve pain
Circulation management Antiplatelet agents: aspirin, clopidogrel, prasugrel, ticlopidine, dipyridamole, abciximab, eptifibatide, tirofiban, ticagrelor, vorapaxar Prevent the aggregation of platelets and fibrinogenesis
Anticoagulants: heparin, fondaparinux, danaparoid, bishydroxycoumarin, warfarin, acenocoumarol, phenindione Cause activation of anticlotting factors, direct inhibition of thrombin, inhibition of synthesis of blood coagulation factor precursors (zymogens), and activation of protein C
Fibrinolytic agents: streptokinase, urokinase, alteplase, reteplase, tenecteplase Cause lysis of thrombi/clot to recanalize the occluded vessels
Antibiotics Penicillins: flucloxacillin Inhibit bacterial cell wall synthesis by binding to specific penicillin-binding proteins located inside the bacterial cell wall
Fluoroquinolones: ciprofloxacin Inhibit topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, strand supercoiling repair, and recombination
Antiprotozoals: metronidazole In reduced form, they covalently bind to DNA, disrupt its helix structure, inhibiting bacterial nucleic acid synthesis, and cause bacterial cell death
Carbapenems: ertapenem, meropenem Show bactericidal activity by inhibiting the bacterial cell wall synthesis
Glycopeptides: teicoplanin, vancomycin Inhibit the bacterial cell wall synthesis and cause cell death
Tetracyclines: doxycycline Reversibly bind to 30S ribosomal subunits and possibly to 50S subunits, block the binding of aminoacyl tRNA to mRNA, and inhibit bacterial protein synthesis
Lincosamides: clindamycin Inhibit bacterial protein synthesis by binding to 50S ribosomal subunits of the bacteria
Oxazolidinones: linezolid Selectively inhibit bacterial protein synthesis by binding to bacterial ribosomes and prevent the formation of a functional 70S initiation complex

Note: Data taken from Tripathi, NHS.org., and Drugbank.ca.

[/stextbox]

Early IV antibiotics

  • Early IV antibiotics with early surgical debridement followed by hyperbaric oxygen therapy can salvage patients with an otherwise nearly always fatal disease. Intravenous antibiotics and early surgical debridement of the necrotic tissue reduce fatality rate to about 30%. With the addition of hyperbaric oxygen therapy, this can be reduced down to 5 to 10%.
  • Hyperbaric oxygen therapy helps by halting exotoxin production by the bacteria, helps to improve the bactericidal effect of the antibiotic, treats the tissue ischemia, improves reperfusion injury of the tissue, and promotes the activation and migration of stem cells and polymorphonuclear cells.

Pain management

  • Gangrene is usually associated with intermittent claudication in the limbs of patients. Thus, it is important to effectively manage the pain to let the patient continue exercises to improve circulation.
  • Opioid analgesics are recommended for pain associated with chronic limb ischemia. Apart from vascular factors, neuropathic pain should also be managed as a priority.

Circulation management

As the senile/dry gangrene is a consequence of ischemia, improving the blood circulation in limbs helps overcome peripheral artery disease. As per the American Diabetes Association, antiplatelet therapy or platelet aggregation inhibitors are highly recommended for preventing the vascular complications in diabetes patients. In some cases, surgery may be carried out to restore the blood flow to the affected area. The main techniques used to achieve this are:

  • Bypass surgery – where the surgeon redirects the flow of blood and bypasses the blockage by connecting (grafting) one of your veins to a healthy part of an artery
  • Angioplasty – where a tiny balloon is placed into a narrow or blocked artery and is inflated to open up the vessel; a small metal tube, known as a stent, may also be inserted into the artery to help keep it open

Research suggests that both techniques are equally effective in restoring blood flow and preventing the need for amputation in the short-term. An angioplasty has the advantage of having a faster recovery time than bypass surgery, although it may not be as effective in the long-term as bypass surgery.

Lipid-lowering agents

  • Dyslipidemia plays a major role in the progression of diabetic toe gangrene. Thus, diabetes patients should undergo a regular lipid profile check-up. In a descriptive case series study performed by Memon et al, 55.11% cases were reported to have abnormal lipid profile and 44.89% cases had lipid profile within the normal range.
  • As per Wagner’s scale, the percentage of patients with superficial ulcers (Grade I), ulcer extension (Grade II), deep ulcer with abscess (Grade III), gangrene of ore foot (Grade IV), and extensive gangrene foot (Grade V) was found to be 30.61%, 19.39%, 21.42%, 16.33%, and 12.25% respectively. A significant difference (p=0.001) was found in the gangrenous diabetic foot, grade IV and grade V.

Larval debridement therapy (biosurgery)

  • In some cases, it may be possible to use larval debridement therapy, also known as biosurgery, instead of conventional surgery to remove the dead tissue. Certain types of fly larvae are ideal for this because they feed on dead and infected tissue but leave healthy tissue alone. They also help fight infection by releasing substances that kill bacteria and stimulate the healing process.
  • Maggots used for larval therapy are specially bred in a laboratory using eggs that have been treated to remove bacteria. The maggots are placed on the wound and covered with gauze, under a firm dressing, which keeps them on the wound (and out of sight). After a few days, the dressing is cut away and the maggots are removed. Medical studies have shown larval debridement therapy can achieve more effective results than surgical debridement. However, because of the nature of this type of treatment, many people are reluctant to try it.

Exercise

  • Apart from drugs, in dry gangrene patients with peripheral arterial disease, guideline-directed management and therapy should be followed to decrease arterial occlusion or impaired perfusion, prevent the progression of chronic critical limb ischemia, and improve the functional status of affected limbs.
  • This involves exercises which are done under structured or unstructured programs. Structured exercise programs include intermittent walking followed by alternate rest time. These are organized in the health care facilities and are supervised by a trained health care professional. Unstructured home-based exercise programs also include walking as a major exercise without any supervisor’s guidance.,

Massage therapy

  • Massage Therapy is also recommended to improve the circulation in limbs. Only light pressure massage is given to the affected limb to avoid any clot formation. Massage should be cautiously done in patients with a stent, with special instructions given by the health care professional.

Fasciotomy

  • It may be necessary to relieve compartment pressures. As the infection progresses into deep tissue along and under the fascia tissue compartment pressures increase, which perpetuates further tissue ischemia and necrosis. Surgical debridement should focus on removing all the necrotic tissue, and foreign bodies such as soil, debris, and shrapnel. It is also important to irrigate the wounds with copious amounts of sterile normal saline.

Hyperbaric oxygen therapy

  • It should be added to standard therapy of antibiotics and surgical debridement to help improve survival. It is important to have coordinated care of these critically ill patients with an intensivist, general surgeon, orthopedic surgeon, urologist (in the setting of Fournier’s gangrene of the testicles and perineal structures), gynecologist (in the setting of uterine gas gangrene), infectious disease specialist, hematologist/oncologist, gastroenterologist (in the setting of spontaneous gas gangrene), and hyperbaric oxygen therapy specialist. The flow of consultation starts with usually an emergency department provider and early recognition of the disease.

Conventional Radiography

  • At radiography, hyperlucencies representing soft tissue gas may be seen in the region overlying the scrotum or perineum. Subcutaneous emphysema may be seen extending from the scrotum and perineum to the inguinal regions, anterior abdominal wall, and thighs.
  • However, the absence of subcutaneous air in the scrotum or perineum does not exclude the diagnosis of Fournier gangrene. Up to 90% of patients with Fournier gangrene have been reported to have subcutaneous emphysema so that at least 10% do not demonstrate this finding [].
  • Radiography may also demonstrate significant swelling of scrotal soft tissue. Deep fascial gas is rarely seen at radiography, which represents a significant weakness of this modality in the diagnosis and evaluation of Fournier gangrene [].

Radical Surgical Debridement

  • A debridement of the necrotic tissue as soon as possible it is widely recommended Laor et al. found no significant difference between the onset time of symptoms, early surgical treatment, and mortality, but other studies from Kabay et al. [] and Korkut et al. [] show that this time interval should be as short as possible.
  • Debridement of deep fascia and muscle is not usually required as these areas are rarely involved similar to testes. Debridement should be stopped when the separation of the skin and the subcutaneous is not performed easily because the cutaneous necrosis is not a good marker. Multiple surgical debridements is the rule rather than the exception, with an average of 3.5 procedures required per patient []

Fecal and Urinary Diversion

  • Colostomy has been used for fecal diversion in cases of severe perineal involvement. The rationale for rectal diversion includes a decrease in the number of germs in the perineal region and improved wound healing. Justifications for its construction are anal sphincter involving, fecal incontinence, or continues fecal contamination of the wound’s margins. In several papers, the percentage of patients with a colostomy is around 15% depending on the series [].

Topical Therapy

  • There have been reports of the use of honey to aid wound healing. Honey has a low pH of 3.6 and contains enzymes which digest necrotic tissues it also has antibacterial property due to phenolic acid. These changes occur within a week of applying honey to the wound. Unfortunately, there is no randomized study on the efficacy of honey in these special situations. []

Hyperbaric Oxygen Therapy

  • Hyperbaric oxygen therapy implies placing the patient in an environment of increased ambient pressure while breathing 100% oxygen, resulting in enhanced oxygenation of the arterial blood and tissues and demonstrated benefits of hyperbaric oxygen include adequate oxygenation for optimal neutrophil phagocytic function, inhibition of anaerobic growth, increased fibroblast proliferation and angiogenesis, reduction of edema by vasoconstriction, and increased intracellular antibiotics transportation [].

Vacuum-Assisted Closure

  • With the recent advent of the vacuum-assisted closure (VAC) system dressing, there seems to be a dramatic improvement with minimizing skin defects and speeding tissue healing. It simply works by exposing a wound to subatmospheric pressure for an extended period to promote debridement and healing.
  • Weinfeld et al. treated four consecutive cases using negative pressure dressings (VAC) to bolster skin grafts in male genital reconstruction.

Plastic Reconstruction

  • Various workers have used different techniques to provide skin cover including transplantation of testes, free skin grafts, axial groin flaps, and myocutaneous flaps. Split thickness skin graft seems to be the treatment of choice in treating perineal and scrotal skin defects.

Home Exercise

  • A healthy, well-balanced diet and regular exercise will keep your blood pressure and cholesterol levels at a healthy level, helping prevent your blood vessels become damaged.
  • Unless advised otherwise by your doctor, you should be aiming for at least 150 minutes (2.5 hours) of moderately intense physical exercise a week.

Moderate-intensity physical activity is any activity that increases your heart and breathing rate. It may make you sweat but you’ll still be able to hold a normal conversation. Examples include:

  • fast walking
  • cycling on level ground or with few hills
  • swimming
  • tennis

You should choose physical activities you enjoy because you’re more likely to continue doing them. It’s probably unrealistic to meet these exercise targets immediately if you haven’t exercised much in the past. Aim to start gradually and build up the amount of exercise you do overtime.

Diet

  • Eating an unhealthy diet high in fat will make any existing atherosclerosis worse and increase your risk of developing gangrene.
  • Continuing to eat high-fat foods will cause more fatty plaques to build-up in your arteries. This is because fatty foods contain cholesterol.

There are 2 types of fat-saturated and unsaturated. Avoid foods that contain saturated fats because they increase levels of “bad cholesterol” in your blood.

Foods high in saturated fat include:

  • meat pies
  • sausages and fatty cuts of meat
  • butter
  • ghee (a type of butter often used in Indian cooking)
  • lard
  • cream
  • hard cheese
  • cakes and biscuits
  • food containing coconut or palm oil


Prevention of Gangrene

  • Our emergency clinicians should be aware of this severe and potentially fatal infectious disease and should not delay treatment or prompt orthopedic surgery consultation. Gas gangrene, while rare in now peace days, can be a devastating complication of almost any small wound or surgical procedure even one as common as closed reduction of fractures. It is our experience that we should give sufficient extension of the wound to provide adequate visualization of the surgical field so as to be certain that all the necrotic or foreign material has been removed.
  • Strict aseptic techniques should be observed for even the most minor procedure. Clostridial spores are ubiquitous and can reside in hospital environments, possibly on surgeons’ hands, patients’ skin, topical application, and so on.
  • The best way to prevent gas gangrene is meticulous wound debridement and delayed closure for all potentially contaminated wounds regardless of closed or open fractures.
  • Once gas gangrene is diagnosed, careful and adequate debridement should be instituted immediately to avoid further deterioration excision of necrotic tissue still the cornerstone of treatment, which should be involved with antibiotics and all other supportive treatments.
  • Systematic resuscitative efforts should be instituted immediately in whom the diagnosis of incipient gas gangrene is even considered. This cannot be overemphasized.
  • Recognized that gas gangrene may occur spontaneously and often in an immunocompromised patient, postoperative wounds may also develop gas gangrene due to the local soft tissue damage and decreasing blood supply.
  • Keep wounds clean and sterile by cleaning all wounds thoroughly with an antiseptic solution.
  • Watch for signs of infection, such as pus, redness, swelling, or unusual pain.
  • Consult a health-care provider if any wound becomes infected.
  • People with diabetes should control their blood sugar levels with proper medication.
  • Education about proper foot care is vital for people with diabetes. They should routinely examine their feet for any signs of injury or change in skin color. Any small injury should be immediately cared for. They should keep their nails trimmed and wear comfortable well-fitting shoes.


References

Dry gangrene

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

What Is The Latest Treatment of Tumor Lysis Syndrome

What Is The Latest Treatment of Tumor Lysis Syndrome/Tumor lysis syndrome (TLS) is characterized by a massive tumor cell death leading to the development of metabolic derangements and target organ dysfunction? TLS can occur as a result of cancer treatment or spontaneously. Blood cancers constitute the vast majority of TLS cases because of the sensitivity to therapy and rapid division rates.

Tumor lysis syndrome (TLS) is a potentially life-threatening condition that occurs in oncologic and hematologic patients with large tumor burden, either due to cytotoxic therapy or, less commonly, spontaneously because of massive tumor cell lysis. TLS is clinically characterized by acute renal failure, hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. While limited options are available for treating TLS, identifying patients at high risk for developing TLS and prevention in high-risk patients remain an important aspect in the treatment of cancer patients. In general, treatment of TLS consists of intensive hydration, stimulation of diuresis, and, more specifically, in the use of allopurinol and rasburicase.

Tumor lysis syndrome (TLS) describes the pathological sequela of the rapid lysis of tumor cells. The shift of potassium, phosphorus, and nucleic acid material into the extracellular space can rapidly overcome existing homeostatic mechanisms, leading to acute kidney failure, arrhythmia, and death. TLS is the most common oncologic emergency, and although commonly seen in the context of initial chemotherapeutic treatment of hematologic malignancies, increasing recognition is being paid to the occurrence of spontaneous TLS and TLS secondary to treatment of bulky solid tumors.,

Tumor lysis syndrome is a group of metabolic abnormalities that can occur as a complication during the treatment of cancer,[rx] where large amounts of tumor cells are killed off (lysed) at the same time by the treatment, releasing their contents into the bloodstream. This occurs most commonly after the treatment of lymphomas and leukemias. In oncology and hematology, this is a potentially fatal complication, and patients at increased risk for TLS should be closely monitored before, during, and after their course of chemotherapy.

What Is The Latest Treatment of Tumor Lysis Syndrome

Pathophysiology

The pathophysiology of tumor lysis syndrome is complicated. Tumor lysis syndrome is caused by the massive release of intracellular ions such as potassium, phosphorus, and nucleic acids that have been metabolized to uric acid. The main organ is responsible for the excretions of these substances in the kidney. When the compensatory response of the kidney is exhausted as a result of the massive release of intracellular ions, uric acid obstructive uropathy develops which can then progress to acute kidney injury.

Molecules called nucleotides comprise DNA. These nucleotides are units made of a phosphate group, a sugar group, and a nitrogen base. The nitrogen base is adenine, thymine, guanine or cytosine. Adenine and guanine are purines while thymine and cytosine are pyrimidines. Ribonucleic acid, however, is made up of a ribose sugar and a nitrogen base adenine, thymine, and uracil.

The metabolism of the purines adenine and guanine in a stepwise process leads to the production of xanthine. Adenine is metabolized to hypoxanthine whereas guanine is metabolized to xanthine. Xanthine is then further metabolized into uric acid in a reaction that is catalyzed by xanthine oxidase. Most mammals have the enzyme urate oxidase that can transform uric acid to allantoin which is a more soluble substance that can be easily excreted by the kidney. Human beings lack this enzyme.

Due to the rapid turnover of tumor cells, there is an overwhelming production of uric acid which then crystallizes in the renal tubules causing obstructive uropathy from and decreased glomerular filtration rate. In rat models, urate nephropathy causes an increase in both proximal and distal tubule pressure. Peritubular capillary pressure and vascular resistance also increase. Uric acid scavenges nitric oxide which is a potent vasodilator. The scavenging of nitric oxide produces vasoconstriction and kidney ischemia. Uric acid is also a potential pro-inflammatory agent and can cause the release of other cytokine-like tumor necrosis factor-alpha, protein I. These cytokines attract white blood cells and facilitate further injury to the kidney.

Electrolyte Imbalance

Hyperkalemia

The concentration of potassium within the cell is about 120 to 130 meq/L. The lysis of tumorous cells leads to a massive release of intracellular potassium. The excess potassium is usually taken up by the liver and skeletal muscle. The rest is excreted via the gastrointestinal system or the kidney. The obstructive uropathy from uric acid salts can limit the excretion of potassium. Sometimes the hyperkalemia from the solid tumor can reach a potentially life-threatening level. The risk of hyperkalemia is cardiac arrest from arrhythmia.

Hyperphosphatemia

Hyperphosphatemia is another electrolyte imbalance associated with tumor lysis syndrome. The nucleic acid has a phosphate group, and the breakdown of the tumorous cell will lead to the release of a significant amount of phosphorus into the bloodstream. Most of the phosphorus is really excreted. This ability of the kidney to handle a high load of phosphorus is inhibited by acute kidney injury or chronic kidney disease.

Hyperphosphatemia is less common in spontaneous tumor lysis syndrome than those induced by chemotherapy. It leads to the chelation of calcium causing hypocalcemia. Deposition of calcium and phosphorus salts in the kidney and soft tissues can also occur.

Hypocalcemia

Hypocalcemia in tumor lysis syndrome is mostly secondary to the chelation of phosphorus. This condition is more potentially life-threatening than hyperphosphatemia. Possible complications from hypocalcemia include arrhythmia, tetany, seizure, and death. The calcium level might still be relatively low even after the normalization of the phosphorus level because of a deficiency of 1, 25 Vitamin D.

Causes of Tumor Lysis Syndrome

Tumor lysis syndrome is most common in patients diagnosed with leukemia who have a very high white blood cell (WBC) count. It can also be seen in high-grade lymphomas especially after the initiation of aggressive chemotherapy. Other solid tumors that can cause tumor lysis syndrome are hepatoblastoma or neuroblastoma. There are reports of tumor lysis syndrome occurring spontaneously before the initiation of chemotherapy.

An international panel of experts has stratified tumors based on the risk of developing tumor lysis syndrome.

High-Risk Tumors

  • Advanced Burkitt lymphoma
  • Advanced leukemia
  • Early-stage Burkitt lymphoma or leukemia with elevated lactate dehydrogenase
  • Acute lymphocytic leukemia with WBC count greater than 100,000/microliters, or if the baseline increase of lactate dehydrogenase is twice the upper limit of normal
  • Diffuse large B-cell lymphoma and bulky disease with an elevated baseline lactate dehydrogenase of twice the upper limit of normal
  • Acute myeloid leukemia with WBC count greater than or equal to 10,000/microliters

Intermediate-Risk Tumors

  • Acute myeloid leukemia with WBC count between 25,000 and 100,000/microliters
  • Acute lymphocytic leukemia with WBC less than 100,000/microL and lactate dehydrogenase of less than twice the upper limit of normal
  • Diffuse large B-cell lymphoma with a baseline increase in lactate dehydrogenase of twice ULN but the non-bulky disease
  • Early-stage Burkitt lymphoma or leukemia with a lactate dehydrogenase of less than twice the upper limit of normal

Low-Risk Tumors

  • Solid cancers
  • Multiple myelomas
  • Indolent lymphomas
  • Chronic lymphocytic leukemia
  • Chronic myeloid leukemia
  • Acute myelogenous leukemia with a WBC count less than 25,000/microliters and a lactate dehydrogenase elevated to less than twice the upper limit of normal

There are case reports of tumor lysis syndrome associated with the administration of steroids, biological immunomodulators, and monoclonal antibodies. Agents are associated with the development of tumor lysis syndrome include:

  • Thalidomide
  • Bortezomib
  • Hydroxyurea
  • Paclitaxel
  • Fludarabine
  • Etoposide
  • Zoledronic acid

In rare instances, tumor lysis syndrome has been observed in patients under general anesthesia undergoing surgery. Other rare occurrences of tumor lysis syndrome are seen in pregnancy or high fever.

High-Risk Tumors

  • Acute lymphocytic leukemia (5.2% to 23%)
  • Acute myeloid leukemia with a WBC count greater than 75,000 (18 %)
  • B-cell acute lymphoblastic leukemia (26.4%)
  • Burkitt lymphoma (14.9%)

Intermediate-Risk Tumors

  • Acute myeloid leukemia with WBC count between 25,000 and 50,000 (6%)
  • Diffuse large B-cell lymphoma (6%)

Low-risk Tumors

  • Acute myeloid leukemia with WBC count less than 25,000 (1%)
  • Chronic lymphocytic leukemia (0.33%)
  • Chronic myelogenous leukemia (Case reports)
  • A solid tumor (Case reports)

Tumor lysis syndrome is most commonly associated with the initiation of cytotoxic chemotherapy. However, there are case reports of tumor lysis syndrome precipitated by radiation therapy, including the use of thalidomide, dexamethasone therapy, and the use of newer chemotherapeutic agents like rituximab and bortezomib.

[stextbox id=’custom’]

Risk Factors for Tumor Lysis Syndrome.

Category of Risk Factor Risk Factor Comments
Cancer mass Bulky tumor or extensive metastasis The larger the cancer mass or the higher the number of cells that will lyse with treatment, the higher the risk of clinical tumor lysis syndrome.
Organ infiltration by cancer cells Hepatomegaly, splenomegaly, and nephromegaly generally represent tumor infiltration into these organs, and therefore a larger tumor burden than that of patients without these findings.
Bone marrow involvement Healthy adults have 1.4 kg of bone marrow. A marrow that has been replaced by leukemic cells contains a cancer mass greater than 1 kg and therefore represents bulky disease.
Renal infiltration or outflow-tract obstruction Cancers that infiltrate the kidney or obstruct urine flow predispose to nephropathy from other causes, such as the tumor lysis syndrome.
Cell lysis potential The high rate of proliferation of cancer cells Lactate dehydrogenase level is a surrogate for tumor proliferation. The higher the level, the greater the risk of the tumor lysis syndrome.
Cancer-cell sensitivity to anticancer therapy Cancers that are inherently more sensitive to therapy have a higher rate of cell lysis and a greater risk of tumor lysis syndrome than the other cancers.
The intensity of initial anticancer therapy The higher the intensity of initial therapy, the greater the rate of cancer-cell lysis and the risk of the tumor lysis syndrome. For example, some protocols for acute lymphoblastic leukemia begin with a week of prednisone monotherapy, and others begin with a combination of a glucocorticoid, vincristine, asparaginase, and daunorubicin. A patient treated on the latter protocol would have a higher risk of tumor lysis syndrome.
Features on patient presentation Nephropathy before a diagnosis of cancer A patient with preexisting nephropathy from hypertension, diabetes, gout, or other causes has a greater risk for acute kidney injury and the tumor lysis syndrome.
Dehydration or volume depletion Dehydration decreases the rate of urine flow through renal tubules and increases the level of solutes (e.g., phosphorus, uric acid) that can crystallize and cause nephropathy.
Acidic urine Uric acid has a lower solubility in acidic urine and therefore crystallizes more rapidly. A patient who presents with acidic urine and hyperuricemia usually already has uric acid crystals or microcrystals in the renal tubules.
Hypotension Hypotension decreases urine flow and increases the level of solutes that can crystallize. Hypotension can also independently cause acute kidney injury.
Exposure to nephrotoxins Vancomycin, aminoglycosides, contrast agents for diagnostic imaging and other potential nephrotoxins increase the risk of acute kidney injury from the lysis of cancer cells.
Supportive care Inadequate hydration Initial boluses of normal saline until the patient is euvolemic followed by infusion of suitable intravenous fluids at two times the maintenance rate (about 180 ml/hr in an adult who can tolerate hyperhydration) increases the rate of urine flow through renal tubules, decreases the level of solutes that can crystallize and cause acute kidney injury, and decreases the time that those solutes remain in the tubules so that even if microcrystals form they may not have time to aggregate into clinically important crystals before removal by the high flow of urine.
Exogenous potassium Unless the patient has severe hypokalemia or a dysrhythmia from hypokalemia, potassium should not be included in the intravenous fluids, and potassium (from food or medications) should be minimized until the risk period for the tumor lysis syndrome has passed.
Exogenous phosphate Restricting dietary phosphate and adding a phosphate binder reduce the exogenous load of phosphate so that the kidneys need only excrete the endogenous load of phosphate released by cancer-cell lysis.
Delayed uric acid removal Allopurinol prevents the formation of new uric acid by inhibiting xanthine oxidase and preventing the conversion of xanthine to uric acid. It does not remove existing uric acid and does increase urinary excretion of xanthine, which can crystallize and cause nephropathy. Rasburicase is an enzyme that rapidly removes uric acid by converting it to allantoin, which is highly soluble and readily excreted in the urine. The longer the uric acid level remains high, the greater the risk of crystal formation and acute kidney injury.

[/stextbox]

Symptoms of Tumor Lysis Syndrome

Hyperkalemia – Potassium is mainly an intracellular ion. High turnover of tumor cells leads to a spill of potassium into the blood. Symptoms usually do not manifest until levels are high (> 7 mmol/L) [normal 3.5–5.0 mmol/L] and they include

  • cardiac conduction abnormalities (can be fatal)
  • severe muscle weakness or paralysis

Hyperphosphatemia – Like potassium, phosphates are also predominantly intracellular. Hyperphosphatemia causes acute kidney failure in tumor lysis syndrome, because of deposition of calcium phosphate crystals in the kidney parenchyma.

Hypocalcemia – Because of the hyperphosphatemia, calcium is precipitated to form calcium phosphate, leading to hypocalcemia. Symptoms of hypocalcemia include (but are not limited to):

  • Tetany
  • Sudden mental incapacity, including emotional lability
  • Parkinsonian (extrapyramidal) movement disorders
  • Papilledema
  • Myopathy

Hyperuricemia[rx] and hyperuricosuria. Massive cell death and nuclear breakdown generate large quantities of nucleic acids. Of these, the purines (adenine and guanine) are converted to uric acid via the purine degradation pathway and excreted in the urine. However, at the high concentrations of uric acid generated by tumor lysis, uric acid is apt to precipitate as monosodium urate crystals.

  • Acute uric acid nephropathy (AUAN) – due to hyperuricosuria has been a dominant cause of acute kidney failure but with the advent of effective treatments for hyperuricosuria, AUAN has become a less common cause than hyperphosphatemia. Two common conditions related to excess uric acid, gout and uric acid nephrolithiasis, are not features of tumor lysis syndrome.
  • Lactic acidosis.[rx][rx]
  • Pretreatment spontaneous tumor lysis syndrome. This entity is associated with acute kidney failure due to uric acid nephropathy prior to the institution of chemotherapy and is largely associated with lymphoma and leukemia. The important distinction between this syndrome and the post-chemotherapy syndrome is that spontaneous TLS is not associated with hyperphosphatemia.
  • One suggestion for the reason for this is that the high cell turnover rate leads to high uric acid levels through nucleobase turnover but the tumor reuses the released phosphate for the growth of new tumor cells. In post-chemotherapy TLS, tumor cells are destroyed and no new tumor cells are being synthesized

TLS is most common during cytotoxic treatment of hematologic neoplasms.[rx]

  • Dark urine reduced urine output or flank pain
  • Lack of appetite and fatigue
  • Numbness, seizures, or hallucinations
  • Muscle cramps and spasms
  • Heart palpitations symptoms are generally nonspecific and can include:
  • Kidney failure and death can occur, especially if TLS is left untreated.
  • TLS is diagnosed based on blood tests, along with signs and symptoms. Its onset may be subtle, with only a few abnormal laboratory values, but it can also present with frank kidney and organ failure.
  • Nausea with or without vomiting


Diagnosis of Tumor Lysis Syndrome

What Is The Latest Treatment of Tumor Lysis Syndrome

 

[stextbox id=’warning’]

Cairo-Bishop grading of clinical tumor lysis syndrome for adults

Variable Grade 0 Grade I Grade II Grade III Grade IV grade D
Creatinine None 1.5 times ULN. The rise in creatinine is not attributable to the chemotherapeutic agent(s) > 1.5-3.0 times ULN. The rise in creatinine is not attributable to the chemotherapeutic agent(s) > 3.0-6.0 times ULN. The rise in creatinine is not attributable to the chemotherapeutic agent(s) > 6.0 times ULN. The rise in creatinine is not attributable to the chemotherapeutic agent(s) Death
Cardiac arrhythmia None Intervention not indicated Nonurgent medical intervention indicated. Cardiac arrhythmias not attributable to the chemotherapeutic agent(s) Symptomatic and incompletely controlled medically or controlled with a device (e.g., defibrillator). Cardiac arrhythmias not attributable to the chemotherapeutic agent(s) Life-threatening (e.g., arrhythmia associated with HF, hypotension, syncope, shock). Cardiac arrhythmias not attributable to the chemotherapeutic agent(s) Death
Seizures None One brief, generalized seizure; seizure(s) well controlled by anticonvulsants or infrequent focal motor seizures not interfering with ADL Seizure in which consciousness is altered; poorly controlled seizure disorder; with breakthrough generalized seizures despite medical intervention Seizure of any kind which is prolonged, repetitive or difficult to control (e.g., status epilepticus, intractable epilepsy)

TLS should be suspected in patients with large tumor burden who develop acute kidney failure along with hyperuricemia (> 15 mg/dL) or hyperphosphatemia (> 8 mg/dL). (Most other acute kidney failure occurs with uric acid < 12 mg/dL and phosphate < 6 mg/dL). Acute uric acid nephropathy is associated with little or no urine output. The urinalysis may show uric acid crystals or amorphous urates. The hypersecretion of uric acid can be detected with a high urine uric acid – creatinine ratio > 1.0, compared to a value of 0.6–0.7 for most other causes of acute kidney failure.

[/stextbox]

Cairo-Bishop definition

In 2004, Cairo and Bishop defined a classification system for tumor lysis syndrome.[rx]

Laboratory tumor lysis syndrome: abnormality in two or more of the following, occurring within three days before or seven days after chemotherapy.

  • uric acid > 8 mg/dL or 25% increase
  • potassium > 6 meq/L or 25% increase
  • phosphate > 4.5 mg/dL or 25% increase
  • calcium < 7 mg/dL or 25% decrease

Clinical tumor lysis syndrome: laboratory tumor lysis syndrome plus one or more of the following:

  • increased serum creatinine (1.5 times upper limit of normal)
  • cardiac arrhythmia or sudden death
  • seizure

A grading scale (0–5) is used depending on the presence of lab TLS, serum creatinine, arrhythmias, or seizures.

Howard definition

In 2011, Howard proposed a refinement of the standard Cairo-Bishop definition of TLS accounting for 2 limitations:[11]

  • Two or more electrolyte laboratory abnormalities must be present simultaneously to be considered related to TLS. In fact, some patients may present with one abnormality, but later another one may develop that is unrelated to the TLS (e.g., hypocalcemia associated with sepsis).
  • A 25% change from baseline should not be considered a criterion since such increases are rarely clinically important unless the value is already outside the normal range.

Moreover, any symptomatic hypocalcemia should constitute clinical TLS.

History

The history and physical examination of patients with tumor lysis syndrome should be focused on the primary causes of the tumor lysis.

  • Time of onset of malignancy should be elicited with attention to the presence of constitutional symptoms like weight loss or anorexia. Presence of respiratory symptoms dyspnea, orthopnea, and tachypnea can be a sign of airway compression from a primary tumor.
  • Urinary symptoms such as dysuria, flank pain, and hematuria
  • Signs and symptoms that can be associated with hypocalcemia include nausea, vomiting, seizure, tetanic spasm, and change in mental status.
  • Other clinical manifestations of tumor lysis syndrome include, but are not limited to, syncopal attack, palpitation lethargy, pitting edema, facial edema, abdominal distention, and other sign of fluid overload.

Physical Examination

The physical examination should focus on the electrolyte abnormalities that are associated with tumor lysis syndrome. The physical findings associated with these abnormalities are listed below.

Hypocalcemia

Uremia for hyperuricemia and obstructive uropathy

  • Weakness
  • Lethargy
  • Malaise
  • Nausea
  • Vomiting
  • Metallic taste in the mouth
  • Irritability
  • Generalized pruritis
  • Rales and Ronchi from volume overload
  • Muffled heart sound from pericarditis secondary to uremia
  • Joint pain
  • Renal colicky pain
  • Calcium phosphate crystal deposits in the skin
  • Pruritis
  • Gangrene

The signs and symptoms of tumor lysis syndrome can develop spontaneously or about 72 hours after the initiation of chemotherapy.

Evaluation

  • Tumor lysis syndrome is diagnosed based on criteria that were developed by Cairo and Bishop. The criteria established by Cairo and Bishop have several limitations. The most crucial drawback is that the definition of tumor lysis syndrome based on this criterion requires the initiation of chemotherapy.
  • However, in clinical practice, tumor lysis syndrome can develop spontaneously without the initiation of chemotherapy. The second limitation is the use of creatinine level greater than 1.5 the upper limit for age and gender.
  • This is not standard as a patient with CKD (Chronic Kidney Disease) will have elevated creatine in the absence of AKI. The Cairo-Bishop criteria also factor the severity of tumor lysis syndrome based on the severity of illness from grade 0 (asymptomatic) to 4 (death).

Laboratory Diagnosis of Tumor Lysis Syndrome

Requires 2 or more of the following criteria achieved in the same 24-hour period from 3 days before to 7 days after chemotherapy initiation:

  • Uric acid 25% increase from baseline or greater than or equal to 8.0 mg/dL
  • Potassium 25% increase from baseline or greater than or equal to 6.0 mEq/L
  • Phosphorus 25% increase from baseline or greater than or equal to 0.5 mg/dL (greater than or equal to 6.5 mg/dL in children)
  • Calcium 25% decrease from baseline or less than or equal to 7.0 mg/dL

Clinical Diagnosis of Tumor Lysis Syndrome

Laboratory tumor lysis syndrome plus 1 or more of the following:

  • Creatinine greater than 1.5 times the upper limit of normal of an age-adjusted reference range
  • Seizure
  • Cardiac arrhythmia or sudden death

Other origins of AKI should be excluded. In the evaluation of tumor lysis syndrome, the following studies are necessary:

Imaging

  • X-Ray and CT scan of the chest to evaluate the presence of mediastinal mass and the presence of a concomitant pleural effusion
  • CT scan and an ultrasound of the abdomen and retroperitoneal structure if the mass lesion is located in the abdomen or retroperitoneum. Care must be taken with intravenous (IV) contrast because of the presence of AKI in tumor lysis syndrome.

Electrocardiography (ECG)

  • ECG is part of the workup for patients with tumor lysis syndrome to check for findings associated with hyperkalemia and hypocalcemia. Hyperkalemia is a potential cause of fatal arrhythmia in tumor lysis syndrome.

Complete Blood Count (CBC)

  • CBC helps in the diagnosis of malignancy associated with tumor lysis syndrome. The hallmark of most malignancy is leukocytosis with anemia and thrombocytopenia.

Comprehensive Metabolic Panel (CMP)

  • The metabolic derangement associated with tumor lysis syndrome is hyperkalemia, hypocalcemia, hyperphosphatemia, and hyperuricemia. Blood urea nitrogen (BUN), creatinine, and lactate dehydrogenase are also elevated in tumor lysis syndrome. CMP must be monitored between two to three times daily before and after initiation of therapy. Elevated laboratory value might be indicative of the beginning of tumor lysis syndrome.

Urine Analysis

  • Precipitation of uric acid salt can cause obstructive uropathy. In the treatment of tumor lysis syndrome, Alkalinisation of urine with sodium bicarbonate is the standard of care. Frequent urine analysis with an assessment of urine pH, specific gravity and output are mandatory.

Differential Diagnosis

Tumor lysis syndrome should be differentiated  from other clinical conditions that can cause

  • Hyperkalemia
  • Hyperphosphatemia
  • Hyperuricemia

The differential diagnosis of each electrolyte abnormalities are listed below:

Hyperkalemia

  • Hypocalcemia
  • Metabolic acidosis
  • Congenital adrenal hyperplasia
  • Toxicity from digitalis
  • Acute tubular necrosis
  • Electrical burn
  • Head trauma
  • Rhabdomyolysis
  • Thermal burns

 Hyperphosphatemia

  • Monoclonal gammopathy
  • Waldenstrom macroglobulinemia
  • Multiple Myeloma
  • Other differentials to be considered in hyperphosphatemia include:
  • Pseudohypoparathyroidism
  • Rhabdomyolysis
  • Vitamin D intoxication
  • Oral saline laxative (Phospho-soda) abuse
  • Pseudohyperphosphatemia

Hyperuricemia

  • Hyperparathyroidism
  • Hypothyroidism
  • Nephrolithiasis
  • Alcoholic ketoacidosis
  • Diabetic ketoacidosis
  • Gout
  • Pseudogout
  • Type 1 a glycogen storage disease
  • Hemolytic anemia
  • Hodgkins lymphoma
  • Uric acid nephropathy


Treatment of Tumor Lysis Syndrome

Electrolytes imbalances

Hyperkalemia – Intravenous calcium gluconate may be given to stabilize cardiac membranes for severe hyperkalemia or for electrocardiogram changes. For temporary serum reductions in potassium levels, intravenous insulin with dextrose or high dose of inhaled beta-agonists may be used. Oral sodium polystyrene resin, i.e. kayexalate, is recommended for definitive treatment of hyperkalemia. If these measures are insufficient or for severe metabolic derangements, renal replacement therapy should be considered with the consultation of nephrology.

Hyperphosphatemia – Aggressive intravenous fluid resuscitation with the maintenance of high urine output and oral phosphate binders such as sevelamer may be sufficient to improve phosphate levels. Hemodialysis may be required for severe hyperphosphatemia not controlled by these methods.

Hypocalcemia – Hypocalcemia will correct without specific intervention as phosphate levels normalize. With the exception of severe symptomatic hypocalcemia, intravenous calcium gluconate can be considered, however, it is otherwise not recommended due to elevated risk of calcium-phosphate precipitation.

Rapid Expansion of Intravascular Volume

Treatment of tumor lysis syndrome starts with rapid volume expansion. It is recommended to use crystalloids in volume expansion as this will help to increase the glomerular filtration rate (GFR) quickly. Improved GFR helps with the excretion of solutes associated with tumor lysis syndrome. The drawback to this is that the kidney functions should still be intact. Intravenous fluid should be initiated 48 hours before the start of chemotherapy and should be continued for 48 hours after chemotherapy. Hydration with about 3 to 3.5 liters/m2 per day or 4 to 5 liters per day might be needed to provide adequate hydration. This will provide a urine output of about 3 liters per day

Medications

Allopurinol

This is a structural isomer of hypoxanthine. Xanthine oxidase converts allopurinol to oxypurinol. This is the active metabolite, and it is excreted primarily by the kidney. CKD or AKI impair the elimination of oxypurinol. The level of xanthine in the urine and serum can be elevated after the administration of allopurinol because of the inhibition of the conversion of xanthine to uric acid. Xanthine by itself has limited solubility and can crystallize in the renal tubules making the obstructive uropathy associated with tumor lysis syndrome worse.

Allopurinol can decrease the production of uric acid in tumor lysis syndrome but is ineffective in the treatment of hyperuricemia associated with tumor lysis syndrome. Allopurinol is a very useful agent to prevent the development of tumor lysis syndrome.

The use of allopurinol is associated with the development of skin rash, eosinophilia, and acute hepatitis. The combination of these symptoms is called allopurinol hypersensitivity syndrome. In the treatment of tumor lysis syndrome, clinicians should be aware of a potential drug to drug interaction with azathioprine, immunosuppressive drug use in patients with solid organ transplant and autoimmune disorder.

Recombinant Urate Oxidase

A recombinant version of urate oxidase is a drug that is used to treat hyperuricemia in patients with leukemia, lymphoma, and solid tumor who are undergoing chemotherapy.

It is derived from Aspergillus by recombinant technology. The drug’s mechanism of action is the catalyzes of uric acid to allantoin, carbon dioxide, and hydrogen peroxide.

Hydrogen peroxide is a potent oxidizing agent and can cause severe methemoglobinemia or hemolytic anemia in patients with glucose 6 phosphate dehydrogenase G6PD deficiency. The Food and Drug Administration approved recombinant urate oxidase in 2009 This medication can be administered intramuscularly. It can also be given intravenously at doses of between 50 to 100 U/kg per day.

Sodium Bicarbonate for Urine Alkalinisation

The normal urine is acidic with a pH of about 5. The solubility of uric acid in urine is increased about 10-fold with the alkalinization of urine. This can be achieved by adding about 40 to 50 mEq/liter of sodium bicarbonate to the fluid use for hydration in tumor lysis syndrome.

The risk of alkalinization of the urine is a decrease in the level of ionized calcium as there is less bonding of calcium to albumin. This can worsen the hypocalcemia associated with tumor lysis syndrome leading o arrhythmia or tetany. That apart, the alkalinization of urine can favor the precipitation of calcium and phosphate salts in the kidney tubules thus making AKI in tumor lysis syndrome worse.

Therefore, alkalinization of urine with sodium bicarbonate is only advisable if rasburicase is not readily available. Even with that, the level of calcium should be serially monitored.

Calcium

Calcium chloride and calcium gluconate can be administered parenterally to treat hypocalcemia. In tumor lysis syndrome hypocalcemia is secondary to hyperphosphatemia; therefore, administration of calcium can potentiate the deposition of calcium phosphate crystals in soft tissues and the kidney making AKI worse. This might sometimes necessitate the use of hemodialysis.

Hemodialysis

This is an option that is available to use in a dire situation if the level of potassium and phosphorus is too high in the face of tumor lysis syndrome associated AKI. In tumor lysis syndrome, there is an ongoing liberation of intracellular ions. If intermittent hemodialysis is utilized for extracorporeal clearance, rebound hyperkalemia or hyperphosphatemia might develop. Because of this, continuous renal replacement therapy is the best modality for solute removal. This is done with a high flow rate for the dialysate or replacement fluid*-+. For life-threating hyperkalemia, early hemodialysis is recommended. For severe hyperphosphatemcnvmb, is, continuous renal replacement therapy might also be the best treatment modality.

Febuxostat

This medication is also a xanthine oxidase inhibitor that is relatively new to the market. It is more expensive than allopurinol. It does not cause the hypersensitivity reaction that is associated with allopurinol.

In the clinical trial, the Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies (FLORENCE), febuxostat provides better control of hyperuricemia of tumor lysis syndrome with a good safety profile and preservation of renal functions.

Alkalinization of urine

Alkalinization of urine was historically recommended in the management of TLS due to the possibility that it may increase the solubility of uric acid in urine. However, recent increasing evidence suggests that urine alkalinization is associated with increased precipitation of calcium phosphate in the renal tubules, particularly in patients with hyperphosphatemia. Therefore, alkalinization of the urine is not recommended in TLS prophylaxis and therapy anymore.

Allopurinol

Allopurinol is available as oral and intravenous formulations and prevents the conversion of hypoxanthine to xanthine and xanthine to uric acid. The renal clearance of hypoxanthine and xanthine are ten times higher than that of uric acid. Allopurinol has several drug-drug interactions, especially with 6-mercaptopurine, thiazide diuretics, azathioprine, cyclosporine, cyclophosphamide, and amoxicillin. It is necessary to adjust the dose or monitor serum levels of these drugs. The drug should be discontinued in case of skin rash due to the possibility of severe hypersensitivity reactions. Indeed, the dose of allopurinol needs to be adjusted in case of renal insufficiency.

Rasburicase

In most mammals, but not in humans, uric acid is oxidized to allantoin using the enzyme urate oxidase. In humans, uric acid is the end product of purine metabolism. Allantoin is ten times more soluble than uric acid and is easily excreted in the urine. Obtained from Aspergillus flavus, a nonrecombinant urate oxidase has been available since 1968.

Hyperkalemia may cause serious cardiac arrhythmias; therefore, potassium should be withheld from hydration fluid. Patients with potassium levels ≥6 mmol/L should be closely monitored and immediate measures should be taken (infusion of calcium gluconate, therapy with β-adrenergic agonists, and intravenous infusion of insulin and glucose).

Treating hyperphosphatemia is difficult, especially if accompanied by AKI. Oral phosphate binders are less effective, and their oral administration could be difficult in these patients. Significant hyperphosphatemia is treated best with renal replacement therapy.

Renal replacement therapy in TLS should be considered for patients with persistent hyperkalemia despite adequate therapy, severe acidosis, and volume overload unresponsive to diuretic therapy.

Volume Expansion

Once TLS has developed, efforts should be made to re-establish normal concentrations of extracellular solutes. Provided that there has not been a complete loss of kidney function, volume expansion, with a goal of increasing kidney excretion of these solutes, is the bedrock of TLS therapy.,

In addition to augmenting potassium, phosphate, and uric acid excretion, a robust urine flow rate will decrease the calcium-phosphate product in the renal tubules, decreasing the risk of crystal formation and micro-obstruction. As we discuss above, we agree with current consensus statements suggesting a target fluid intake of 3 L per day, barring contraindications.

Diuretics

Although the use of diuretics to enhance urinary flow rate may be expected to decrease the risk of tubular calcium-phosphate precipitation, this practice has not been studied. Furthermore, the hemodynamic changes associated with diuretic use may further compromise kidney function in this population. Barring clinically important volume overload, we do not routinely use diuretics in the care of patients with TLS.

[stextbox id=’grey’]

Recommendations for the prevention and treatment of tumor lysis syndrome

Low-risk disease Intermediate-risk disease High-risk disease
Diagnostic measures • No specific measures • Daily monitoring of laboratory abnormalities before and during the first 7 days of anticancer therapy • At least twice daily monitoring of laboratory abnormalities before and during the first 7 days of anticancer therapy
Preventive measures • Moderate hydration is recommended • Vigorous hydration
• Keep urinary output >100 mL/h
• Treatment with allopurinol or febuxostat should be started at least 24 hours before initiation of anticancer therapy and should be continued till normalization of uric acid levels and signs of large tumor burden are absent
• Vigorous hydration
• Keep urinary output >100 mL/h
• Single-dose 6 mg of rasburicase. Repeat doses as necessary. In the case of contraindication treatment with febuxostat
Treatment of established tumor lysis syndrome • Admission to intensive care unit with continuous cardiac monitoring and monitoring of laboratory abnormalities every 4–6 hours
• Early nephrology consultation to estimate the indications for renal replacement therapy
• Correction of electrolyte abnormalities
• Vigorous hydration, keep urinary output >100 mL/h
• Single-dose 6 mg of rasburicase. Repeat doses as necessary. In the case of contraindication, treatment with febuxostat

 

[/stextbox]


References

What Is The Latest Treatment of Tumor Lysis Syndrome

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

How Can I Insure Tumor Lysis Syndrome Not Going Doctor

How Can I Insure Tumor Lysis Syndrome Not Going Doctor/Tumor lysis syndrome (TLS) is characterized by a massive tumor cell death leading to the development of metabolic derangements and target organ dysfunction? TLS can occur as a result of cancer treatment or spontaneously. Blood cancers constitute the vast majority of TLS cases because of the sensitivity to therapy and rapid division rates.

Tumor lysis syndrome (TLS) is a potentially life-threatening condition that occurs in oncologic and hematologic patients with large tumor burden, either due to cytotoxic therapy or, less commonly, spontaneously because of massive tumor cell lysis. TLS is clinically characterized by acute renal failure, hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. While limited options are available for treating TLS, identifying patients at high risk for developing TLS and prevention in high-risk patients remain an important aspect in the treatment of cancer patients. In general, treatment of TLS consists of intensive hydration, stimulation of diuresis, and, more specifically, in the use of allopurinol and rasburicase.

Tumor lysis syndrome (TLS) describes the pathological sequela of the rapid lysis of tumor cells. The shift of potassium, phosphorus, and nucleic acid material into the extracellular space can rapidly overcome existing homeostatic mechanisms, leading to acute kidney failure, arrhythmia, and death. TLS is the most common oncologic emergency, and although commonly seen in the context of initial chemotherapeutic treatment of hematologic malignancies, increasing recognition is being paid to the occurrence of spontaneous TLS and TLS secondary to treatment of bulky solid tumors.,

Tumor lysis syndrome is a group of metabolic abnormalities that can occur as a complication during the treatment of cancer,[rx] where large amounts of tumor cells are killed off (lysed) at the same time by the treatment, releasing their contents into the bloodstream. This occurs most commonly after the treatment of lymphomas and leukemias. In oncology and hematology, this is a potentially fatal complication, and patients at increased risk for TLS should be closely monitored before, during, and after their course of chemotherapy.

How Can I Insure Tumor Lysis Syndrome Not Going Doctor

Pathophysiology

The pathophysiology of tumor lysis syndrome is complicated. Tumor lysis syndrome is caused by the massive release of intracellular ions such as potassium, phosphorus, and nucleic acids that have been metabolized to uric acid. The main organ is responsible for the excretions of these substances in the kidney. When the compensatory response of the kidney is exhausted as a result of the massive release of intracellular ions, uric acid obstructive uropathy develops which can then progress to acute kidney injury.

Molecules called nucleotides comprise DNA. These nucleotides are units made of a phosphate group, a sugar group, and a nitrogen base. The nitrogen base is adenine, thymine, guanine or cytosine. Adenine and guanine are purines while thymine and cytosine are pyrimidines. Ribonucleic acid, however, is made up of a ribose sugar and a nitrogen base adenine, thymine, and uracil.

The metabolism of the purines adenine and guanine in a stepwise process leads to the production of xanthine. Adenine is metabolized to hypoxanthine whereas guanine is metabolized to xanthine. Xanthine is then further metabolized into uric acid in a reaction that is catalyzed by xanthine oxidase. Most mammals have the enzyme urate oxidase that can transform uric acid to allantoin which is a more soluble substance that can be easily excreted by the kidney. Human beings lack this enzyme.

Due to the rapid turnover of tumor cells, there is an overwhelming production of uric acid which then crystallizes in the renal tubules causing obstructive uropathy from and decreased glomerular filtration rate. In rat models, urate nephropathy causes an increase in both proximal and distal tubule pressure. Peritubular capillary pressure and vascular resistance also increase. Uric acid scavenges nitric oxide which is a potent vasodilator. The scavenging of nitric oxide produces vasoconstriction and kidney ischemia. Uric acid is also a potential pro-inflammatory agent and can cause the release of other cytokine-like tumor necrosis factor-alpha, protein I. These cytokines attract white blood cells and facilitate further injury to the kidney.

Electrolyte Imbalance

Hyperkalemia

The concentration of potassium within the cell is about 120 to 130 meq/L. The lysis of tumorous cells leads to a massive release of intracellular potassium. The excess potassium is usually taken up by the liver and skeletal muscle. The rest is excreted via the gastrointestinal system or the kidney. The obstructive uropathy from uric acid salts can limit the excretion of potassium. Sometimes the hyperkalemia from the solid tumor can reach a potentially life-threatening level. The risk of hyperkalemia is cardiac arrest from arrhythmia.

Hyperphosphatemia

Hyperphosphatemia is another electrolyte imbalance associated with tumor lysis syndrome. The nucleic acid has a phosphate group, and the breakdown of the tumorous cell will lead to the release of a significant amount of phosphorus into the bloodstream. Most of the phosphorus is really excreted. This ability of the kidney to handle a high load of phosphorus is inhibited by acute kidney injury or chronic kidney disease.

Hyperphosphatemia is less common in spontaneous tumor lysis syndrome than those induced by chemotherapy. It leads to the chelation of calcium causing hypocalcemia. Deposition of calcium and phosphorus salts in the kidney and soft tissues can also occur.

Hypocalcemia

Hypocalcemia in tumor lysis syndrome is mostly secondary to the chelation of phosphorus. This condition is more potentially life-threatening than hyperphosphatemia. Possible complications from hypocalcemia include arrhythmia, tetany, seizure, and death. The calcium level might still be relatively low even after the normalization of the phosphorus level because of a deficiency of 1, 25 Vitamin D.

Causes of Tumor Lysis Syndrome

Tumor lysis syndrome is most common in patients diagnosed with leukemia who have a very high white blood cell (WBC) count. It can also be seen in high-grade lymphomas especially after the initiation of aggressive chemotherapy. Other solid tumors that can cause tumor lysis syndrome are hepatoblastoma or neuroblastoma. There are reports of tumor lysis syndrome occurring spontaneously before the initiation of chemotherapy.

An international panel of experts has stratified tumors based on the risk of developing tumor lysis syndrome.

High-Risk Tumors

  • Advanced Burkitt lymphoma
  • Advanced leukemia
  • Early-stage Burkitt lymphoma or leukemia with elevated lactate dehydrogenase
  • Acute lymphocytic leukemia with WBC count greater than 100,000/microliters, or if the baseline increase of lactate dehydrogenase is twice the upper limit of normal
  • Diffuse large B-cell lymphoma and bulky disease with an elevated baseline lactate dehydrogenase of twice the upper limit of normal
  • Acute myeloid leukemia with WBC count greater than or equal to 10,000/microliters

Intermediate-Risk Tumors

  • Acute myeloid leukemia with WBC count between 25,000 and 100,000/microliters
  • Acute lymphocytic leukemia with WBC less than 100,000/microL and lactate dehydrogenase of less than twice the upper limit of normal
  • Diffuse large B-cell lymphoma with a baseline increase in lactate dehydrogenase of twice ULN but the non-bulky disease
  • Early-stage Burkitt lymphoma or leukemia with a lactate dehydrogenase of less than twice the upper limit of normal

Low-Risk Tumors

  • Solid cancers
  • Multiple myelomas
  • Indolent lymphomas
  • Chronic lymphocytic leukemia
  • Chronic myeloid leukemia
  • Acute myelogenous leukemia with a WBC count less than 25,000/microliters and a lactate dehydrogenase elevated to less than twice the upper limit of normal

There are case reports of tumor lysis syndrome associated with the administration of steroids, biological immunomodulators, and monoclonal antibodies. Agents are associated with the development of tumor lysis syndrome include:

  • Thalidomide
  • Bortezomib
  • Hydroxyurea
  • Paclitaxel
  • Fludarabine
  • Etoposide
  • Zoledronic acid

In rare instances, tumor lysis syndrome has been observed in patients under general anesthesia undergoing surgery. Other rare occurrences of tumor lysis syndrome are seen in pregnancy or high fever.

High-Risk Tumors

  • Acute lymphocytic leukemia (5.2% to 23%)
  • Acute myeloid leukemia with a WBC count greater than 75,000 (18 %)
  • B-cell acute lymphoblastic leukemia (26.4%)
  • Burkitt lymphoma (14.9%)

Intermediate-Risk Tumors

  • Acute myeloid leukemia with WBC count between 25,000 and 50,000 (6%)
  • Diffuse large B-cell lymphoma (6%)

Low-risk Tumors

  • Acute myeloid leukemia with WBC count less than 25,000 (1%)
  • Chronic lymphocytic leukemia (0.33%)
  • Chronic myelogenous leukemia (Case reports)
  • A solid tumor (Case reports)

Tumor lysis syndrome is most commonly associated with the initiation of cytotoxic chemotherapy. However, there are case reports of tumor lysis syndrome precipitated by radiation therapy, including the use of thalidomide, dexamethasone therapy, and the use of newer chemotherapeutic agents like rituximab and bortezomib.

[stextbox id=’custom’]

Risk Factors for Tumor Lysis Syndrome.

Category of Risk Factor Risk Factor Comments
Cancer mass Bulky tumor or extensive metastasis The larger the cancer mass or the higher the number of cells that will lyse with treatment, the higher the risk of clinical tumor lysis syndrome.
Organ infiltration by cancer cells Hepatomegaly, splenomegaly, and nephromegaly generally represent tumor infiltration into these organs, and therefore a larger tumor burden than that of patients without these findings.
Bone marrow involvement Healthy adults have 1.4 kg of bone marrow. A marrow that has been replaced by leukemic cells contains a cancer mass greater than 1 kg and therefore represents bulky disease.
Renal infiltration or outflow-tract obstruction Cancers that infiltrate the kidney or obstruct urine flow predispose to nephropathy from other causes, such as the tumor lysis syndrome.
Cell lysis potential The high rate of proliferation of cancer cells Lactate dehydrogenase level is a surrogate for tumor proliferation. The higher the level, the greater the risk of the tumor lysis syndrome.
Cancer-cell sensitivity to anticancer therapy Cancers that are inherently more sensitive to therapy have a higher rate of cell lysis and a greater risk of tumor lysis syndrome than the other cancers.
The intensity of initial anticancer therapy The higher the intensity of initial therapy, the greater the rate of cancer-cell lysis and the risk of the tumor lysis syndrome. For example, some protocols for acute lymphoblastic leukemia begin with a week of prednisone monotherapy, and others begin with a combination of a glucocorticoid, vincristine, asparaginase, and daunorubicin. A patient treated on the latter protocol would have a higher risk of tumor lysis syndrome.
Features on patient presentation Nephropathy before a diagnosis of cancer A patient with preexisting nephropathy from hypertension, diabetes, gout, or other causes has a greater risk for acute kidney injury and the tumor lysis syndrome.
Dehydration or volume depletion Dehydration decreases the rate of urine flow through renal tubules and increases the level of solutes (e.g., phosphorus, uric acid) that can crystallize and cause nephropathy.
Acidic urine Uric acid has a lower solubility in acidic urine and therefore crystallizes more rapidly. A patient who presents with acidic urine and hyperuricemia usually already has uric acid crystals or microcrystals in the renal tubules.
Hypotension Hypotension decreases urine flow and increases the level of solutes that can crystallize. Hypotension can also independently cause acute kidney injury.
Exposure to nephrotoxins Vancomycin, aminoglycosides, contrast agents for diagnostic imaging and other potential nephrotoxins increase the risk of acute kidney injury from the lysis of cancer cells.
Supportive care Inadequate hydration Initial boluses of normal saline until the patient is euvolemic followed by infusion of suitable intravenous fluids at two times the maintenance rate (about 180 ml/hr in an adult who can tolerate hyperhydration) increases the rate of urine flow through renal tubules, decreases the level of solutes that can crystallize and cause acute kidney injury, and decreases the time that those solutes remain in the tubules so that even if microcrystals form they may not have time to aggregate into clinically important crystals before removal by the high flow of urine.
Exogenous potassium Unless the patient has severe hypokalemia or a dysrhythmia from hypokalemia, potassium should not be included in the intravenous fluids, and potassium (from food or medications) should be minimized until the risk period for the tumor lysis syndrome has passed.
Exogenous phosphate Restricting dietary phosphate and adding a phosphate binder reduce the exogenous load of phosphate so that the kidneys need only excrete the endogenous load of phosphate released by cancer-cell lysis.
Delayed uric acid removal Allopurinol prevents the formation of new uric acid by inhibiting xanthine oxidase and preventing the conversion of xanthine to uric acid. It does not remove existing uric acid and does increase urinary excretion of xanthine, which can crystallize and cause nephropathy. Rasburicase is an enzyme that rapidly removes uric acid by converting it to allantoin, which is highly soluble and readily excreted in the urine. The longer the uric acid level remains high, the greater the risk of crystal formation and acute kidney injury.

[/stextbox]

Symptoms of Tumor Lysis Syndrome

Hyperkalemia – Potassium is mainly an intracellular ion. High turnover of tumor cells leads to a spill of potassium into the blood. Symptoms usually do not manifest until levels are high (> 7 mmol/L) [normal 3.5–5.0 mmol/L] and they include

  • cardiac conduction abnormalities (can be fatal)
  • severe muscle weakness or paralysis

Hyperphosphatemia – Like potassium, phosphates are also predominantly intracellular. Hyperphosphatemia causes acute kidney failure in tumor lysis syndrome, because of deposition of calcium phosphate crystals in the kidney parenchyma.

Hypocalcemia – Because of the hyperphosphatemia, calcium is precipitated to form calcium phosphate, leading to hypocalcemia. Symptoms of hypocalcemia include (but are not limited to):

  • Tetany
  • Sudden mental incapacity, including emotional lability
  • Parkinsonian (extrapyramidal) movement disorders
  • Papilledema
  • Myopathy

Hyperuricemia[rx] and hyperuricosuria. Massive cell death and nuclear breakdown generate large quantities of nucleic acids. Of these, the purines (adenine and guanine) are converted to uric acid via the purine degradation pathway and excreted in the urine. However, at the high concentrations of uric acid generated by tumor lysis, uric acid is apt to precipitate as monosodium urate crystals.

  • Acute uric acid nephropathy (AUAN) – due to hyperuricosuria has been a dominant cause of acute kidney failure but with the advent of effective treatments for hyperuricosuria, AUAN has become a less common cause than hyperphosphatemia. Two common conditions related to excess uric acid, gout and uric acid nephrolithiasis, are not features of tumor lysis syndrome.
  • Lactic acidosis.[rx][rx]
  • Pretreatment spontaneous tumor lysis syndrome. This entity is associated with acute kidney failure due to uric acid nephropathy prior to the institution of chemotherapy and is largely associated with lymphoma and leukemia. The important distinction between this syndrome and the post-chemotherapy syndrome is that spontaneous TLS is not associated with hyperphosphatemia.
  • One suggestion for the reason for this is that the high cell turnover rate leads to high uric acid levels through nucleobase turnover but the tumor reuses the released phosphate for the growth of new tumor cells. In post-chemotherapy TLS, tumor cells are destroyed and no new tumor cells are being synthesized

TLS is most common during cytotoxic treatment of hematologic neoplasms.[rx]

  • Dark urine reduced urine output or flank pain
  • Lack of appetite and fatigue
  • Numbness, seizures, or hallucinations
  • Muscle cramps and spasms
  • Heart palpitations symptoms are generally nonspecific and can include:
  • Kidney failure and death can occur, especially if TLS is left untreated.
  • TLS is diagnosed based on blood tests, along with signs and symptoms. Its onset may be subtle, with only a few abnormal laboratory values, but it can also present with frank kidney and organ failure.
  • Nausea with or without vomiting


Diagnosis of Tumor Lysis Syndrome

How Can I Insure Tumor Lysis Syndrome Not Going Doctor

 

[stextbox id=’warning’]

Cairo-Bishop grading of clinical tumor lysis syndrome for adults

Variable Grade 0 Grade I Grade II Grade III Grade IV GradeV
Creatinine None 1.5 times ULN. The rise in creatinine is not attributable to the chemotherapeutic agent(s) > 1.5-3.0 times ULN. The rise in creatinine is not attributable to the chemotherapeutic agent(s) > 3.0-6.0 times ULN. The rise in creatinine is not attributable to the chemotherapeutic agent(s) > 6.0 times ULN. The rise in creatinine is not attributable to the chemotherapeutic agent(s) Death
Cardiac arrhythmia None Intervention not indicated Nonurgent medical intervention indicated. Cardiac arrhythmias not attributable to the chemotherapeutic agent(s) Symptomatic and incompletely controlled medically or controlled with a device (e.g., defibrillator). Cardiac arrhythmias not attributable to the chemotherapeutic agent(s) Life-threatening (e.g., arrhythmia associated with HF, hypotension, syncope, shock). Cardiac arrhythmias not attributable to the chemotherapeutic agent(s) Death
Seizures None One brief, generalized seizure; seizure(s) well controlled by anticonvulsants or infrequent focal motor seizures not interfering with ADL Seizure in which consciousness is altered; poorly controlled seizure disorder; with breakthrough generalized seizures despite medical intervention Seizure of any kind which is prolonged, repetitive or difficult to control (e.g., status epilepticus, intractable epilepsy)

TLS should be suspected in patients with large tumor burden who develop acute kidney failure along with hyperuricemia (> 15 mg/dL) or hyperphosphatemia (> 8 mg/dL). (Most other acute kidney failure occurs with uric acid < 12 mg/dL and phosphate < 6 mg/dL). Acute uric acid nephropathy is associated with little or no urine output. The urinalysis may show uric acid crystals or amorphous urates. The hypersecretion of uric acid can be detected with a high urine uric acid – creatinine ratio > 1.0, compared to a value of 0.6–0.7 for most other causes of acute kidney failure.

[/stextbox]

Cairo-Bishop definition

In 2004, Cairo and Bishop defined a classification system for tumor lysis syndrome.[rx]

Laboratory tumor lysis syndrome: abnormality in two or more of the following, occurring within three days before or seven days after chemotherapy.

  • uric acid > 8 mg/dL or 25% increase
  • potassium > 6 meq/L or 25% increase
  • phosphate > 4.5 mg/dL or 25% increase
  • calcium < 7 mg/dL or 25% decrease

Clinical tumor lysis syndrome: laboratory tumor lysis syndrome plus one or more of the following:

  • increased serum creatinine (1.5 times upper limit of normal)
  • cardiac arrhythmia or sudden death
  • seizure

A grading scale (0–5) is used depending on the presence of lab TLS, serum creatinine, arrhythmias, or seizures.

Howard definition

In 2011, Howard proposed a refinement of the standard Cairo-Bishop definition of TLS accounting for 2 limitations:[11]

  • Two or more electrolyte laboratory abnormalities must be present simultaneously to be considered related to TLS. In fact, some patients may present with one abnormality, but later another one may develop that is unrelated to the TLS (e.g., hypocalcemia associated with sepsis).
  • A 25% change from baseline should not be considered a criterion since such increases are rarely clinically important unless the value is already outside the normal range.

Moreover, any symptomatic hypocalcemia should constitute clinical TLS.

History

The history and physical examination of patients with tumor lysis syndrome should be focused on the primary causes of the tumor lysis.

  • Time of onset of malignancy should be elicited with attention to the presence of constitutional symptoms like weight loss or anorexia. Presence of respiratory symptoms dyspnea, orthopnea, and tachypnea can be a sign of airway compression from a primary tumor.
  • Urinary symptoms such as dysuria, flank pain, and hematuria
  • Signs and symptoms that can be associated with hypocalcemia include nausea, vomiting, seizure, tetanic spasm, and change in mental status.
  • Other clinical manifestations of tumor lysis syndrome include, but are not limited to, syncopal attack, palpitation lethargy, pitting edema, facial edema, abdominal distention, and other sign of fluid overload.

Physical Examination

The physical examination should focus on the electrolyte abnormalities that are associated with tumor lysis syndrome. The physical findings associated with these abnormalities are listed below.

Hypocalcemia

Uremia for hyperuricemia and obstructive uropathy

  • Weakness
  • Lethargy
  • Malaise
  • Nausea
  • Vomiting
  • Metallic taste in the mouth
  • Irritability
  • Generalized pruritis
  • Rales and Ronchi from volume overload
  • Muffled heart sound from pericarditis secondary to uremia
  • Joint pain
  • Renal colicky pain
  • Calcium phosphate crystal deposits in the skin
  • Pruritis
  • Gangrene

The signs and symptoms of tumor lysis syndrome can develop spontaneously or about 72 hours after the initiation of chemotherapy.

Evaluation

  • Tumor lysis syndrome is diagnosed based on criteria that were developed by Cairo and Bishop. The criteria established by Cairo and Bishop have several limitations. The most crucial drawback is that the definition of tumor lysis syndrome based on this criterion requires the initiation of chemotherapy.
  • However, in clinical practice, tumor lysis syndrome can develop spontaneously without the initiation of chemotherapy. The second limitation is the use of creatinine level greater than 1.5 the upper limit for age and gender.
  • This is not standard as a patient with CKD (Chronic Kidney Disease) will have elevated creatine in the absence of AKI. The Cairo-Bishop criteria also factor the severity of tumor lysis syndrome based on the severity of illness from grade 0 (asymptomatic) to 4 (death).

Laboratory Diagnosis of Tumor Lysis Syndrome

Requires 2 or more of the following criteria achieved in the same 24-hour period from 3 days before to 7 days after chemotherapy initiation:

  • Uric acid 25% increase from baseline or greater than or equal to 8.0 mg/dL
  • Potassium 25% increase from baseline or greater than or equal to 6.0 mEq/L
  • Phosphorus 25% increase from baseline or greater than or equal to 0.5 mg/dL (greater than or equal to 6.5 mg/dL in children)
  • Calcium 25% decrease from baseline or less than or equal to 7.0 mg/dL

Clinical Diagnosis of Tumor Lysis Syndrome

Laboratory tumor lysis syndrome plus 1 or more of the following:

  • Creatinine greater than 1.5 times the upper limit of normal of an age-adjusted reference range
  • Seizure
  • Cardiac arrhythmia or sudden death

Other origins of AKI should be excluded. In the evaluation of tumor lysis syndrome, the following studies are necessary:

Imaging

  • X-Ray and CT scan of the chest to evaluate the presence of mediastinal mass and the presence of a concomitant pleural effusion
  • CT scan and an ultrasound of the abdomen and retroperitoneal structure if the mass lesion is located in the abdomen or retroperitoneum. Care must be taken with intravenous (IV) contrast because of the presence of AKI in tumor lysis syndrome.

Electrocardiography (ECG)

  • ECG is part of the workup for patients with tumor lysis syndrome to check for findings associated with hyperkalemia and hypocalcemia. Hyperkalemia is a potential cause of fatal arrhythmia in tumor lysis syndrome.

Complete Blood Count (CBC)

  • CBC helps in the diagnosis of malignancy associated with tumor lysis syndrome. The hallmark of most malignancy is leukocytosis with anemia and thrombocytopenia.

Comprehensive Metabolic Panel (CMP)

  • The metabolic derangement associated with tumor lysis syndrome is hyperkalemia, hypocalcemia, hyperphosphatemia, and hyperuricemia. Blood urea nitrogen (BUN), creatinine, and lactate dehydrogenase are also elevated in tumor lysis syndrome. CMP must be monitored between two to three times daily before and after initiation of therapy. Elevated laboratory value might be indicative of the beginning of tumor lysis syndrome.

Urine Analysis

  • Precipitation of uric acid salt can cause obstructive uropathy. In the treatment of tumor lysis syndrome, Alkalinisation of urine with sodium bicarbonate is the standard of care. Frequent urine analysis with an assessment of urine pH, specific gravity and output are mandatory.

Differential Diagnosis

Tumor lysis syndrome should be differentiated  from other clinical conditions that can cause

  • Hyperkalemia
  • Hyperphosphatemia
  • Hyperuricemia

The differential diagnosis of each electrolyte abnormalities are listed below:

Hyperkalemia

  • Hypocalcemia
  • Metabolic acidosis
  • Congenital adrenal hyperplasia
  • Toxicity from digitalis
  • Acute tubular necrosis
  • Electrical burn
  • Head trauma
  • Rhabdomyolysis
  • Thermal burns

 Hyperphosphatemia

  • Monoclonal gammopathy
  • Waldenstrom macroglobulinemia
  • Multiple Myeloma
  • Other differentials to be considered in hyperphosphatemia include:
  • Pseudohypoparathyroidism
  • Rhabdomyolysis
  • Vitamin D intoxication
  • Oral saline laxative (Phospho-soda) abuse
  • Pseudohyperphosphatemia

Hyperuricemia

  • Hyperparathyroidism
  • Hypothyroidism
  • Nephrolithiasis
  • Alcoholic ketoacidosis
  • Diabetic ketoacidosis
  • Gout
  • Pseudogout
  • Type 1 a glycogen storage disease
  • Hemolytic anemia
  • Hodgkins lymphoma
  • Uric acid nephropathy


Treatment of Tumor Lysis Syndrome

Electrolytes imbalances

Hyperkalemia – Intravenous calcium gluconate may be given to stabilize cardiac membranes for severe hyperkalemia or for electrocardiogram changes. For temporary serum reductions in potassium levels, intravenous insulin with dextrose or high dose of inhaled beta-agonists may be used. Oral sodium polystyrene resin, i.e. kayexalate, is recommended for definitive treatment of hyperkalemia. If these measures are insufficient or for severe metabolic derangements, renal replacement therapy should be considered with the consultation of nephrology.

Hyperphosphatemia – Aggressive intravenous fluid resuscitation with the maintenance of high urine output and oral phosphate binders such as sevelamer may be sufficient to improve phosphate levels. Hemodialysis may be required for severe hyperphosphatemia not controlled by these methods.

Hypocalcemia – Hypocalcemia will correct without specific intervention as phosphate levels normalize. With the exception of severe symptomatic hypocalcemia, intravenous calcium gluconate can be considered, however, it is otherwise not recommended due to elevated risk of calcium-phosphate precipitation.

Rapid Expansion of Intravascular Volume

Treatment of tumor lysis syndrome starts with rapid volume expansion. It is recommended to use crystalloids in volume expansion as this will help to increase the glomerular filtration rate (GFR) quickly. Improved GFR helps with the excretion of solutes associated with tumor lysis syndrome. The drawback to this is that the kidney functions should still be intact. Intravenous fluid should be initiated 48 hours before the start of chemotherapy and should be continued for 48 hours after chemotherapy. Hydration with about 3 to 3.5 liters/m2 per day or 4 to 5 liters per day might be needed to provide adequate hydration. This will provide a urine output of about 3 liters per day

Medications

Allopurinol

This is a structural isomer of hypoxanthine. Xanthine oxidase converts allopurinol to oxypurinol. This is the active metabolite, and it is excreted primarily by the kidney. CKD or AKI impair the elimination of oxypurinol. The level of xanthine in the urine and serum can be elevated after the administration of allopurinol because of the inhibition of the conversion of xanthine to uric acid. Xanthine by itself has limited solubility and can crystallize in the renal tubules making the obstructive uropathy associated with tumor lysis syndrome worse.

Allopurinol can decrease the production of uric acid in tumor lysis syndrome but is ineffective in the treatment of hyperuricemia associated with tumor lysis syndrome. Allopurinol is a very useful agent to prevent the development of tumor lysis syndrome.

The use of allopurinol is associated with the development of skin rash, eosinophilia, and acute hepatitis. The combination of these symptoms is called allopurinol hypersensitivity syndrome. In the treatment of tumor lysis syndrome, clinicians should be aware of a potential drug to drug interaction with azathioprine, immunosuppressive drug use in patients with solid organ transplant and autoimmune disorder.

Recombinant Urate Oxidase

A recombinant version of urate oxidase is a drug that is used to treat hyperuricemia in patients with leukemia, lymphoma, and solid tumor who are undergoing chemotherapy.

It is derived from Aspergillus by recombinant technology. The drug’s mechanism of action is the catalyzes of uric acid to allantoin, carbon dioxide, and hydrogen peroxide.

Hydrogen peroxide is a potent oxidizing agent and can cause severe methemoglobinemia or hemolytic anemia in patients with glucose 6 phosphate dehydrogenase G6PD deficiency. The Food and Drug Administration approved recombinant urate oxidase in 2009 This medication can be administered intramuscularly. It can also be given intravenously at doses of between 50 to 100 U/kg per day.

Sodium Bicarbonate for Urine Alkalinisation

The normal urine is acidic with a pH of about 5. The solubility of uric acid in urine is increased about 10-fold with the alkalinization of urine. This can be achieved by adding about 40 to 50 mEq/liter of sodium bicarbonate to the fluid use for hydration in tumor lysis syndrome.

The risk of alkalinization of the urine is a decrease in the level of ionized calcium as there is less bonding of calcium to albumin. This can worsen the hypocalcemia associated with tumor lysis syndrome leading o arrhythmia or tetany. That apart, the alkalinization of urine can favor the precipitation of calcium and phosphate salts in the kidney tubules thus making AKI in tumor lysis syndrome worse.

Therefore, alkalinization of urine with sodium bicarbonate is only advisable if rasburicase is not readily available. Even with that, the level of calcium should be serially monitored.

Calcium

Calcium chloride and calcium gluconate can be administered parenterally to treat hypocalcemia. In tumor lysis syndrome hypocalcemia is secondary to hyperphosphatemia; therefore, administration of calcium can potentiate the deposition of calcium phosphate crystals in soft tissues and the kidney making AKI worse. This might sometimes necessitate the use of hemodialysis.

Hemodialysis

This is an option that is available to use in a dire situation if the level of potassium and phosphorus is too high in the face of tumor lysis syndrome associated AKI. In tumor lysis syndrome, there is an ongoing liberation of intracellular ions. If intermittent hemodialysis is utilized for extracorporeal clearance, rebound hyperkalemia or hyperphosphatemia might develop. Because of this, continuous renal replacement therapy is the best modality for solute removal. This is done with a high flow rate for the dialysate or replacement fluid*-+. For life-threating hyperkalemia, early hemodialysis is recommended. For severe hyperphosphatemcnvmb, is, continuous renal replacement therapy might also be the best treatment modality.

Febuxostat

This medication is also a xanthine oxidase inhibitor that is relatively new to the market. It is more expensive than allopurinol. It does not cause the hypersensitivity reaction that is associated with allopurinol.

In the clinical trial, the Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies (FLORENCE), febuxostat provides better control of hyperuricemia of tumor lysis syndrome with a good safety profile and preservation of renal functions.

Alkalinization of urine

Alkalinization of urine was historically recommended in the management of TLS due to the possibility that it may increase the solubility of uric acid in urine. However, recent increasing evidence suggests that urine alkalinization is associated with increased precipitation of calcium phosphate in the renal tubules, particularly in patients with hyperphosphatemia. Therefore, alkalinization of the urine is not recommended in TLS prophylaxis and therapy anymore.

Allopurinol

Allopurinol is available as oral and intravenous formulations and prevents the conversion of hypoxanthine to xanthine and xanthine to uric acid. The renal clearance of hypoxanthine and xanthine are ten times higher than that of uric acid. Allopurinol has several drug-drug interactions, especially with 6-mercaptopurine, thiazide diuretics, azathioprine, cyclosporine, cyclophosphamide, and amoxicillin. It is necessary to adjust the dose or monitor serum levels of these drugs. The drug should be discontinued in case of skin rash due to the possibility of severe hypersensitivity reactions. Indeed, the dose of allopurinol needs to be adjusted in case of renal insufficiency.

Rasburicase

In most mammals, but not in humans, uric acid is oxidized to allantoin using the enzyme urate oxidase. In humans, uric acid is the end product of purine metabolism. Allantoin is ten times more soluble than uric acid and is easily excreted in the urine. Obtained from Aspergillus flavus, a nonrecombinant urate oxidase has been available since 1968.

Hyperkalemia may cause serious cardiac arrhythmias; therefore, potassium should be withheld from hydration fluid. Patients with potassium levels ≥6 mmol/L should be closely monitored and immediate measures should be taken (infusion of calcium gluconate, therapy with β-adrenergic agonists, and intravenous infusion of insulin and glucose).

Treating hyperphosphatemia is difficult, especially if accompanied by AKI. Oral phosphate binders are less effective, and their oral administration could be difficult in these patients. Significant hyperphosphatemia is treated best with renal replacement therapy.

Renal replacement therapy in TLS should be considered for patients with persistent hyperkalemia despite adequate therapy, severe acidosis, and volume overload unresponsive to diuretic therapy.

Volume Expansion

Once TLS has developed, efforts should be made to re-establish normal concentrations of extracellular solutes. Provided that there has not been a complete loss of kidney function, volume expansion, with a goal of increasing kidney excretion of these solutes, is the bedrock of TLS therapy.,

In addition to augmenting potassium, phosphate, and uric acid excretion, a robust urine flow rate will decrease the calcium-phosphate product in the renal tubules, decreasing the risk of crystal formation and micro-obstruction. As we discuss above, we agree with current consensus statements suggesting a target fluid intake of 3 L per day, barring contraindications.

Diuretics

Although the use of diuretics to enhance urinary flow rate may be expected to decrease the risk of tubular calcium-phosphate precipitation, this practice has not been studied. Furthermore, the hemodynamic changes associated with diuretic use may further compromise kidney function in this population. Barring clinically important volume overload, we do not routinely use diuretics in the care of patients with TLS.

[stextbox id=’grey’]

Recommendations for the prevention and treatment of tumor lysis syndrome

Low-risk disease Intermediate-risk disease High-risk disease
Diagnostic measures • No specific measures • Daily monitoring of laboratory abnormalities before and during the first 7 days of anticancer therapy • At least twice daily monitoring of laboratory abnormalities before and during the first 7 days of anticancer therapy
Preventive measures • Moderate hydration is recommended • Vigorous hydration
• Keep urinary output >100 mL/h
• Treatment with allopurinol or febuxostat should be started at least 24 hours before initiation of anticancer therapy and should be continued till normalization of uric acid levels and signs of large tumor burden are absent
• Vigorous hydration
• Keep urinary output >100 mL/h
• Single-dose 6 mg of rasburicase. Repeat doses as necessary. In the case of contraindication treatment with febuxostat
Treatment of established tumor lysis syndrome • Admission to intensive care unit with continuous cardiac monitoring and monitoring of laboratory abnormalities every 4–6 hours
• Early nephrology consultation to estimate the indications for renal replacement therapy
• Correction of electrolyte abnormalities
• Vigorous hydration, keep urinary output >100 mL/h
• Single-dose 6 mg of rasburicase. Repeat doses as necessary. In the case of contraindication, treatment with febuxostat

 

[/stextbox]


References

How Can I Insure Tumor Lysis Syndrome Not Going Doctor

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

Penile Fracture; Causes, Symptoms, Diagnosis, Treatment

Penile fracture is defined as the traumatic rupture of the tunica albuginea of the corpora cavernosum. Traumatic rupture of the penis is relatively uncommon and is considered a urologic emergency [. The tunica albuginea is a bilaminar structure (inner circular, outer longitudinal) composed of collagen and elastin. Penile fracture has typical clinical signs reported as trauma to the penis, audible clicking sound, post erection detumescence with hematoma, and swelling. Structural anomalies could alter the mechanical properties of the tunica albuginea, representing a weakening factor of the corpora cavernosa and thus a predisposing factor for traumatic rupture of the penis. The need for immediate surgery is emphasized, in order to avoid erectile failure and curvature, which are typical complications of conservative treatment. Many conditions can simulate fracture penis as dorsal vein tears in the penis may mimic penile fracture.

Penile fracture is a rupture of one or both of the tunica albuginea, the fibrous coverings that envelop the penis’s corpora cavernosa. It is caused by rapid blunt force to an erect penis, usually during Sexual intercourse, or aggressive masturbation.[rx] It sometimes also involves partial or complete rupture of the urethra or injury to the dorsal nerves, veins, and arteries.[rx]

Anatomy of Penile Fracture

Fracture of the penis is a relatively uncommon form of urologic trauma. It is a disruption of the tunica albuginea of one or both corpus cavernosum due to blunt trauma to the erect penis []. It can be accompanied by partial or complete urethral rupture or by injury of the dorsal nerve and vessels [].

Tunica albuginea is one of the strongest fasciae in the human body. One reason for the increased risk of penile fracture is that the tunica albuginea stretches and thins significantly during erection: in the flaccid state it is up to 2.4 mm thick; during erection, it becomes as thin as 0.25 to 0.5 mm. Bitsch et al. and De Rose et al. proposed that an intracorporal pressure of 1500 mmHg or more during erection can tear the tunica albuginea [,].

Penile fracture

Causes of Penile Fracture

  • Vigorous sexual intercourse is the main cause of penile fracture in the Western world.
  • Trauma during sexual intercourse was the most common cause of the penile fracture.
  • Because of high energy trauma, urethral rupture is associated in up to 38% of penile fractures [].
  • Fracture of the penis is a urological emergency resulting from a tear in the tunica albuginea of the penis often due to forceful manipulation, vigorous vaginal or anal intercourse or masturbation, gunshot wounds, or any other mechanical trauma that causes forcible bending of an erect penis.
  • Less common etiologies include turning over in bed, a direct blow, forced bending, or hastily removing or applying to clothe when the penis is erect [.
  • Most commonly, it involves one of the corpora cavernosa. It may also affect both corpora cavernous, corpus spongiosum or urethra [.
  • During an erection, the thickness of the tunica albuginea decreases from 2 mm in the flaccid state to 0.25–0.5 mm. Therefore the penis is more vulnerable to traumatic injury [.
  • The most common mechanism of injury is when the penis slips out of the vagina and strikes against the symphysis pubis or perineum.

Symptoms of Penile Fracture

  • A popping or cracking sound, significant pain, swelling, immediate loss of erection leading to flaccidity, and skin hematoma of various sizes are commonly associated with the sexual event.[rx][rx]
  • Acute onset of pain, swelling, and ecchymosis of the penis during sexual intercourse indicate a penile fracture until proven otherwise.
  • Detumescence voiding difficulties and penile swelling and deviation may accompany.
  • Swelling and ecchymosis spreads to perineum, scrotum, and lower abdominal wall within the Colles fascia if the buck’s fascia gives way and produces typical butterfly-pattern ecchymosis.
  • Rolling sign can be demonstrated in fracture penis which is the movement of penile skin over the organized hematoma at the site of rupture of tunica albuginea.
  • Audible snapping or popping sound
  • Sudden loss of your erection
  • Severe pain following the injury
  • Dark bruising above the injured area
  • Bent penis
  • Blood leaking from penis
  • Difficult urination

Diagnosis of Penile Fracture

A doctor can typically diagnose a penile fracture by asking questions about how the fracture occurred and inspecting the penis.

Imaging studies for penile injuries include

  •  X-ray can be used to map out an injury to the penis that is thought to be a penile fracture. These techniques can be used to detect whether the urethra has been torn or damaged. They can also be used to identify other concerns such as injury to the arteries and veins of the penis.
  • Ultrasound Tunica albuginea is usually seen as a hyperechoic linear band in the penis covering two corpora cavernosa and the corpora spongiosa. A hypoechoic breach in this band may be seen especially along the longitudinal axis of the penis. The associated collection is also seen along with the breach.
  • MRI Tunica albuginea is a hypointense band on all sequences. A tear can be seen as a T2 hyperintense breach in this band. MRI can accurately determine if the fracture is transversely or longitudinally oriented. Also, it can accurately depict the depth and extent of tear. Magnetic resonance imaging (MRI) with a scanner that uses a magnetic field and radio-energy pulses to create detailed images of the inside of the penis.
  • Cavernosography – It is an interventional procedure and usually avoided, however, may depict the tear in corpora cavernosa.
  • Retrograde urethrography – Urethral rupture or post-traumatic stricture can be depicted by this imaging.

Treatment of Penile Fracture

  • Attempts to minimize the long-term complications of penile fractures involved the use of compression bandages, erection- inhibiting estrogens, penis splints, antibiotics, and fibrinolytic agents
  • Early conservative treatment with cold applications – pressure dressings, catheterization, anti-inflammatory drugs, antibiotics and erection suppressing drugs is now replaced with immediate surgical repair.
  • A broad-spectrum antibiotic low molecular heparin (dalteparin) were given during the hospital stay. Nocturnal erections recovered on the third postoperative day and they were mitigated with diazepam. On day 12 the catheter was removed and on day 13 the patient was released home. The antibiotic was continued at home for the next 10 days.

Surgery

  • Penile fracture is a medical emergency – and emergency surgical repair is the usual treatment. Delay in seeking treatment increases the complication rate. Non-surgical approaches result in 10–50% complication rates including erectile dysfunction, permanent penile curvature, damage to the urethra and pain during sexual intercourse, while operatively treated patients experience an 11% complication rate.[rx][rx] In some cases, retrograde urethrogram may be performed to rule out concurrent urethral injury.
  • Recovery time varies significantly – depending on the type of fracture and the specific surgical procedure. Men may be in the hospital for anywhere between one day and three weeks.
  • Fortunately – only a small fraction of men with penile fractures experience significant complications after surgery. Found that fewer than 2 percent of men who had surgery for penile fracture experienced long-term erectile dysfunction.
  • In addition – less than 3 percent experienced permanent curvature of the penis. Those numbers were significantly higher for men whose penile fractures were managed more conservatively.


References


Penile fracture

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

How Can I Enlarge My Panis Not Going To Doctor

How Can I Enlarge My Panis Not Going To Doctor/Penis Enlargement or male enhancement is any technique aimed to increase the size of a human penis. Some methods aim to increase total length, others the shaft’s girth, and yet others the glans size. Techniques include surgery, supplements, ointments, patches, and physical methods like pumping, jelqing, and traction.

Inflatable penile prosthetic (IPP) devices have been available and used for more than four decades. Often times, medical conditions causing erectile dysfunction also cause penis shortening, causing the decreased patient quality of life. To identify and review all available penis lengthening procedures that can be performed at the time of IPP insertion. An extensive, systematic literature review was performed using PubMed searching for key terms penis lengthening, inflatable penis prosthesis, penile girth, clitoroplasty, glans augmentation, and penis enhancement; all articles with subjective or objective penis length outcomes were reviewed.

Anatomy of Penis Enlargement

Lateral cross-section of the penis.

How Can I Enlarge My Panis Not Going To Doctor

Parts

  • The root of the penis (radix): It is the attached part, consisting of the bulb of the penis in the middle and the crus of the penis, one on either side of the bulb. It lies within the superficial perineal pouch.
  • Body of the penis (corpus): It has two surfaces: dorsal (posterosuperior in the erect penis), and ventral or urethral (facing downwards and backward in the flaccid penis). The ventral surface is marked by a groove in a lateral direction.
  • Epithelium of the penis consists of the shaft skin, the foreskin, and the preputial mucosa on the inside of the foreskin and covering the glans penis. The epithelium is not attached to the underlying shaft so it is free to glide to and fro.[rx]

Structure

The human penis is made up of three columns of tissue –  two corpora cavernosa lie next to each other on the dorsal side and one corpus spongiosum lies between them on the ventral side.[rx]

The enlarged and bulbous-shaped end of the corpus spongiosum forms the glans penis with two specific types of sinusoids, which supports the foreskin, or prepuce, a loose fold of skin that in adults can retract to expose the glans.[rx] The area on the underside of the penis, where the foreskin is attached, is called the frenum, or frenulum. The rounded base of the glans is called the corona. The perineal raphe is the noticeable line along the underside of the penis.

[stextbox id=’custom’]

Comparison of mean body weight, mean testicular weight, mean plasma testosterone and mean IGF-1 among experimental groups.

C MP G Testosterone GT
Bodyweight (g, s.d.) 588 (34) 579 (28) 575 (39) 552 (44) 567 (45)
Testis volume (mL, s.d.) 1.36 (0.11) 0.97 (0.05)b 1.26 (0.08)a 0.83 (0.06)ab 1.10 (0.09)a,b
Tibial length (mm) 38.4 (2.6) 36.6 (3.1) 39.1 (2.2) 35.5 (3.3) 36.8 (2.9)
Plasma testosterone (ng/mL, s.d.) 3.72 (1.91)a 0.44 (0.05)b 2.08 (0.51)a 27.5a,b 29.2a,b
Plasma IGF-1 (ng/mL, s.d.) 1445 (155) 1432 (232) 1704 (116)a,b 628 (206)a,b 1197 (126)a,b

denotes statistical significance (P < 0.05) compared to MP; denotes statistical significance (P < 0.05) compared to C.

[/stextbox]

Disorders of Penis Enlargement

How Can I Enlarge My Panis Not Going To Doctor

  • Paraphimosis – is an inability to move the foreskin forward over the glans. It can result from fluid trapped in a foreskin left retracted, perhaps following a medical procedure, or accumulation of fluid in the foreskin because of friction during vigorous sexual activity.
  • In Peyronie’s disease – anomalous scar tissue grows in the soft tissue of the penis, causing curvature. Severe cases can be improved by surgical correction.
  • A thrombosis can occur during periods of frequent and prolonged sexual activity – especially fellatio. It is usually harmless and self-corrects within a few weeks.
  • Infection with the herpes virus can occur after sexual contact with an infected carrier –  this may lead to the development of herpes sores.
  • Pudendal nerve entrapment – is a condition characterized by pain on sitting and the loss of penile sensation and orgasm. Occasionally there is a total loss of sensation and orgasm. The pudendal nerve can be damaged by narrow, hard bicycle seats and accidents. This can also occur in the clitoris of females.
  • Penile fracture – can occur if the erect penis is bent excessively. A popping or cracking sound and pain is normally associated with this event. Emergency medical assistance should be obtained as soon as possible. Prompt medical attention lowers the likelihood of permanent penile curvature.
  • In diabetes – peripheral neuropathy can cause tingling in the penile skin and possibly reduced or completely absent sensation. The reduced sensations can lead to injuries for either partner and their absence can make it impossible to have sexual pleasure through stimulation of the penis. Since the problems are caused by permanent nerve damage, preventive treatment through good control of diabetes is the primary treatment. Some limited recovery may be possible through improved diabetes control.
  • Erectile dysfunction is the inability to develop and maintain an erection sufficiently firm for satisfactory sexual performance. Diabetes is a leading cause, as is natural aging. A variety of treatments exist, most notably including the phosphodiesterase type 5 inhibitor drugs (such as sildenafil citrate, marketed as Viagra), which work by vasodilation.
  • Priapism – is a painful and potentially harmful medical condition in which the erect penis does not return to its flaccid state. Priapism lasting over four hours is a medical emergency. The causative mechanisms are poorly understood but involve complex neurological and vascular factors. Potential complications include ischemia, thrombosis, and impotence. In serious cases, the condition may result in gangrene, which may result in amputation. However, that is usually only the case if the organ is broke out and injured because of it. The condition has been associated with a variety of drugs including prostaglandin. Contrary to common knowledge, sildenafil (Viagra) will not cause it.[rx]
  • Lymphangiosclerosis – is a hardened lymph vessel, although it can feel like a hardened, almost calcified or fibrous, vein. It tends not to share the common blue tint with a vein, however. It can be felt as a hardened lump or “vein” even when the penis is flaccid and is even more prominent during an erection. It is considered a benign physical condition. It is fairly common and can follow a particularly vigorous sexual activity for men, and tends to go away if given rest and more gentle care, for example by use of lubricants.
  • Carcinoma of the penis – is rare with a reported rate of 1 person in 100,000 in developed countries. Some sources state that circumcision can protect against this disease, but this notion remains controversial among medical circles.[rx]

Developmental Disorders

Hypospadias
  • Hypospadias is a developmental disorder where the meatus is positioned wrongly at birth. Hypospadias can also occur iatrogenically by the downward pressure of an indwelling urethral catheter.[rx] It is usually corrected by surgery.
  • A micropenis is a very small penis caused by developmental or congenital problems.
  • Diphallia, or penile duplication (PD), is the condition of having two penises. However, this disorder is extremely rare.

Alleged and observed psychological disorders

  • Penis panic (koro in Malaysian/Indonesian) – delusion of shrinkage of the penis and retraction into the body. This appears to be culturally conditioned and largely limited to Ghana, Sudan, China, Japan, Southeast Asia, and West Africa.
  • In April 2008, the Kinshasa Democratic Republic of Congo, West Africa’s ‘Police arrested 14 suspected victims (of penis snatching) and sorcerers accused of using black magic or witchcraft to steal (make disappear) or shrink men’s penises to extort cash for cure, amid a wave of panic. Arrests were made in an effort to avoid bloodshed seen in Ghana a decade before when 12 penis snatchers were beaten to death by mobs.[rx]
  • Penis envy—the contested Freudian belief of all women inherently envying men for having penises.

The technique of Penis Enlargement


Physical Techniques

  • Physical techniques involve extension devices, hanging weights, and vacuum pressure. There is also significant overlap between techniques intended to enlarge the penis and techniques intended to achieve other, related objectives, such as reversing impotence, extending the duration of erections, or enhancing sexual climax.

Pumping

  • Water-based vacuum pump commonly called a “penis pump”, a vacuum erection device, or VED, creates negative pressure that expands and thereby draws blood into the penis.[rx][rx] Medically approved VEDs, which treat erectile dysfunction, limit maximum pressure, whereas the pumps commonly bought by consumers seeking penis enlargement can reach dangerous pressure, damaging penis tissue.[rx]
  • To retain tumescence after breaking the device’s airtight seal, one must constrict the penis’ base, but constriction worn over 30 minutes can permanently damage the penis and cause erectile dysfunction.[rx] Although vacuum therapy can treat erectile dysfunction sufficiently to prevent penis deterioration and shrinkage,[rx] clinical trials have not found it effective for penis enlargement.[rx][rx]


Jelqing

  • Performed on the halfway tumescent penis, jelqing is a manual manipulation of simultaneous squeezing and stroking the shaft from base to corona. Also called “milking”,[rx] the technique has ancient Arab origins.[rx] Despite many anecdotal reports of success, medical evidence is absent.[rx]
  • Journalists have dismissed the method as biologically implausible,[rx] or even impossible, albeit unlikely to seriously damage the penis.[rx] Still, if done excessively or harshly, jelqing could conceivably cause ruptures, scarring, disfigurement, and desensitization.[rx][rx]

Traction

  • Traction is a nonsurgical method to lengthen the penis by employing devices that pull at the glans of the penis for extended periods of time. As of 2013, the majority of research investigating the use of penile traction focuses on treating the curvature and shrinkage of the penis as a result of Peyronie’s disease, although some literature exists on the impact on men with short penises.[rx] Scientific evidence supports some elongation by prolonged traction.[rx]

Jelqing exercises

  • Jelqing is an exercise that some people use to try to naturally increase the size of their penis. It involves using a hand-over-hand rolling motion to move blood to the head of your penis and stretch it. It’s sometimes called “milking.”
  • There aren’t enough medical studies to suggest that jelqing can actually increase your penis size. It’s a fairly safe practice, but it may lead to pain, irritation, or scar tissue formation if you do it too often or aggressively.

Clamps and rings

  • Some people use a clamp or ring to try to stretch and elongate their penis. To use one of these devices, you place it around the base of your penis after you’ve developed an erection. It’s meant to prevent blood from flowing out of your penis.
  • Wearing one of these devices may temporarily enlarge your penis. But wearing it for more than 30 minutes can cut off blood flow and cause damage to your penile tissue.

Diet, Exercise, and Lifestyle

  • The sad truth is that in a significant number of cases, erectile dysfunction is a condition we bring upon ourselves. Even when these things aren’t the outright cause of ED, they’re almost certain to be contributing factors that make your condition worse. This is a big, expansive category that covers a lot of ground, but in a nutshell, here’s what you need to know.
  • Eating lots of leafy greens, whole grains, oysters, watermelon, and blueberries (most any fruit will work, really) will help you give your body all that it needs to improve the quality of your erections while cutting out processed foods, cigarettes and alcohol will provide further benefits. Add in a healthy dose of exercise at least three times per week, and you’re well on your way to better sexual health!

References

How Can I Enlarge My Panis Not Going To Doctor

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

Catheter Ablation, Uses, Indications, Contraindications

Catheter ablation is a procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias such as atrial fibrillation, atrial flutter, supraventricular tachycardias (SVT) and Wolff-Parkinson-White syndrome (WPW syndrome). If not controlled, such arrhythmias increase the risk of ventricular fibrillation and sudden cardiac arrest. The ablation procedure can be classified by energy source: radiofrequency ablation and cryoablation.

Ablation is the removal of material from the surface of an object by vaporization, chipping, or other erosive processes. Examples of ablative materials are described below and include spacecraft material for ascent and atmospheric reentry, ice and snow in glaciology, biological tissues in medicine and passive fire protection materials.

Sudden cardiac death (SCD) is a vital public health issue, accountable for almost 50% of all cardiovascular deaths[]. In the last three decades, SCD was the leading cause of almost 230000 to 350000 deaths per annum in the United States[]. Ventricular arrhythmias account for 25% to 36% of witnessed sudden cardiac arrests (SCA) at home and 38% to 79% of witnessed SCA in public[].

Ischemic heart disease, structural disorders, various forms of cardiomyopathy associated with myocardial fibrosis, cardiac channelopathies, myocarditis, congenital heart diseases, and other genetic rare disorders are associated with ventricular arrhythmias[].

Even though treatment for heart failure lowers mortality and SCD, it was unsuccessful in lessening ventricular tachycardia (VT) recurrences[]. Implantable cardioverter defibrillators (ICD) are very effective in eliminating VT episodes and in lowering the possibility of SCD, but they are not useful for arrhythmia prevention[]. When the VT substrate manifests, anti-arrhythmic drug treatment or catheter ablation are the current choices to reduce VT episodes[]. Catheter ablation and antiarrhythmic drug therapy though, are also limited by incomplete efficacy, unfavorable side effects, and procedural risk[]. In this review, we outline the current advances in VT treatment options and describe the imaging modalities, progress, and novel strategies.

Epicardial catheter ablation

Endocardial catheter ablation and antiarrhythmic drug treatment are currently the mainstays of VT treatment[,]. However, the procedural success rates of VT are quite variable due to the heterogeneous substrates that reflect the variety of pathophysiological processes[,]. The success rate of endocardial ablation in patients with outflow tract VT is 84%, in patients with papillary muscle VT is 60%, and in patients with idiopathic left ventricular VT is 70%[]. Moreover, the VT recurrence rates of endocardial ablation in ischemic cardiomyopathy patients are between 23% and 49% and in dilated cardiomyopathy patients between 46% and 61%[]. Non-ischemic cardiomyopathy patients have worse outcomes than ischemic cardiomyopathy patients due to scar patterns with epicardial and intramural sites[].

Epicardial ablation has emerged as a potential alternative ablation strategy in order to increase the success rate in complex substrates and to eliminate VT in patients with different cardiomyopathies and more recently in patients with Brugada syndrome[]. Percutaneous approach to the pericardial area facilitates epicardial ablation when the VT substrate is situated in the subepicardium[] (Figure ​[rx]. Adjacency to coronary circulation and the phrenic nerve may hinder the procedure in certain situations[]. In patients with previous heart surgery or previous epicardial ablation attempts, percutaneous access may not be possible and as such, video-assisted thoracoscopy may be a good and minimally invasive alternative to open surgery[].

Arrhythmia substrate is deep (blue arrow), but the radiofrequency ablation lesions are not that deep. RF: Radiofrequency.

Epicardial ablation is a safe procedure with low complication rates[]. Pericardial effusion is the most common complication[]. Damage to subdiaphragmatic organs and hemorrhage from diaphragmatic vessels have also been reported[].

Della Bella et al[] evaluated the possible benefit of endo-epicardial catheter ablation for the management of VT in 528 patients with any form of the structural cardiac disorder (Figure ​[rx]. Endo-epicardial catheter ablation resulted in a VT recurrence rate of 34.1%, in comparison to a rate of up to 50% with the standard endocardial approach[].

Endocardial and epicardial voltage mapping. A: The voltage map of the endocardium shows an area of the scar. The map is color-coded to represent bipolar electro-gram voltage (red: Dense scar, 0.5 mV; purple: Normal tissue, 1.5 mV, intervening colors represent voltage values in between); B: The voltage map of the epicardium shows a larger area of scar.

Intramyocardial infusion-needle catheter ablation

Transcoronary alcohol ablation has emerged to approach deep intramyocardial substrate in patients not amenable to endo-epicardial catheter ablation (mechanical valve, thrombus, significant comorbidities)[,]. Transcoronary alcohol ablation requires the injected dose of sterile pure ethanol with proximal balloon expansion to a culprit vessel with a target of abolishing perfusion[,] . This method can prevent recurrent VT, VT storm and can control incessant VT[,]. The exact recognition of the target vessel and the existence of collaterals may hinder the adoption of the method[].

Transcoronary alcohol ablation. Coronary angiography of the left anterior descending artery shows a septal perforator with a course to the site of the earliest activity. A balloon catheter occludes this branch and ethanol is infused (blue arrows). The ablation catheter is placed in the region of the earliest activity (red circle).

Kim et al[] introduced the novel use of cardioplegia as a mapping technique in order to identify the critical VT isthmus to facilitate effective transcoronary ethanol ablation and avoid irreversible myocardial injury. Furthermore, Sapp et al[] showed that intramyocardial needle mapping and ablation with saline infusion could create deep injuries and is a practical and efficient method. Intracoronary wire mapping and coil embolization have also been utilized just as alcohol ablation to target VT arising from intraventricular septum[]. After intracoronary wire mapping and recognition of a culprit’s vessel, coils are directed to embolize the branch, eliminating the desired target perfusion[].

Bipolar ablation

Bipolar ablation between two ablation catheters located on either position of the septum from both ventricles improves lesion transmurality because it depends less on catheter contact and alignment[,]. Bipolar ablation has the theoretical benefit of producing more powerful energy and providing deeper lesions, in comparison to two separate unipolar catheters[,]. Sakamoto et al[] recently successfully eliminated the critical VT circuit in a patient with an arrhythmogenic substrate (cardiac sarcoidosis), utilizing bipolar ablation.

Bipolar ablation. Bipolar radiofrequency ablation between the right and left ventricular septum using two catheters.

Cardiac sympathetic denervation

Accumulated evidence strongly suggests the role of sympathetic neuromodulation in controlling refractory VT[]. Cardiac sympathetic denervation surgery has been proven to be useful for the management of congenital long QT syndrome and catecholaminergic polymorphic VT[]. The procedure requires extraction of the lower fraction of the stellate ganglion and T2-T4 sympathetic thoracic ganglia[]. Complications regarding the procedure were infrequent, with 4% developing acute ptosis or Horner syndrome[]. Vaseghi et al[] showed that cardiac sympathetic denervation has greater shock-free survival as well as a considerable decline in shock burden in patients with recurrent VT or VT storm, regardless of antiarrhythmic drug therapy and catheter ablation. In addition, bilateral cardiac sympathetic denervation appeared to be more efficacious than left-sided denervation[,].

Augmented sympathetic activity leads to early and delayed afterdepolarization, enhances diffuse repolarization, leading to ventricular electrical susceptibility and increases the possibility of malignant VT[]. Stellate ganglionectomy lengthens the ventricular refractory period and raises the VF threshold, decreasing VT or VF inducibility in the context of myocardial infarction[,]. Locally invasive sympathetic ganglion block could select individuals with greater possibilities of long-term clinical benefits prior to sympathetic denervation[,].

Renal sympathetic denervation

Enhanced sympathetic tone shortens the ventricular effective refractory period, enhances automaticity, and lowers the threshold for ventricular arrhythmias[]. Feyz et al[] performed bilateral renal denervation in a patient with polymorphic VT with excellent results. Aksu et al[] also showed that catheter-based renal denervation was successful in a patient with an electrical storm due to catecholaminergic polymorphic VT. However, the microanatomy of human renal vessels has great variability. Accessory renal vessels that bifurcated early can also influence the result negatively, and there is still the absence of procedural endpoint during the technique[].

As a result, renal sympathetic denervation is not currently recognized as an ideal or approved VT treatment method[]. However, certain ventricular arrhythmias do not terminate after catheter ablation, thus making renal sympathetic denervation a possible option for patients in whom other ablative approaches were ineffective[,].

Stereotactic radioactive therapies

Despite catheter-oriented ablation, which applies radiofrequency or freezing to damaged tissues, radiotherapy is based on photons from X-rays or gamma rays to injure the desired target, mainly cancer. Through novel distribution methods such as intensity-modulated radiotherapy, a dosage of radiotherapy can be precisely and accurately directed to the desired size, while diminishing dosage to adjoining healthy tissues[,].

Ablative radiotherapy is generally a noninvasive, outpatient method, which does not involve anesthesia[,]. Potential risks consist of damage to tissue next to the ablated site, such as brain edema for intracranial lesions, pneumonitis for chest therapies, myelopathy for spinal carcinomas, or bowel perforation for abdominal locations[,]. In comparison to radiofrequency or cryo energy, the damage from ablative radiotherapy progresses over days to months, needing time for the total tissue damage to be shown[,].

The first patient was treated on a robotic radiosurgery system (CyberKnife®, Accuray, Sunnyvale, CA, United States) in 2012[]. The follow-up revealed no definite acute or late adverse effects, and a seven-month reduction burden in VT on standard antiarrhythmic drug therapy, suggesting a potential transient benefit of this method[].

Cuculich et al[] investigated five patients with increased-risk, refractory VT. The authors focused on arrhythmogenic scar sites by merging anatomical imaging with noninvasive electrocardiographic imaging during VT that was produced using an ICD[]. Patients were treated with a single dose of 25 Gy while awake, using a noninvasive distribution of accurate ablative radiation with stereotactic body radiation treatment[]. Cuculich et al[] reported a reduction in events of VT in all five patients.

Cryoablation

Catheter radiofrequency ablation of VT originating from the left ventricle’s papillary muscles has been linked to conflicting outcomes[,]. Rivera et al[] investigated twenty-one patients with drug-refractory VT, who underwent catheter cryoablation or radiofrequency ablation. Cryoablation was correlated with greater success rates and smaller recurrence rates than radiofrequency procedures, superior catheter support, and smaller frequency of polymorphic arrhythmias[]. Marai et al[] recently used cryoablation guided by intracardiac echocardiography, 3-dimensional mapping system, and image integration to treat a patient with refractory VT originating from papillary muscle with excellent results.

Surgical therapy for VT

Catheter ablation provides efficient outcomes for sustained monomorphic VT, but certain situations, such as the existence of mural thrombus and heavy calcification, can lead to adverse results[,]. Higuchi et al[] successfully treated a 67-year-old patient with sustained monomorphic VT due to ventricular scar and resistant to endocardial radiofrequency ablation, by left ventricular reconstruction with cryoablation. Li et al[] conducted a retrospective investigation of 38 consecutive surgical epicardial VT ablation procedures and compared the results with those of a propensity-matched percutaneous epicardial access control group. Surgical epicardial access after heart surgery for VT ablation showed no statistical difference in long-term results in comparison to the percutaneous epicardial group[].

Recently, Berte et al[] presented the first animal survey utilizing a more potent cryoablation system that can generate larger, transmural ventricular lesions from both the endocardium and the epicardium. Surgical cryoablation in sheep had no acute macroscopic vascular or extracardiac damage and resulted in 100% successful lesions at necropsy[].

In some patients with non-ischemic cardiomyopathy and VT refractory to standard therapy or undergoing cardiac surgery, surgical ablation may be an alternative option for potentially reducing the burden of ICD shocks during long-term follow-up[]. Liang et al[] showed that detailed arrhythmogenic substrate in the electrophysiology lab before surgery, in conjunction with a direct scar and radiofrequency ablation lesions visualization in the operating room, is crucial for guiding surgical ablation.

Extracorporeal life support for refractory VT

Extracorporeal life support is a highly efficient bridging treatment in patients with refractory VT associated with cardiogenic shock[]. Extracorporeal life support allows the usage of negative inotropic antiarrhythmic drug therapy, leads to the weaning of catecholamine delivery, thus resolving the dangerous period of the catecholamine driven electrical storm[]. The utilization of extracorporeal life support maintains hemodynamic support during an ablation procedure, while mapping and induction of VT are commenced and provides sufficient vital organ perfusion in patients with refractory VT[]. Current literature suggests the usage of extracorporeal life support, as it has proven to be a safe, practical and efficient therapeutic solution when traditional treatments have failed[].

Steroid pulse therapy

Okabe et al[] successfully treated a patient with cardiac sarcoidosis associated with VT using steroid pulse therapy.

Gene therapy

Catecholaminergic polymorphic VT (CPVT) is a rare cardiac ion channelopathy induced by anomalies in proteins that regulate Ca2+ transport in heart cells that can lead to SCD[,]. CPVT is associated with mutations in the gene encoding the cardiac RyR2, a cardiac ryanodine receptor protein which is involved in calcium homeostasis and mutations in the gene that encodes calsequestrin (CASQ2), a protein that interacts with RyR2[].

References

 

Tachycardia

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

Tachycardia Treatment, Complication, Prevention

Tachycardia Treatment/Tachycardia conventionally but arbitrarily defined as an atrial and/or ventricular rate of >100 beats per minute, is encountered commonly and can be physiological or pathological in origin. Various adverse consequences from tachycardia have been recognized, and an important one is an association between persistent tachycardia and cardiomyopathy.

Tachycardia also called tachyarrhythmia, is a heart rate that exceeds the normal resting rate.[rx] In general, a resting heart rate over 100 beats per minute is accepted as tachycardia in adults.[rx] Heart rates above the resting rate may be normal (such as with exercise) or abnormal (such as with electrical problems within the heart). The upper threshold of a normal human resting heart rate is based on age.

Cutoff values for tachycardia in different age groups are fairly well standardized; typical cutoffs are listed below:[rx]

  • 1–2 days – Tachycardia > 159 beats per minute (bpm)
  • 3–6 days – Tachycardia >166 bpm
  • 1–3 weeks – Tachycardia >182 bpm
  • 1–2 months – Tachycardia >179 bpm
  • 3–5 months – Tachycardia >186 bpm
  • 6–11 months – Tachycardia >169 bpm
  • 1–2 years – Tachycardia >151 bpm
  • 3–4 years – Tachycardia >137 bpm
  • 5–7 years – Tachycardia >133 bpm
  • 8–11 years – Tachycardia >130 bpm
  • 12–15 years – Tachycardia >119 bpm
  • >15 years – adult – Tachycardia >100 bpm

Heart rate is considered in the context of the prevailing clinical picture. For example: in sepsis >90 bpm is considered tachycardia.

Types of Tachycardia

Supraventricular

  • Atrial fibrillation
  • Atrial flutter
  • Atrial tachycardia
  • AV nodal reentrant tachycardia
  • AV reentrant tachycardia
  • Permanent junctional reciprocating tachycardia (PJRT)

Ventricular

  • Idiopathic ventricular tachycardia
  • Fascicular tachycardia (left septal ventricular tachycardia)

Ectopy

  • Frequent premature ventricular contractions
  • Frequent premature atrial contractions

Pacing

  • High-rate atrial pacing
  • Persistent rapid ventricular pacing

Atrial tachycardia tends to occur in individuals with structural heart disease, with or without heart failure, and ischemic coronary artery disease. However, focal atrial tachycardia often occurs in healthy individuals without structural heart disease. Other possible etiologies are listed below:

Causes of Tachycardia

Etiological causes

  • Hypoxia
  • Pulmonary disease
  • Ischemic heart disease
  • Stimulants: cocaine, caffeine, chocolate, ephedra
  • Alcohol
  • Metabolic disturbances
  • Digoxin toxicity
  • Heightened sympathetic tone

Some other causes of tachycardia include

  • Adrenergic storm
  • Alcohol
  • Amphetamine
  • Anemia
  • Antiarrhythmic agents
  • Anxiety
  • Atrial fibrillation
  • Atrial flutter
  • Atrial tachycardia
  • AV nodal reentrant tachycardia
  • Brugada syndrome
  • Caffeine
  • Cannabis (drug)
  • The early manifestation of circulatory shock
  • Cocaine
  • Dysautonomia
  • Exercise
  • Fear
  • Fever
  • Hypoglycemia
  • Hypovolemia
  • Hyperthyroidism
  • Hyperventilation
  • Infection
  • Junctional tachycardia
  • Methamphetamine
  • Methylphenidate
  • Multifocal atrial tachycardia
  • Nicotine
  • Pacemaker mediated
  • Pain
  • Pheochromocytoma
  • Sinus tachycardia
  • Supraventricular tachycardia
  • Tricyclic antidepressants
  • Ventricular tachycardia
  • Wolff–Parkinson–White syndrome

Symptoms of Tachycardia

  • Dizziness
  • Lightheadedness
  • Shortness of breath
  • Chest pain
  • Heart palpitations
  • Fainting (syncope)
  • Lightheadedness or dizziness
  • Rapid heartbeat or palpitations
  • Fluttering in the chest
  • Bounding pulse
  • Chest pressure, tightness or pain (angina)
  • Shortness of breath
  • Cardiac arrest
  • Fatigue
  • Unconsciousness

Diagnosis of Tachycardia

EKG can aid the diagnosis of focal atrial tachycardia. EKG features may also inform the origin of focal atrial tachycardias. Electrocardiographic features include:

  • Atrial rate: 100 to 250 BPM
  • Ventricular conduction can be variable
    • Irregular or irregularly irregular in the setting of variable AV block
    • Regular if 1 to 1, 2 to 1, or 4 to 1 AV block
  • P wave morphology
  • Unifocal, but similar in morphology to each other
  • Might be inverted
  • Differs from normal sinus P wave
  • May exhibit either long RP or short PR intervals
  • Rhythm may be paroxysmal or sustained
    • May demonstrate an increase in the rate at initiation (i.e., “warm-up,” or “rev up”)
    • May demonstrate a decrease in the rate at termination (i.e., “cool down”)

Below is a differential of similar appearing arrhythmias with their identifying features.

Narrow complex, regular tachycardias

Sinus tachycardia

  • P wave with superior axis

Atrial flutter

  • Biphasic, sawtooth appearing F wave
  • Difficult to identify isoelectric, baseline PR segment

Typical atrial flutter

  • Involves circuit around the tricuspid annulus
  • Counterclockwise flutter produces F waves that are negative in lead II and positive in lead V1
  • Clockwise flutter produces F waves that are positive in lead II and negative in lead V1

Atypical atrial flutter

  • Involves circuit around the scar, left atrium, otherwise non-cavotricuspid isthmus dependent

AVNRT

Typical, slow-fast AVNRT

  • Short RP interval
  • P wave may be absent or within the S wave

Atypical, fast-slow AVNRT

  • Long RP interval
  • P wave negative before QRS

AVRT

  • Baseline EKG may demonstrate pre-excitation
  • Antidromic (propagation proceeds through the accessory pathway, and then retrogradely through the Purkinje system, to His bundle, through the AV node and back through accessory pathway)
    • QRS width: Wide
    • RP interval: Short
  • P wave, PR interval, QRS are variable depending on accessory pathway location and conduction direction
  • Orthodromic (propagation proceeds down AV node, His bundle, Purkinje fibers, retrograde through accessory pathway and back to AV node)
  • QRS width: Narrow
  • RP interval: Long
  • Atrial tachycardia (Focal)
  • Junctional tachycardia
    • P wave may be absent or inverted
    • If retrograde VA conduction, inverted P wave may occur just before or after the QRS complex

Narrow complex, irregular tachycardia

  • Atrial fibrillation
  • Irregularly irregular rhythm
  • Atrial flutter, atrial tachycardia with variable AV block
    • Has features of atrial flutter or atrial tachycardia, although variable block leads to irregular rhythm
  •  Multifocal atrial tachycardia
    • P wave morphology with greater than or equal to 3 distinct morphologies
  •  Resting ECG
  • Holter monitoring, as arrhythmias develop when heart rate increases
  • Exercise stress test both for diagnosis and monitoring of therapy
  • Echocardiogram and/or MRI to evaluate for structural defects
  • Consultation with a clinical geneticist and/or genetic counselor

Suggestive Findings

Catecholaminergic polymorphic ventricular tachycardia (CPVT) should be suspected in individuals who have one or more of the following []:

  • Syncope occurring during physical activity or acute emotion; mean onset age seven to 12 years. Less frequently, first manifestations may occur later in life; individuals with the first event up to age 40 years are reported.
  • History of exercise- or emotion-related palpitations and dizziness in some individuals
  • Sudden unexpected cardiac death triggered by acute emotional stress or exercise
  • Family history of juvenile sudden cardiac death triggered by exercise or acute emotion
Exercise-induced polymorphic ventricular arrhythmias
  • ECG during a graded exercise (exercise stress test)* allows ventricular arrhythmias to be reproducibly elicited in the majority of affected individuals. Typically, the onset of ventricular arrhythmias is 100-120 beats/min.
  • With an increase in workload, the complexity of arrhythmias progressively increases from isolated premature beats to bigeminy and runs of non-sustained ventricular tachycardia (VT). If the affected individual continues exercising, the duration of the runs of VT progressively increases and VT may become sustained.
  • An alternating 180°-QRS axis on a beat-to-beat basis, so-called bidirectional VT, is often the distinguishing presentation of CPVT arrhythmias.
  • Some individuals with CPVT may also present with irregular polymorphic VT without a “stable” QRS vector alternans [].
  • Exercise-induced supraventricular arrhythmias (supraventricular tachycardia and atrial fibrillation) are common [].
  • Ventricular fibrillation occurring in the setting of acute stress
  • Absence of structural cardiac abnormalities

Establishing the Diagnosis

According to the most recent version of the International Guidelines on sudden cardiac death [], the diagnosis of CPVT is established

  • In the presence of a structurally normal heart, normal resting ECG, and exercise- or emotion-induced bidirectional or polymorphic ventricular tachycardia;
OR
  • In individuals who have a heterozygous pathogenic variant in RYR2 or CALM1 or biallelic pathogenic variants in CASQ2 or TRDN [rx].
  • Molecular testing approaches can include serial single-gene testing, use of a multigene panel, and more comprehensive genomic testing
Serial single-gene testing
  • Sequence analysis of RYR2 can be performed first and followed by sequence analysis of CASQ2 if no pathogenic variant is found. If no pathogenic variant in CASQ2 is found, sequence analysis of CALM1and TRDN should be performed next, keeping in mind that pathogenic variants in CALM1 and TRDN are extremely rare causes of CPVT.
  • Gene-targeted deletion/duplication analysis of RYR2 can be performed next if a pathogenic variant in RYR2 or CALM1 or biallelic pathogenic variants in CASQ2 or TRDN have not been identified [rx].
A multigene panel that includes CALM1CASQ2RYR2, and TRDN and other genes of interest (see Differential Diagnosis) may also be considered. Note:
  • The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time.
  • Some multigene panels may include genes not associated with the condition discussed in this GeneReview; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype.
  • In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician.
  • Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
    For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
More comprehensive genomic testing – (when available) including exome sequencing and genome sequencing may be considered if serial single-gene testing (and/or use of a multigene panel that includes CALM1CASQ2RYR2, and TRDN) fails to confirm a diagnosis in an individual with features of CPVT. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation).
  • Magnetic resonance imaging (MRI) A cardiac MRI can provide still or moving pictures of how the blood is flowing through the heart and detect irregularities.
  • Computerized tomography (CT)CT scans combine several X-ray images to provide a more detailed cross-sectional view of the heart.
  • Coronary angiogram –  To study the flow of blood through your heart and blood vessels, your doctor may use a coronary angiogram to reveal potential blockages or abnormalities. It uses a dye and special X-rays to show the inside of your coronary arteries.
  • Chest X-ray – This test is used to take still pictures of your heart and lungs and can detect if your heart is enlarged.

Stress Test

  • Your doctor may recommend a stress test to see how your heart functions while it is working hard during exercise or when medication is given to make it beat fast. In an exercise stress test, electrodes are placed on your chest to monitor heart function while you exercise, usually by walking on a treadmill. Other heart tests may also be performed in conjunction with a stress test.

Additional Tests

  • Your doctor may order additional tests as needed to diagnose an underlying condition that is contributing to tachycardia and judge the condition of your heart.

Event Recorder

This device is similar to a Holter monitor, but it does not record all the heartbeats. There are two types:

  • One type uses a phone to transmit signals from the recorder while the person is experiencing symptoms.
  • The other type is worn all the time for a long time. These can sometimes be worn for as long as a month.

This event recorder is good for diagnosing rhythm disturbances that happen at random moments.

Electrophysiological Testing (EP studies)

  • This is an invasive, relatively painless, non-surgical test and can help determine the type of arrhythmia, its origin, and potential response to treatment. The test is carried out in an EP lab by an electrophysiologist and makes it possible to reproduce troubling arrhythmias in a controlled setting.

Tilt-Table Test

  • If an individual experiences fainting spells, dizziness, or lightheadedness, and neither the ECG nor the Holter revealed any arrhythmias, a tilt-table test might be performed. This monitors blood pressure, heart rhythm, and heart rate while they are moved from a lying to an upright position. When reflexes work correctly, they cause the heart rate and blood pressure to change when moved to an upright position. This is to make sure the brain gets an adequate supply of blood.

Treatment of Tachycardia

But if the episodes are prolonged, or recur often, your doctor may recommend treatment, including

  • Carotid sinus massage – A healthcare professional can apply gentle pressure on the neck, where the carotid artery splits into two branches.
  • Pressing gently on the eyeballs with eyes closed. Caution – This procedure should be supervised carefully by a healthcare physician.
  • Valsalva maneuver – This consists of holding your nostrils closed while blowing air through your nose.
  • Using the dive reflex – The dive reflex is the body’s response to sudden immersion in water, especially cold water.
  • Sedation
  • Cutting down on coffee or caffeinated substances
  • Cutting down on alcohol
  • Quitting tobacco use
  • Getting more rest

Pharmacologic Treatment


  • If vagal maneuvers fail – a trial of intravenous adenosine may be given at an initial dose of 6 mg and a subsequent dose of 12 mg., Its use may serve as a diagnostic and therapeutic tool because it will terminate almost all AVNRTs and AVRTs by breaking the AV-nodal dependent circuit. In patients with non–AV-nodal dependent circuits (i.e., focal atrial tachycardia and atrial flutter), intravenous use of adenosine may prove to be a valuable diagnostic tool because the transient AV block may unmask ectopic atrial P waves or flutter waves. Patients should always be monitored by ECG during adenosine administration.
  • Adenosine – may induce a wide range of transient bradycardias (including sinus arrest and asystole) as well as atrial fibrillation, SVT and ventricular tachycardia. Albeit very rare, cases of sustained ventricular tachycardia, ventricular fibrillation, and Torsades de pointes have been reported. In patients with underlying coronary disease, adenosine may lead to coronary steal syndrome and subsequent myocardial ischemia.  Adenosine should therefore always be administered with an external pacemaker or defibrillator nearby.
  • When vagal maneuvers and adenosine – fail to terminate a narrow-complex tachycardia, intravenous treatment with a nondihydropiridine calcium-channel blocker (e.g., diltiazem and verapamil) or β-blocker may be used. Calcium-channel blockers terminate 64%–98% of SVTs in hemodynamically stable patients. Administering a calcium-channel blocker intravenously over 20 minutes has been shown to reduce the rate of hypotension. There are fewer data supporting the use of β-blockers in the acute treatment of SVT; however, they are considered reasonable choices because of their safety profile.,
  • If all aforementioned pharmacologic therapies fail – synchronized cardioversion is recommended, even in hemodynamically stable patients.
  • In patients presenting in atrial fibrillation who have known Wolff–Parkinson – White or new pre-excitation pattern on ECG, the use of potent AV-nodal blockers (i.e., β-blockers, diltiazem, verapamil, and digoxin) should be avoided because these medications may potentiate conduction over the accessory pathway and lead to potentially life-threatening ventricular arrhythmias. In these cases, intravenous use of procainamide is the preferred approach in the acute setting.
  • Adenosine is rapidly metabolized in the periphery – and therefore must be given as a rapid push through a large, ideally peripheral, intravenous route. The initial dose is 6 mg intravenously (IV) (pediatric dose 0.1 mg/kg, maximum dose of 6 mg). If the initial dose is ineffective, adenosine may be dosed again at 12 mg IVP (pediatric dose 0.2 mg/kg, maximum dose 12 mg). The second dose of adenosine 12 mg IVP may be repeated one additional time if there is no effect. Each dose of adenosine needs to be flushed rapidly with 10 mL to 20 mL normal saline. Often two-person administration, with one person administering the adenosine at a proximal IV port, and a second person flushing the IV line via a distal port immediately after adenosine administration, is required to adequate flush in the adenosine.
  • Consider reducing the adenosine dose to 3 mg – IVP if the patient is currently receiving carbamazepine or dipyridamole, is the recipient of a heart transplant, or adenosine is being given through a central line.
  • If adenosine fails – second line medications include diltiazem (0.25 mg/kg IV loading dose followed by 5mg/hr to 15 mg/hr infusion), esmolol (0.5 mg/kg IV loading dose, then 0.5 mg/kg/min up to 0.2 mg/kg/min, will need to repeat bolus for every up-titration), or metoprolol (2.5 mg to 5 mg IV every two to five minutes, not to exceed 15 mg over 10 to 15 minutes).

Summary of recommendations from the 2015 guideline of the American College of Cardiology, the American Heart Association and the Heart Rhythm Society on the management of adults with supraventricular tachycardia (SVT) [

Acute treatment

  • Vagal maneuvers are recommended for acute treatment in patients with regular SVT (class I recommendation, level B-R evidence)
  • Intravenous administration of adenosine is recommended for acute treatment in patients with regular SVT (class I recommendation, level B-R evidence)
  • Synchronized cardioversion is recommended for acute treatment in patients with hemodynamically stable SVT when pharmacologic treatment is ineffective or contraindicated (class I recommendation, level B-NR evidence)
  • Intravenous administration of diltiazem or verapamil can be effective for acute treatment in patients with hemodynamically stable SVT (class IIa recommendation, level B-R evidence)
  • Intravenous use of β-blockers is reasonable for acute treatment in patients with hemodynamically stable SVT (class IIa recommendation, level C-LD evidence)

Ongoing management

  • Oral β-blocker – diltiazem or verapamil treatment is useful for ongoing management in patients with symptomatic SVT who do not have ventricular pre-excitation during sinus rhythm (class I recommendation, level B-R evidence)
  • Electrophysiologic study – with the option of radiofrequency catheter ablation is useful for the diagnosis and potential treatment of SVT (class I recommendation, level B-NR evidence)
  • Patients with SVT – should be educated on how to perform vagal maneuvers for ongoing management of SVT (class I recommendation, level C-LD evidence)

Referral for radiofrequency catheter ablation

  • Catheter ablation of the slow pathway is recommended in patients with AVNRT (class I recommendation, level B-NR evidence)
  • Catheter ablation is recommended in patients with symptomatic focal atrial tachycardia as an alternative to pharmacologic treatment (class I recommendation, level B-NR evidence)
  • Catheter ablation of the accessory pathway is recommended in patients with AVRT or pre-excited atrial fibrillation (class I recommendation, level B-NR evidence)
  • An electrophysiologic study is reasonable in asymptomatic patients with pre-excitation to stratify risk for arrhythmic events (class IIa recommendation, level B-NR evidence)
  • Catheter ablation of the cavotricuspid isthmus is useful in patients with atrial flutter that is either symptomatic or refractory to pharmacologic rate control (class I recommendation, level B-R evidence)

Note: AVNRT = atrioventricular nodal re-entrant tachycardia, AVRT = atrioventricular re-entrant tachycardia.

  • Class I = strong recommendation where benefits > risks; class IIa = moderate-strength recommendation where benefits >> risks.
  • Level B-R = moderate-quality evidence from one or more randomized controlled trials (RCTs) or meta-analyses of moderate-quality RCTs;
  • Level B-NR = moderate-quality evidence from one or more nonrandomized or observational or registry studies;
  • Level C-LD = limited data from RCTs or nonrandomized observational or registry studies with limitations of design or execution.


Complications

Complications are either related to the medications or radiofrequency ablation. Since the latter is an invasive procedure the following complications may occur:

  • Hematoma
  • Pseudoaneurysm of the artery
  • Bleeding
  • Myocardial infarction
  • Heart block and the need for a pacemaker
  • Stroke
  • Death
  • Overall, focal atrial tachycardia is a benign arrhythmia.
  • Focal atrial tachycardia typically occurs secondary to an underlying disease process or acute illness.
  • Focal atrial tachycardia is one form of atrial tachycardia. Atrial activation patterns in focal atrial tachycardia will be similar during the tachycardia, yet distinct from the normal sinus P wave. Focal atrial tachycardia can be regular or irregular if variable block exists. A “warm-up” and “cool down” pattern can occur during initiation and termination, respectively.
  • Patients can be asymptomatic or present with palpitations, chest pain, lightheadedness, dizziness, or presyncope. Focal atrial tachycardia often presents on telemetry on asymptomatic or sleeping patients.
  • Ventricular rate control is achievable with calcium channel or beta-blockers. If the patient remains persistently tachycardic or has uncontrolled symptoms, the patient may benefit from antiarrhythmic therapy with class IC or III antiarrhythmics.
  • A possible significant cardiac sequella of prolonged atrial tachycardia (or any tachycardia) is tachycardia-induced cardiomyopathy. If there are concerns for high tachycardia burden, outpatient monitoring may be necessary.

Prevention

The most effective way to prevent tachycardia is to maintain a healthy heart and reduce your risk of developing heart disease. If you already have heart disease, monitor it and follow your treatment plan to lower your tachycardia risk.

Prevent Heart Disease

Treat or eliminate risk factors that may lead to heart disease. Take the following steps:

  • Exercise and eat a healthy diet – Live a heart-healthy lifestyle by exercising regularly and eating a healthy, low-fat diet that’s rich in fruits, vegetables, and whole grains.
  • Maintain a healthy weight – Being overweight increases your risk of developing heart disease.
  • Keep blood pressure and cholesterol levels under control – Make lifestyle changes and take medications as prescribed to correct high blood pressure (hypertension) or high cholesterol.
  • Stop smoking – If you smoke and can’t quit on your own, talk to your doctor about strategies or programs to help you break a smoking habit.
  • Drink in moderation – If you choose to drink alcohol, do so in moderation. For healthy adults, that means up to one drink a day for women of all ages and men older than age 65, and up to two drinks a day for men age 65 and younger. For some conditions, it’s recommended that you completely avoid alcohol. Ask your doctor for advice specific to your condition.
  • Don’t use recreational drugs – Don’t use stimulants, such as cocaine. Talk to your doctor about an appropriate program for you if you need help ending recreational drug use.
  • Use over-the-counter medications with caution – Some cold and cough medications contain stimulants that may trigger a rapid heartbeat. Ask your doctor which medications you need to avoid.
  • Limit caffeine – If you drink caffeinated beverages, do so in moderation (no more than one to two beverages daily).
  • Control stress – Avoid unnecessary stress and learn coping techniques to handle normal stress in a healthy way.
  • Go to scheduled checkups – Have regular physical exams and report any signs or symptoms to your doctor.

Monitor and treat existing heart disease

If you already have heart disease, you can take steps to lower your risk of developing tachycardia or another arrhythmia:

  • Follow the plan – Be sure you understand your treatment plan and take all medications as prescribed.
  • Report changes immediately – If your symptoms change or get worse or you develop new symptoms, tell your doctor immediately.


References

Tachycardia Treatment

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

Which Test May Help To Confirm Diagnosis Tachycardia

Which Test May Help To Confirm Diagnosis Tachycardia/Tachycardia conventionally but arbitrarily defined as an atrial and/or ventricular rate of >100 beats per minute, is encountered commonly and can be physiological or pathological in origin. Various adverse consequences from tachycardia have been recognized, and an important one is an association between persistent tachycardia and cardiomyopathy.

Tachycardia also called tachyarrhythmia, is a heart rate that exceeds the normal resting rate.[rx] In general, a resting heart rate over 100 beats per minute is accepted as tachycardia in adults.[rx] Heart rates above the resting rate may be normal (such as with exercise) or abnormal (such as with electrical problems within the heart). The upper threshold of a normal human resting heart rate is based on age.

Cutoff values for tachycardia in different age groups are fairly well standardized; typical cutoffs are listed below:[rx]

  • 1–2 days – Tachycardia > 159 beats per minute (bpm)
  • 3–6 days – Tachycardia >166 bpm
  • 1–3 weeks – Tachycardia >182 bpm
  • 1–2 months – Tachycardia >179 bpm
  • 3–5 months – Tachycardia >186 bpm
  • 6–11 months – Tachycardia >169 bpm
  • 1–2 years – Tachycardia >151 bpm
  • 3–4 years – Tachycardia >137 bpm
  • 5–7 years – Tachycardia >133 bpm
  • 8–11 years – Tachycardia >130 bpm
  • 12–15 years – Tachycardia >119 bpm
  • >15 years – adult – Tachycardia >100 bpm

Heart rate is considered in the context of the prevailing clinical picture. For example: in sepsis >90 bpm is considered tachycardia.

Types of Tachycardia

Supraventricular

  • Atrial fibrillation
  • Atrial flutter
  • Atrial tachycardia
  • AV nodal reentrant tachycardia
  • AV reentrant tachycardia
  • Permanent junctional reciprocating tachycardia (PJRT)

Ventricular

  • Idiopathic ventricular tachycardia
  • Fascicular tachycardia (left septal ventricular tachycardia)

Ectopy

  • Frequent premature ventricular contractions
  • Frequent premature atrial contractions

Pacing

  • High-rate atrial pacing
  • Persistent rapid ventricular pacing

Atrial tachycardia tends to occur in individuals with structural heart disease, with or without heart failure, and ischemic coronary artery disease. However, focal atrial tachycardia often occurs in healthy individuals without structural heart disease. Other possible etiologies are listed below:

Causes of Tachycardia

Etiological causes

  • Hypoxia
  • Pulmonary disease
  • Ischemic heart disease
  • Stimulants: cocaine, caffeine, chocolate, ephedra
  • Alcohol
  • Metabolic disturbances
  • Digoxin toxicity
  • Heightened sympathetic tone

Some other causes of tachycardia include

  • Adrenergic storm
  • Alcohol
  • Amphetamine
  • Anemia
  • Antiarrhythmic agents
  • Anxiety
  • Atrial fibrillation
  • Atrial flutter
  • Atrial tachycardia
  • AV nodal reentrant tachycardia
  • Brugada syndrome
  • Caffeine
  • Cannabis (drug)
  • The early manifestation of circulatory shock
  • Cocaine
  • Dysautonomia
  • Exercise
  • Fear
  • Fever
  • Hypoglycemia
  • Hypovolemia
  • Hyperthyroidism
  • Hyperventilation
  • Infection
  • Junctional tachycardia
  • Methamphetamine
  • Methylphenidate
  • Multifocal atrial tachycardia
  • Nicotine
  • Pacemaker mediated
  • Pain
  • Pheochromocytoma
  • Sinus tachycardia
  • Supraventricular tachycardia
  • Tricyclic antidepressants
  • Ventricular tachycardia
  • Wolff–Parkinson–White syndrome

Symptoms of Tachycardia

  • Dizziness
  • Lightheadedness
  • Shortness of breath
  • Chest pain
  • Heart palpitations
  • Fainting (syncope)
  • Lightheadedness or dizziness
  • Rapid heartbeat or palpitations
  • Fluttering in the chest
  • Bounding pulse
  • Chest pressure, tightness or pain (angina)
  • Shortness of breath
  • Cardiac arrest
  • Fatigue
  • Unconsciousness

Diagnosis of Tachycardia

EKG can aid the diagnosis of focal atrial tachycardia. EKG features may also inform the origin of focal atrial tachycardias. Electrocardiographic features include:

  • Atrial rate: 100 to 250 BPM
  • Ventricular conduction can be variable
    • Irregular or irregularly irregular in the setting of variable AV block
    • Regular if 1 to 1, 2 to 1, or 4 to 1 AV block
  • P wave morphology
  • Unifocal, but similar in morphology to each other
  • Might be inverted
  • Differs from normal sinus P wave
  • May exhibit either long RP or short PR intervals
  • Rhythm may be paroxysmal or sustained
    • May demonstrate an increase in the rate at initiation (i.e., “warm-up,” or “rev up”)
    • May demonstrate a decrease in the rate at termination (i.e., “cool down”)

Below is a differential of similar appearing arrhythmias with their identifying features.

Narrow complex, regular tachycardias

Sinus tachycardia

  • P wave with superior axis

Atrial flutter

  • Biphasic, sawtooth appearing F wave
  • Difficult to identify isoelectric, baseline PR segment

Typical atrial flutter

  • Involves circuit around the tricuspid annulus
  • Counterclockwise flutter produces F waves that are negative in lead II and positive in lead V1
  • Clockwise flutter produces F waves that are positive in lead II and negative in lead V1

Atypical atrial flutter

  • Involves circuit around the scar, left atrium, otherwise non-cavotricuspid isthmus dependent

AVNRT

Typical, slow-fast AVNRT

  • Short RP interval
  • P wave may be absent or within the S wave

Atypical, fast-slow AVNRT

  • Long RP interval
  • P wave negative before QRS

AVRT

  • Baseline EKG may demonstrate pre-excitation
  • Antidromic (propagation proceeds through the accessory pathway, and then retrogradely through the Purkinje system, to His bundle, through the AV node and back through accessory pathway)
    • QRS width: Wide
    • RP interval: Short
  • P wave, PR interval, QRS are variable depending on accessory pathway location and conduction direction
  • Orthodromic (propagation proceeds down AV node, His bundle, Purkinje fibers, retrograde through accessory pathway and back to AV node)
  • QRS width: Narrow
  • RP interval: Long
  • Atrial tachycardia (Focal)
  • Junctional tachycardia
    • P wave may be absent or inverted
    • If retrograde VA conduction, inverted P wave may occur just before or after the QRS complex

Narrow complex, irregular tachycardia

  • Atrial fibrillation
  • Irregularly irregular rhythm
  • Atrial flutter, atrial tachycardia with variable AV block
    • Has features of atrial flutter or atrial tachycardia, although variable block leads to irregular rhythm
  •  Multifocal atrial tachycardia
    • P wave morphology with greater than or equal to 3 distinct morphologies
  •  Resting ECG
  • Holter monitoring, as arrhythmias develop when heart rate increases
  • Exercise stress test both for diagnosis and monitoring of therapy
  • Echocardiogram and/or MRI to evaluate for structural defects
  • Consultation with a clinical geneticist and/or genetic counselor

Suggestive Findings

Catecholaminergic polymorphic ventricular tachycardia (CPVT) should be suspected in individuals who have one or more of the following []:

  • Syncope occurring during physical activity or acute emotion; mean onset age seven to 12 years. Less frequently, first manifestations may occur later in life; individuals with the first event up to age 40 years are reported.
  • History of exercise- or emotion-related palpitations and dizziness in some individuals
  • Sudden unexpected cardiac death triggered by acute emotional stress or exercise
  • Family history of juvenile sudden cardiac death triggered by exercise or acute emotion
Exercise-induced polymorphic ventricular arrhythmias
  • ECG during a graded exercise (exercise stress test)* allows ventricular arrhythmias to be reproducibly elicited in the majority of affected individuals. Typically, the onset of ventricular arrhythmias is 100-120 beats/min.
  • With an increase in workload, the complexity of arrhythmias progressively increases from isolated premature beats to bigeminy and runs of non-sustained ventricular tachycardia (VT). If the affected individual continues exercising, the duration of the runs of VT progressively increases and VT may become sustained.
  • An alternating 180°-QRS axis on a beat-to-beat basis, so-called bidirectional VT, is often the distinguishing presentation of CPVT arrhythmias.
  • Some individuals with CPVT may also present with irregular polymorphic VT without a “stable” QRS vector alternans [].
  • Exercise-induced supraventricular arrhythmias (supraventricular tachycardia and atrial fibrillation) are common [].
  • Ventricular fibrillation occurring in the setting of acute stress
  • Absence of structural cardiac abnormalities

Establishing the Diagnosis

According to the most recent version of the International Guidelines on sudden cardiac death [], the diagnosis of CPVT is established

  • In the presence of a structurally normal heart, normal resting ECG, and exercise- or emotion-induced bidirectional or polymorphic ventricular tachycardia;
OR
  • In individuals who have a heterozygous pathogenic variant in RYR2 or CALM1 or biallelic pathogenic variants in CASQ2 or TRDN [rx].
  • Molecular testing approaches can include serial single-gene testing, use of a multigene panel, and more comprehensive genomic testing
Serial single-gene testing
  • Sequence analysis of RYR2 can be performed first and followed by sequence analysis of CASQ2 if no pathogenic variant is found. If no pathogenic variant in CASQ2 is found, sequence analysis of CALM1and TRDN should be performed next, keeping in mind that pathogenic variants in CALM1 and TRDN are extremely rare causes of CPVT.
  • Gene-targeted deletion/duplication analysis of RYR2 can be performed next if a pathogenic variant in RYR2 or CALM1 or biallelic pathogenic variants in CASQ2 or TRDN have not been identified [rx].
A multigene panel that includes CALM1CASQ2RYR2, and TRDN and other genes of interest (see Differential Diagnosis) may also be considered. Note:
  • The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time.
  • Some multigene panels may include genes not associated with the condition discussed in this GeneReview; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype.
  • In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician.
  • Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
    For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
More comprehensive genomic testing – (when available) including exome sequencing and genome sequencing may be considered if serial single-gene testing (and/or use of a multigene panel that includes CALM1CASQ2RYR2, and TRDN) fails to confirm a diagnosis in an individual with features of CPVT. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation).
  • Magnetic resonance imaging (MRI) A cardiac MRI can provide still or moving pictures of how the blood is flowing through the heart and detect irregularities.
  • Computerized tomography (CT)CT scans combine several X-ray images to provide a more detailed cross-sectional view of the heart.
  • Coronary angiogram –  To study the flow of blood through your heart and blood vessels, your doctor may use a coronary angiogram to reveal potential blockages or abnormalities. It uses a dye and special X-rays to show the inside of your coronary arteries.
  • Chest X-ray – This test is used to take still pictures of your heart and lungs and can detect if your heart is enlarged.

Stress Test

  • Your doctor may recommend a stress test to see how your heart functions while it is working hard during exercise or when medication is given to make it beat fast. In an exercise stress test, electrodes are placed on your chest to monitor heart function while you exercise, usually by walking on a treadmill. Other heart tests may also be performed in conjunction with a stress test.

Additional Tests

  • Your doctor may order additional tests as needed to diagnose an underlying condition that is contributing to tachycardia and judge the condition of your heart.

Event Recorder

This device is similar to a Holter monitor, but it does not record all the heartbeats. There are two types:

  • One type uses a phone to transmit signals from the recorder while the person is experiencing symptoms.
  • The other type is worn all the time for a long time. These can sometimes be worn for as long as a month.

This event recorder is good for diagnosing rhythm disturbances that happen at random moments.

Electrophysiological Testing (EP studies)

  • This is an invasive, relatively painless, non-surgical test and can help determine the type of arrhythmia, its origin, and potential response to treatment. The test is carried out in an EP lab by an electrophysiologist and makes it possible to reproduce troubling arrhythmias in a controlled setting.

Tilt-Table Test

  • If an individual experiences fainting spells, dizziness, or lightheadedness, and neither the ECG nor the Holter revealed any arrhythmias, a tilt-table test might be performed. This monitors blood pressure, heart rhythm, and heart rate while they are moved from a lying to an upright position. When reflexes work correctly, they cause the heart rate and blood pressure to change when moved to an upright position. This is to make sure the brain gets an adequate supply of blood.

Treatment of Tachycardia

But if the episodes are prolonged, or recur often, your doctor may recommend treatment, including

  • Carotid sinus massage – A healthcare professional can apply gentle pressure on the neck, where the carotid artery splits into two branches.
  • Pressing gently on the eyeballs with eyes closed. Caution – This procedure should be supervised carefully by a healthcare physician.
  • Valsalva maneuver – This consists of holding your nostrils closed while blowing air through your nose.
  • Using the dive reflex – The dive reflex is the body’s response to sudden immersion in water, especially cold water.
  • Sedation
  • Cutting down on coffee or caffeinated substances
  • Cutting down on alcohol
  • Quitting tobacco use
  • Getting more rest

Pharmacologic Treatment


  • If vagal maneuvers fail – a trial of intravenous adenosine may be given at an initial dose of 6 mg and a subsequent dose of 12 mg., Its use may serve as a diagnostic and therapeutic tool because it will terminate almost all AVNRTs and AVRTs by breaking the AV-nodal dependent circuit. In patients with non–AV-nodal dependent circuits (i.e., focal atrial tachycardia and atrial flutter), intravenous use of adenosine may prove to be a valuable diagnostic tool because the transient AV block may unmask ectopic atrial P waves or flutter waves. Patients should always be monitored by ECG during adenosine administration.
  • Adenosine – may induce a wide range of transient bradycardias (including sinus arrest and asystole) as well as atrial fibrillation, SVT and ventricular tachycardia. Albeit very rare, cases of sustained ventricular tachycardia, ventricular fibrillation, and Torsades de pointes have been reported. In patients with underlying coronary disease, adenosine may lead to coronary steal syndrome and subsequent myocardial ischemia.  Adenosine should therefore always be administered with an external pacemaker or defibrillator nearby.
  • When vagal maneuvers and adenosine – fail to terminate a narrow-complex tachycardia, intravenous treatment with a nondihydropiridine calcium-channel blocker (e.g., diltiazem and verapamil) or β-blocker may be used. Calcium-channel blockers terminate 64%–98% of SVTs in hemodynamically stable patients. Administering a calcium-channel blocker intravenously over 20 minutes has been shown to reduce the rate of hypotension. There are fewer data supporting the use of β-blockers in the acute treatment of SVT; however, they are considered reasonable choices because of their safety profile.,
  • If all aforementioned pharmacologic therapies fail – synchronized cardioversion is recommended, even in hemodynamically stable patients.
  • In patients presenting in atrial fibrillation who have known Wolff–Parkinson – White or new pre-excitation pattern on ECG, the use of potent AV-nodal blockers (i.e., β-blockers, diltiazem, verapamil, and digoxin) should be avoided because these medications may potentiate conduction over the accessory pathway and lead to potentially life-threatening ventricular arrhythmias. In these cases, intravenous use of procainamide is the preferred approach in the acute setting.
  • Adenosine is rapidly metabolized in the periphery – and therefore must be given as a rapid push through a large, ideally peripheral, intravenous route. The initial dose is 6 mg intravenously (IV) (pediatric dose 0.1 mg/kg, maximum dose of 6 mg). If the initial dose is ineffective, adenosine may be dosed again at 12 mg IVP (pediatric dose 0.2 mg/kg, maximum dose 12 mg). The second dose of adenosine 12 mg IVP may be repeated one additional time if there is no effect. Each dose of adenosine needs to be flushed rapidly with 10 mL to 20 mL normal saline. Often two-person administration, with one person administering the adenosine at a proximal IV port, and a second person flushing the IV line via a distal port immediately after adenosine administration, is required to adequate flush in the adenosine.
  • Consider reducing the adenosine dose to 3 mg – IVP if the patient is currently receiving carbamazepine or dipyridamole, is the recipient of a heart transplant, or adenosine is being given through a central line.
  • If adenosine fails – second line medications include diltiazem (0.25 mg/kg IV loading dose followed by 5mg/hr to 15 mg/hr infusion), esmolol (0.5 mg/kg IV loading dose, then 0.5 mg/kg/min up to 0.2 mg/kg/min, will need to repeat bolus for every up-titration), or metoprolol (2.5 mg to 5 mg IV every two to five minutes, not to exceed 15 mg over 10 to 15 minutes).

Summary of recommendations from the 2015 guideline of the American College of Cardiology, the American Heart Association and the Heart Rhythm Society on the management of adults with supraventricular tachycardia (SVT) [

Acute treatment

  • Vagal maneuvers are recommended for acute treatment in patients with regular SVT (class I recommendation, level B-R evidence)
  • Intravenous administration of adenosine is recommended for acute treatment in patients with regular SVT (class I recommendation, level B-R evidence)
  • Synchronized cardioversion is recommended for acute treatment in patients with hemodynamically stable SVT when pharmacologic treatment is ineffective or contraindicated (class I recommendation, level B-NR evidence)
  • Intravenous administration of diltiazem or verapamil can be effective for acute treatment in patients with hemodynamically stable SVT (class IIa recommendation, level B-R evidence)
  • Intravenous use of β-blockers is reasonable for acute treatment in patients with hemodynamically stable SVT (class IIa recommendation, level C-LD evidence)

Ongoing management

  • Oral β-blocker – diltiazem or verapamil treatment is useful for ongoing management in patients with symptomatic SVT who do not have ventricular pre-excitation during sinus rhythm (class I recommendation, level B-R evidence)
  • Electrophysiologic study – with the option of radiofrequency catheter ablation is useful for the diagnosis and potential treatment of SVT (class I recommendation, level B-NR evidence)
  • Patients with SVT – should be educated on how to perform vagal maneuvers for ongoing management of SVT (class I recommendation, level C-LD evidence)

Referral for radiofrequency catheter ablation

  • Catheter ablation of the slow pathway is recommended in patients with AVNRT (class I recommendation, level B-NR evidence)
  • Catheter ablation is recommended in patients with symptomatic focal atrial tachycardia as an alternative to pharmacologic treatment (class I recommendation, level B-NR evidence)
  • Catheter ablation of the accessory pathway is recommended in patients with AVRT or pre-excited atrial fibrillation (class I recommendation, level B-NR evidence)
  • An electrophysiologic study is reasonable in asymptomatic patients with pre-excitation to stratify risk for arrhythmic events (class IIa recommendation, level B-NR evidence)
  • Catheter ablation of the cavotricuspid isthmus is useful in patients with atrial flutter that is either symptomatic or refractory to pharmacologic rate control (class I recommendation, level B-R evidence)

Note: AVNRT = atrioventricular nodal re-entrant tachycardia, AVRT = atrioventricular re-entrant tachycardia.

  • Class I = strong recommendation where benefits > risks; class IIa = moderate-strength recommendation where benefits >> risks.
  • Level B-R = moderate-quality evidence from one or more randomized controlled trials (RCTs) or meta-analyses of moderate-quality RCTs;
  • Level B-NR = moderate-quality evidence from one or more nonrandomized or observational or registry studies;
  • Level C-LD = limited data from RCTs or nonrandomized observational or registry studies with limitations of design or execution.


Complications

Complications are either related to the medications or radiofrequency ablation. Since the latter is an invasive procedure the following complications may occur:

  • Hematoma
  • Pseudoaneurysm of the artery
  • Bleeding
  • Myocardial infarction
  • Heart block and the need for a pacemaker
  • Stroke
  • Death
  • Overall, focal atrial tachycardia is a benign arrhythmia.
  • Focal atrial tachycardia typically occurs secondary to an underlying disease process or acute illness.
  • Focal atrial tachycardia is one form of atrial tachycardia. Atrial activation patterns in focal atrial tachycardia will be similar during the tachycardia, yet distinct from the normal sinus P wave. Focal atrial tachycardia can be regular or irregular if variable block exists. A “warm-up” and “cool down” pattern can occur during initiation and termination, respectively.
  • Patients can be asymptomatic or present with palpitations, chest pain, lightheadedness, dizziness, or presyncope. Focal atrial tachycardia often presents on telemetry on asymptomatic or sleeping patients.
  • Ventricular rate control is achievable with calcium channel or beta-blockers. If the patient remains persistently tachycardic or has uncontrolled symptoms, the patient may benefit from antiarrhythmic therapy with class IC or III antiarrhythmics.
  • A possible significant cardiac sequella of prolonged atrial tachycardia (or any tachycardia) is tachycardia-induced cardiomyopathy. If there are concerns for high tachycardia burden, outpatient monitoring may be necessary.

Prevention

The most effective way to prevent tachycardia is to maintain a healthy heart and reduce your risk of developing heart disease. If you already have heart disease, monitor it and follow your treatment plan to lower your tachycardia risk.

Prevent Heart Disease

Treat or eliminate risk factors that may lead to heart disease. Take the following steps:

  • Exercise and eat a healthy diet – Live a heart-healthy lifestyle by exercising regularly and eating a healthy, low-fat diet that’s rich in fruits, vegetables, and whole grains.
  • Maintain a healthy weight – Being overweight increases your risk of developing heart disease.
  • Keep blood pressure and cholesterol levels under control – Make lifestyle changes and take medications as prescribed to correct high blood pressure (hypertension) or high cholesterol.
  • Stop smoking – If you smoke and can’t quit on your own, talk to your doctor about strategies or programs to help you break a smoking habit.
  • Drink in moderation – If you choose to drink alcohol, do so in moderation. For healthy adults, that means up to one drink a day for women of all ages and men older than age 65, and up to two drinks a day for men age 65 and younger. For some conditions, it’s recommended that you completely avoid alcohol. Ask your doctor for advice specific to your condition.
  • Don’t use recreational drugs – Don’t use stimulants, such as cocaine. Talk to your doctor about an appropriate program for you if you need help ending recreational drug use.
  • Use over-the-counter medications with caution – Some cold and cough medications contain stimulants that may trigger a rapid heartbeat. Ask your doctor which medications you need to avoid.
  • Limit caffeine – If you drink caffeinated beverages, do so in moderation (no more than one to two beverages daily).
  • Control stress – Avoid unnecessary stress and learn coping techniques to handle normal stress in a healthy way.
  • Go to scheduled checkups – Have regular physical exams and report any signs or symptoms to your doctor.

Monitor and treat existing heart disease

If you already have heart disease, you can take steps to lower your risk of developing tachycardia or another arrhythmia:

  • Follow the plan – Be sure you understand your treatment plan and take all medications as prescribed.
  • Report changes immediately – If your symptoms change or get worse or you develop new symptoms, tell your doctor immediately.


References

Which Test May Help To Confirm Diagnosis Tachycardia

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

What Is The Main Sign Symptoms of Tachycardia

What Is The Main Sign Symptoms of Tachycardia/Tachycardia conventionally but arbitrarily defined as an atrial and/or ventricular rate of >100 beats per minute, is encountered commonly and can be physiological or pathological in origin. Various adverse consequences from tachycardia have been recognized, and an important one is an association between persistent tachycardia and cardiomyopathy.

Tachycardia also called tachyarrhythmia, is a heart rate that exceeds the normal resting rate.[rx] In general, a resting heart rate over 100 beats per minute is accepted as tachycardia in adults.[rx] Heart rates above the resting rate may be normal (such as with exercise) or abnormal (such as with electrical problems within the heart). The upper threshold of a normal human resting heart rate is based on age.

Cutoff values for tachycardia in different age groups are fairly well standardized; typical cutoffs are listed below:[rx]

  • 1–2 days – Tachycardia > 159 beats per minute (bpm)
  • 3–6 days – Tachycardia >166 bpm
  • 1–3 weeks – Tachycardia >182 bpm
  • 1–2 months – Tachycardia >179 bpm
  • 3–5 months – Tachycardia >186 bpm
  • 6–11 months – Tachycardia >169 bpm
  • 1–2 years – Tachycardia >151 bpm
  • 3–4 years – Tachycardia >137 bpm
  • 5–7 years – Tachycardia >133 bpm
  • 8–11 years – Tachycardia >130 bpm
  • 12–15 years – Tachycardia >119 bpm
  • >15 years – adult – Tachycardia >100 bpm

Heart rate is considered in the context of the prevailing clinical picture. For example: in sepsis >90 bpm is considered tachycardia.

Types of Tachycardia

Supraventricular

  • Atrial fibrillation
  • Atrial flutter
  • Atrial tachycardia
  • AV nodal reentrant tachycardia
  • AV reentrant tachycardia
  • Permanent junctional reciprocating tachycardia (PJRT)

Ventricular

  • Idiopathic ventricular tachycardia
  • Fascicular tachycardia (left septal ventricular tachycardia)

Ectopy

  • Frequent premature ventricular contractions
  • Frequent premature atrial contractions

Pacing

  • High-rate atrial pacing
  • Persistent rapid ventricular pacing

Atrial tachycardia tends to occur in individuals with structural heart disease, with or without heart failure, and ischemic coronary artery disease. However, focal atrial tachycardia often occurs in healthy individuals without structural heart disease. Other possible etiologies are listed below:

Causes of Tachycardia

Etiological causes

  • Hypoxia
  • Pulmonary disease
  • Ischemic heart disease
  • Stimulants: cocaine, caffeine, chocolate, ephedra
  • Alcohol
  • Metabolic disturbances
  • Digoxin toxicity
  • Heightened sympathetic tone

Some other causes of tachycardia include

  • Adrenergic storm
  • Alcohol
  • Amphetamine
  • Anemia
  • Antiarrhythmic agents
  • Anxiety
  • Atrial fibrillation
  • Atrial flutter
  • Atrial tachycardia
  • AV nodal reentrant tachycardia
  • Brugada syndrome
  • Caffeine
  • Cannabis (drug)
  • The early manifestation of circulatory shock
  • Cocaine
  • Dysautonomia
  • Exercise
  • Fear
  • Fever
  • Hypoglycemia
  • Hypovolemia
  • Hyperthyroidism
  • Hyperventilation
  • Infection
  • Junctional tachycardia
  • Methamphetamine
  • Methylphenidate
  • Multifocal atrial tachycardia
  • Nicotine
  • Pacemaker mediated
  • Pain
  • Pheochromocytoma
  • Sinus tachycardia
  • Supraventricular tachycardia
  • Tricyclic antidepressants
  • Ventricular tachycardia
  • Wolff–Parkinson–White syndrome

Symptoms of Tachycardia

  • Dizziness
  • Lightheadedness
  • Shortness of breath
  • Chest pain
  • Heart palpitations
  • Fainting (syncope)
  • Lightheadedness or dizziness
  • Rapid heartbeat or palpitations
  • Fluttering in the chest
  • Bounding pulse
  • Chest pressure, tightness or pain (angina)
  • Shortness of breath
  • Cardiac arrest
  • Fatigue
  • Unconsciousness

Diagnosis of Tachycardia

EKG can aid the diagnosis of focal atrial tachycardia. EKG features may also inform the origin of focal atrial tachycardias. Electrocardiographic features include:

  • Atrial rate: 100 to 250 BPM
  • Ventricular conduction can be variable
    • Irregular or irregularly irregular in the setting of variable AV block
    • Regular if 1 to 1, 2 to 1, or 4 to 1 AV block
  • P wave morphology
  • Unifocal, but similar in morphology to each other
  • Might be inverted
  • Differs from normal sinus P wave
  • May exhibit either long RP or short PR intervals
  • Rhythm may be paroxysmal or sustained
    • May demonstrate an increase in the rate at initiation (i.e., “warm-up,” or “rev up”)
    • May demonstrate a decrease in the rate at termination (i.e., “cool down”)

Below is a differential of similar appearing arrhythmias with their identifying features.

Narrow complex, regular tachycardias

Sinus tachycardia

  • P wave with superior axis

Atrial flutter

  • Biphasic, sawtooth appearing F wave
  • Difficult to identify isoelectric, baseline PR segment

Typical atrial flutter

  • Involves circuit around the tricuspid annulus
  • Counterclockwise flutter produces F waves that are negative in lead II and positive in lead V1
  • Clockwise flutter produces F waves that are positive in lead II and negative in lead V1

Atypical atrial flutter

  • Involves circuit around the scar, left atrium, otherwise non-cavotricuspid isthmus dependent

AVNRT

Typical, slow-fast AVNRT

  • Short RP interval
  • P wave may be absent or within the S wave

Atypical, fast-slow AVNRT

  • Long RP interval
  • P wave negative before QRS

AVRT

  • Baseline EKG may demonstrate pre-excitation
  • Antidromic (propagation proceeds through the accessory pathway, and then retrogradely through the Purkinje system, to His bundle, through the AV node and back through accessory pathway)
    • QRS width: Wide
    • RP interval: Short
  • P wave, PR interval, QRS are variable depending on accessory pathway location and conduction direction
  • Orthodromic (propagation proceeds down AV node, His bundle, Purkinje fibers, retrograde through accessory pathway and back to AV node)
  • QRS width: Narrow
  • RP interval: Long
  • Atrial tachycardia (Focal)
  • Junctional tachycardia
    • P wave may be absent or inverted
    • If retrograde VA conduction, inverted P wave may occur just before or after the QRS complex

Narrow complex, irregular tachycardia

  • Atrial fibrillation
  • Irregularly irregular rhythm
  • Atrial flutter, atrial tachycardia with variable AV block
    • Has features of atrial flutter or atrial tachycardia, although variable block leads to irregular rhythm
  •  Multifocal atrial tachycardia
    • P wave morphology with greater than or equal to 3 distinct morphologies
  •  Resting ECG
  • Holter monitoring, as arrhythmias develop when heart rate increases
  • Exercise stress test both for diagnosis and monitoring of therapy
  • Echocardiogram and/or MRI to evaluate for structural defects
  • Consultation with a clinical geneticist and/or genetic counselor

Suggestive Findings

Catecholaminergic polymorphic ventricular tachycardia (CPVT) should be suspected in individuals who have one or more of the following []:

  • Syncope occurring during physical activity or acute emotion; mean onset age seven to 12 years. Less frequently, first manifestations may occur later in life; individuals with the first event up to age 40 years are reported.
  • History of exercise- or emotion-related palpitations and dizziness in some individuals
  • Sudden unexpected cardiac death triggered by acute emotional stress or exercise
  • Family history of juvenile sudden cardiac death triggered by exercise or acute emotion
Exercise-induced polymorphic ventricular arrhythmias
  • ECG during a graded exercise (exercise stress test)* allows ventricular arrhythmias to be reproducibly elicited in the majority of affected individuals. Typically, the onset of ventricular arrhythmias is 100-120 beats/min.
  • With an increase in workload, the complexity of arrhythmias progressively increases from isolated premature beats to bigeminy and runs of non-sustained ventricular tachycardia (VT). If the affected individual continues exercising, the duration of the runs of VT progressively increases and VT may become sustained.
  • An alternating 180°-QRS axis on a beat-to-beat basis, so-called bidirectional VT, is often the distinguishing presentation of CPVT arrhythmias.
  • Some individuals with CPVT may also present with irregular polymorphic VT without a “stable” QRS vector alternans [].
  • Exercise-induced supraventricular arrhythmias (supraventricular tachycardia and atrial fibrillation) are common [].
  • Ventricular fibrillation occurring in the setting of acute stress
  • Absence of structural cardiac abnormalities

Establishing the Diagnosis

According to the most recent version of the International Guidelines on sudden cardiac death [], the diagnosis of CPVT is established

  • In the presence of a structurally normal heart, normal resting ECG, and exercise- or emotion-induced bidirectional or polymorphic ventricular tachycardia;
OR
  • In individuals who have a heterozygous pathogenic variant in RYR2 or CALM1 or biallelic pathogenic variants in CASQ2 or TRDN [rx].
  • Molecular testing approaches can include serial single-gene testing, use of a multigene panel, and more comprehensive genomic testing
Serial single-gene testing
  • Sequence analysis of RYR2 can be performed first and followed by sequence analysis of CASQ2 if no pathogenic variant is found. If no pathogenic variant in CASQ2 is found, sequence analysis of CALM1and TRDN should be performed next, keeping in mind that pathogenic variants in CALM1 and TRDN are extremely rare causes of CPVT.
  • Gene-targeted deletion/duplication analysis of RYR2 can be performed next if a pathogenic variant in RYR2 or CALM1 or biallelic pathogenic variants in CASQ2 or TRDN have not been identified [rx].
A multigene panel that includes CALM1CASQ2RYR2, and TRDN and other genes of interest (see Differential Diagnosis) may also be considered. Note:
  • The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time.
  • Some multigene panels may include genes not associated with the condition discussed in this GeneReview; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype.
  • In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician.
  • Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
    For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
More comprehensive genomic testing – (when available) including exome sequencing and genome sequencing may be considered if serial single-gene testing (and/or use of a multigene panel that includes CALM1CASQ2RYR2, and TRDN) fails to confirm a diagnosis in an individual with features of CPVT. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation).
  • Magnetic resonance imaging (MRI) A cardiac MRI can provide still or moving pictures of how the blood is flowing through the heart and detect irregularities.
  • Computerized tomography (CT)CT scans combine several X-ray images to provide a more detailed cross-sectional view of the heart.
  • Coronary angiogram –  To study the flow of blood through your heart and blood vessels, your doctor may use a coronary angiogram to reveal potential blockages or abnormalities. It uses a dye and special X-rays to show the inside of your coronary arteries.
  • Chest X-ray – This test is used to take still pictures of your heart and lungs and can detect if your heart is enlarged.

Stress Test

  • Your doctor may recommend a stress test to see how your heart functions while it is working hard during exercise or when medication is given to make it beat fast. In an exercise stress test, electrodes are placed on your chest to monitor heart function while you exercise, usually by walking on a treadmill. Other heart tests may also be performed in conjunction with a stress test.

Additional Tests

  • Your doctor may order additional tests as needed to diagnose an underlying condition that is contributing to tachycardia and judge the condition of your heart.

Event Recorder

This device is similar to a Holter monitor, but it does not record all the heartbeats. There are two types:

  • One type uses a phone to transmit signals from the recorder while the person is experiencing symptoms.
  • The other type is worn all the time for a long time. These can sometimes be worn for as long as a month.

This event recorder is good for diagnosing rhythm disturbances that happen at random moments.

Electrophysiological Testing (EP studies)

  • This is an invasive, relatively painless, non-surgical test and can help determine the type of arrhythmia, its origin, and potential response to treatment. The test is carried out in an EP lab by an electrophysiologist and makes it possible to reproduce troubling arrhythmias in a controlled setting.

Tilt-Table Test

  • If an individual experiences fainting spells, dizziness, or lightheadedness, and neither the ECG nor the Holter revealed any arrhythmias, a tilt-table test might be performed. This monitors blood pressure, heart rhythm, and heart rate while they are moved from a lying to an upright position. When reflexes work correctly, they cause the heart rate and blood pressure to change when moved to an upright position. This is to make sure the brain gets an adequate supply of blood.

Treatment of Tachycardia

But if the episodes are prolonged, or recur often, your doctor may recommend treatment, including

  • Carotid sinus massage – A healthcare professional can apply gentle pressure on the neck, where the carotid artery splits into two branches.
  • Pressing gently on the eyeballs with eyes closed. Caution – This procedure should be supervised carefully by a healthcare physician.
  • Valsalva maneuver – This consists of holding your nostrils closed while blowing air through your nose.
  • Using the dive reflex – The dive reflex is the body’s response to sudden immersion in water, especially cold water.
  • Sedation
  • Cutting down on coffee or caffeinated substances
  • Cutting down on alcohol
  • Quitting tobacco use
  • Getting more rest

Pharmacologic Treatment


  • If vagal maneuvers fail – a trial of intravenous adenosine may be given at an initial dose of 6 mg and a subsequent dose of 12 mg., Its use may serve as a diagnostic and therapeutic tool because it will terminate almost all AVNRTs and AVRTs by breaking the AV-nodal dependent circuit. In patients with non–AV-nodal dependent circuits (i.e., focal atrial tachycardia and atrial flutter), intravenous use of adenosine may prove to be a valuable diagnostic tool because the transient AV block may unmask ectopic atrial P waves or flutter waves. Patients should always be monitored by ECG during adenosine administration.
  • Adenosine – may induce a wide range of transient bradycardias (including sinus arrest and asystole) as well as atrial fibrillation, SVT and ventricular tachycardia. Albeit very rare, cases of sustained ventricular tachycardia, ventricular fibrillation, and Torsades de pointes have been reported. In patients with underlying coronary disease, adenosine may lead to coronary steal syndrome and subsequent myocardial ischemia.  Adenosine should therefore always be administered with an external pacemaker or defibrillator nearby.
  • When vagal maneuvers and adenosine – fail to terminate a narrow-complex tachycardia, intravenous treatment with a nondihydropiridine calcium-channel blocker (e.g., diltiazem and verapamil) or β-blocker may be used. Calcium-channel blockers terminate 64%–98% of SVTs in hemodynamically stable patients. Administering a calcium-channel blocker intravenously over 20 minutes has been shown to reduce the rate of hypotension. There are fewer data supporting the use of β-blockers in the acute treatment of SVT; however, they are considered reasonable choices because of their safety profile.,
  • If all aforementioned pharmacologic therapies fail – synchronized cardioversion is recommended, even in hemodynamically stable patients.
  • In patients presenting in atrial fibrillation who have known Wolff–Parkinson – White or new pre-excitation pattern on ECG, the use of potent AV-nodal blockers (i.e., β-blockers, diltiazem, verapamil, and digoxin) should be avoided because these medications may potentiate conduction over the accessory pathway and lead to potentially life-threatening ventricular arrhythmias. In these cases, intravenous use of procainamide is the preferred approach in the acute setting.
  • Adenosine is rapidly metabolized in the periphery – and therefore must be given as a rapid push through a large, ideally peripheral, intravenous route. The initial dose is 6 mg intravenously (IV) (pediatric dose 0.1 mg/kg, maximum dose of 6 mg). If the initial dose is ineffective, adenosine may be dosed again at 12 mg IVP (pediatric dose 0.2 mg/kg, maximum dose 12 mg). The second dose of adenosine 12 mg IVP may be repeated one additional time if there is no effect. Each dose of adenosine needs to be flushed rapidly with 10 mL to 20 mL normal saline. Often two-person administration, with one person administering the adenosine at a proximal IV port, and a second person flushing the IV line via a distal port immediately after adenosine administration, is required to adequate flush in the adenosine.
  • Consider reducing the adenosine dose to 3 mg – IVP if the patient is currently receiving carbamazepine or dipyridamole, is the recipient of a heart transplant, or adenosine is being given through a central line.
  • If adenosine fails – second line medications include diltiazem (0.25 mg/kg IV loading dose followed by 5mg/hr to 15 mg/hr infusion), esmolol (0.5 mg/kg IV loading dose, then 0.5 mg/kg/min up to 0.2 mg/kg/min, will need to repeat bolus for every up-titration), or metoprolol (2.5 mg to 5 mg IV every two to five minutes, not to exceed 15 mg over 10 to 15 minutes).

Summary of recommendations from the 2015 guideline of the American College of Cardiology, the American Heart Association and the Heart Rhythm Society on the management of adults with supraventricular tachycardia (SVT) [

Acute treatment

  • Vagal maneuvers are recommended for acute treatment in patients with regular SVT (class I recommendation, level B-R evidence)
  • Intravenous administration of adenosine is recommended for acute treatment in patients with regular SVT (class I recommendation, level B-R evidence)
  • Synchronized cardioversion is recommended for acute treatment in patients with hemodynamically stable SVT when pharmacologic treatment is ineffective or contraindicated (class I recommendation, level B-NR evidence)
  • Intravenous administration of diltiazem or verapamil can be effective for acute treatment in patients with hemodynamically stable SVT (class IIa recommendation, level B-R evidence)
  • Intravenous use of β-blockers is reasonable for acute treatment in patients with hemodynamically stable SVT (class IIa recommendation, level C-LD evidence)

Ongoing management

  • Oral β-blocker – diltiazem or verapamil treatment is useful for ongoing management in patients with symptomatic SVT who do not have ventricular pre-excitation during sinus rhythm (class I recommendation, level B-R evidence)
  • Electrophysiologic study – with the option of radiofrequency catheter ablation is useful for the diagnosis and potential treatment of SVT (class I recommendation, level B-NR evidence)
  • Patients with SVT – should be educated on how to perform vagal maneuvers for ongoing management of SVT (class I recommendation, level C-LD evidence)

Referral for radiofrequency catheter ablation

  • Catheter ablation of the slow pathway is recommended in patients with AVNRT (class I recommendation, level B-NR evidence)
  • Catheter ablation is recommended in patients with symptomatic focal atrial tachycardia as an alternative to pharmacologic treatment (class I recommendation, level B-NR evidence)
  • Catheter ablation of the accessory pathway is recommended in patients with AVRT or pre-excited atrial fibrillation (class I recommendation, level B-NR evidence)
  • An electrophysiologic study is reasonable in asymptomatic patients with pre-excitation to stratify risk for arrhythmic events (class IIa recommendation, level B-NR evidence)
  • Catheter ablation of the cavotricuspid isthmus is useful in patients with atrial flutter that is either symptomatic or refractory to pharmacologic rate control (class I recommendation, level B-R evidence)

Note: AVNRT = atrioventricular nodal re-entrant tachycardia, AVRT = atrioventricular re-entrant tachycardia.

  • Class I = strong recommendation where benefits > risks; class IIa = moderate-strength recommendation where benefits >> risks.
  • Level B-R = moderate-quality evidence from one or more randomized controlled trials (RCTs) or meta-analyses of moderate-quality RCTs;
  • Level B-NR = moderate-quality evidence from one or more nonrandomized or observational or registry studies;
  • Level C-LD = limited data from RCTs or nonrandomized observational or registry studies with limitations of design or execution.


Complications

Complications are either related to the medications or radiofrequency ablation. Since the latter is an invasive procedure the following complications may occur:

  • Hematoma
  • Pseudoaneurysm of the artery
  • Bleeding
  • Myocardial infarction
  • Heart block and the need for a pacemaker
  • Stroke
  • Death
  • Overall, focal atrial tachycardia is a benign arrhythmia.
  • Focal atrial tachycardia typically occurs secondary to an underlying disease process or acute illness.
  • Focal atrial tachycardia is one form of atrial tachycardia. Atrial activation patterns in focal atrial tachycardia will be similar during the tachycardia, yet distinct from the normal sinus P wave. Focal atrial tachycardia can be regular or irregular if variable block exists. A “warm-up” and “cool down” pattern can occur during initiation and termination, respectively.
  • Patients can be asymptomatic or present with palpitations, chest pain, lightheadedness, dizziness, or presyncope. Focal atrial tachycardia often presents on telemetry on asymptomatic or sleeping patients.
  • Ventricular rate control is achievable with calcium channel or beta-blockers. If the patient remains persistently tachycardic or has uncontrolled symptoms, the patient may benefit from antiarrhythmic therapy with class IC or III antiarrhythmics.
  • A possible significant cardiac sequella of prolonged atrial tachycardia (or any tachycardia) is tachycardia-induced cardiomyopathy. If there are concerns for high tachycardia burden, outpatient monitoring may be necessary.

Prevention

The most effective way to prevent tachycardia is to maintain a healthy heart and reduce your risk of developing heart disease. If you already have heart disease, monitor it and follow your treatment plan to lower your tachycardia risk.

Prevent Heart Disease

Treat or eliminate risk factors that may lead to heart disease. Take the following steps:

  • Exercise and eat a healthy diet – Live a heart-healthy lifestyle by exercising regularly and eating a healthy, low-fat diet that’s rich in fruits, vegetables, and whole grains.
  • Maintain a healthy weight – Being overweight increases your risk of developing heart disease.
  • Keep blood pressure and cholesterol levels under control – Make lifestyle changes and take medications as prescribed to correct high blood pressure (hypertension) or high cholesterol.
  • Stop smoking – If you smoke and can’t quit on your own, talk to your doctor about strategies or programs to help you break a smoking habit.
  • Drink in moderation – If you choose to drink alcohol, do so in moderation. For healthy adults, that means up to one drink a day for women of all ages and men older than age 65, and up to two drinks a day for men age 65 and younger. For some conditions, it’s recommended that you completely avoid alcohol. Ask your doctor for advice specific to your condition.
  • Don’t use recreational drugs – Don’t use stimulants, such as cocaine. Talk to your doctor about an appropriate program for you if you need help ending recreational drug use.
  • Use over-the-counter medications with caution – Some cold and cough medications contain stimulants that may trigger a rapid heartbeat. Ask your doctor which medications you need to avoid.
  • Limit caffeine – If you drink caffeinated beverages, do so in moderation (no more than one to two beverages daily).
  • Control stress – Avoid unnecessary stress and learn coping techniques to handle normal stress in a healthy way.
  • Go to scheduled checkups – Have regular physical exams and report any signs or symptoms to your doctor.

Monitor and treat existing heart disease

If you already have heart disease, you can take steps to lower your risk of developing tachycardia or another arrhythmia:

  • Follow the plan – Be sure you understand your treatment plan and take all medications as prescribed.
  • Report changes immediately – If your symptoms change or get worse or you develop new symptoms, tell your doctor immediately.


References

What Is The Main Sign Symptoms of Tachycardia

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

Tachycardia; Causes, Symptoms, Diagnosis, Treatment

Tachycardia conventionally, but arbitrarily, defined as an atrial and/or ventricular rate of >100 beats per minute, is encountered commonly and can be physiological or pathological in origin. Various adverse consequences from tachycardia have been recognized, and an important one is an association between persistent tachycardia and cardiomyopathy.

Tachycardia also called tachyarrhythmia, is a heart rate that exceeds the normal resting rate.[rx] In general, a resting heart rate over 100 beats per minute is accepted as tachycardia in adults.[rx] Heart rates above the resting rate may be normal (such as with exercise) or abnormal (such as with electrical problems within the heart). The upper threshold of a normal human resting heart rate is based on age.

Cutoff values for tachycardia in different age groups are fairly well standardized; typical cutoffs are listed below:[rx]

  • 1–2 days – Tachycardia > 159 beats per minute (bpm)
  • 3–6 days – Tachycardia >166 bpm
  • 1–3 weeks – Tachycardia >182 bpm
  • 1–2 months – Tachycardia >179 bpm
  • 3–5 months – Tachycardia >186 bpm
  • 6–11 months – Tachycardia >169 bpm
  • 1–2 years – Tachycardia >151 bpm
  • 3–4 years – Tachycardia >137 bpm
  • 5–7 years – Tachycardia >133 bpm
  • 8–11 years – Tachycardia >130 bpm
  • 12–15 years – Tachycardia >119 bpm
  • >15 years – adult – Tachycardia >100 bpm

Heart rate is considered in the context of the prevailing clinical picture. For example: in sepsis >90 bpm is considered tachycardia.

Types of Tachycardia

Supraventricular

  • Atrial fibrillation
  • Atrial flutter
  • Atrial tachycardia
  • AV nodal reentrant tachycardia
  • AV reentrant tachycardia
  • Permanent junctional reciprocating tachycardia (PJRT)

Ventricular

  • Idiopathic ventricular tachycardia
  • Fascicular tachycardia (left septal ventricular tachycardia)

Ectopy

  • Frequent premature ventricular contractions
  • Frequent premature atrial contractions

Pacing

  • High-rate atrial pacing
  • Persistent rapid ventricular pacing

Atrial tachycardia tends to occur in individuals with structural heart disease, with or without heart failure, and ischemic coronary artery disease. However, focal atrial tachycardia often occurs in healthy individuals without structural heart disease. Other possible etiologies are listed below:

Causes of Tachycardia

Etiological causes

  • Hypoxia
  • Pulmonary disease
  • Ischemic heart disease
  • Stimulants: cocaine, caffeine, chocolate, ephedra
  • Alcohol
  • Metabolic disturbances
  • Digoxin toxicity
  • Heightened sympathetic tone

Some other causes of tachycardia include

  • Adrenergic storm
  • Alcohol
  • Amphetamine
  • Anemia
  • Antiarrhythmic agents
  • Anxiety
  • Atrial fibrillation
  • Atrial flutter
  • Atrial tachycardia
  • AV nodal reentrant tachycardia
  • Brugada syndrome
  • Caffeine
  • Cannabis (drug)
  • The early manifestation of circulatory shock
  • Cocaine
  • Dysautonomia
  • Exercise
  • Fear
  • Fever
  • Hypoglycemia
  • Hypovolemia
  • Hyperthyroidism
  • Hyperventilation
  • Infection
  • Junctional tachycardia
  • Methamphetamine
  • Methylphenidate
  • Multifocal atrial tachycardia
  • Nicotine
  • Pacemaker mediated
  • Pain
  • Pheochromocytoma
  • Sinus tachycardia
  • Supraventricular tachycardia
  • Tricyclic antidepressants
  • Ventricular tachycardia
  • Wolff–Parkinson–White syndrome

Symptoms of Tachycardia

  • Dizziness
  • Lightheadedness
  • Shortness of breath
  • Chest pain
  • Heart palpitations
  • Fainting (syncope)
  • Lightheadedness or dizziness
  • Rapid heartbeat or palpitations
  • Fluttering in the chest
  • Bounding pulse
  • Chest pressure, tightness or pain (angina)
  • Shortness of breath
  • Cardiac arrest
  • Fatigue
  • Unconsciousness

Diagnosis of Tachycardia

EKG can aid the diagnosis of focal atrial tachycardia. EKG features may also inform the origin of focal atrial tachycardias. Electrocardiographic features include:

  • Atrial rate: 100 to 250 BPM
  • Ventricular conduction can be variable
    • Irregular or irregularly irregular in the setting of variable AV block
    • Regular if 1 to 1, 2 to 1, or 4 to 1 AV block
  • P wave morphology
  • Unifocal, but similar in morphology to each other
  • Might be inverted
  • Differs from normal sinus P wave
  • May exhibit either long RP or short PR intervals
  • Rhythm may be paroxysmal or sustained
    • May demonstrate an increase in the rate at initiation (i.e., “warm-up,” or “rev up”)
    • May demonstrate a decrease in the rate at termination (i.e., “cool down”)

Below is a differential of similar appearing arrhythmias with their identifying features.

Narrow complex, regular tachycardias

Sinus tachycardia

  • P wave with superior axis

Atrial flutter

  • Biphasic, sawtooth appearing F wave
  • Difficult to identify isoelectric, baseline PR segment

Typical atrial flutter

  • Involves circuit around the tricuspid annulus
  • Counterclockwise flutter produces F waves that are negative in lead II and positive in lead V1
  • Clockwise flutter produces F waves that are positive in lead II and negative in lead V1

Atypical atrial flutter

  • Involves circuit around the scar, left atrium, otherwise non-cavotricuspid isthmus dependent

AVNRT

Typical, slow-fast AVNRT

  • Short RP interval
  • P wave may be absent or within the S wave

Atypical, fast-slow AVNRT

  • Long RP interval
  • P wave negative before QRS

AVRT

  • Baseline EKG may demonstrate pre-excitation
  • Antidromic (propagation proceeds through the accessory pathway, and then retrogradely through the Purkinje system, to His bundle, through the AV node and back through accessory pathway)
    • QRS width: Wide
    • RP interval: Short
  • P wave, PR interval, QRS are variable depending on accessory pathway location and conduction direction
  • Orthodromic (propagation proceeds down AV node, His bundle, Purkinje fibers, retrograde through accessory pathway and back to AV node)
  • QRS width: Narrow
  • RP interval: Long
  • Atrial tachycardia (Focal)
  • Junctional tachycardia
    • P wave may be absent or inverted
    • If retrograde VA conduction, inverted P wave may occur just before or after the QRS complex

Narrow complex, irregular tachycardia

  • Atrial fibrillation
  • Irregularly irregular rhythm
  • Atrial flutter, atrial tachycardia with variable AV block
    • Has features of atrial flutter or atrial tachycardia, although variable block leads to irregular rhythm
  •  Multifocal atrial tachycardia
    • P wave morphology with greater than or equal to 3 distinct morphologies
  •  Resting ECG
  • Holter monitoring, as arrhythmias develop when heart rate increases
  • Exercise stress test both for diagnosis and monitoring of therapy
  • Echocardiogram and/or MRI to evaluate for structural defects
  • Consultation with a clinical geneticist and/or genetic counselor

Suggestive Findings

Catecholaminergic polymorphic ventricular tachycardia (CPVT) should be suspected in individuals who have one or more of the following []:

  • Syncope occurring during physical activity or acute emotion; mean onset age seven to 12 years. Less frequently, first manifestations may occur later in life; individuals with the first event up to age 40 years are reported.
  • History of exercise- or emotion-related palpitations and dizziness in some individuals
  • Sudden unexpected cardiac death triggered by acute emotional stress or exercise
  • Family history of juvenile sudden cardiac death triggered by exercise or acute emotion
Exercise-induced polymorphic ventricular arrhythmias
  • ECG during a graded exercise (exercise stress test)* allows ventricular arrhythmias to be reproducibly elicited in the majority of affected individuals. Typically, the onset of ventricular arrhythmias is 100-120 beats/min.
  • With an increase in workload, the complexity of arrhythmias progressively increases from isolated premature beats to bigeminy and runs of non-sustained ventricular tachycardia (VT). If the affected individual continues exercising, the duration of the runs of VT progressively increases and VT may become sustained.
  • An alternating 180°-QRS axis on a beat-to-beat basis, so-called bidirectional VT, is often the distinguishing presentation of CPVT arrhythmias.
  • Some individuals with CPVT may also present with irregular polymorphic VT without a “stable” QRS vector alternans [].
  • Exercise-induced supraventricular arrhythmias (supraventricular tachycardia and atrial fibrillation) are common [].
  • Ventricular fibrillation occurring in the setting of acute stress
  • Absence of structural cardiac abnormalities

Establishing the Diagnosis

According to the most recent version of the International Guidelines on sudden cardiac death [], the diagnosis of CPVT is established

  • In the presence of a structurally normal heart, normal resting ECG, and exercise- or emotion-induced bidirectional or polymorphic ventricular tachycardia;
OR
  • In individuals who have a heterozygous pathogenic variant in RYR2 or CALM1 or biallelic pathogenic variants in CASQ2 or TRDN [rx].
  • Molecular testing approaches can include serial single-gene testing, use of a multigene panel, and more comprehensive genomic testing
Serial single-gene testing
  • Sequence analysis of RYR2 can be performed first and followed by sequence analysis of CASQ2 if no pathogenic variant is found. If no pathogenic variant in CASQ2 is found, sequence analysis of CALM1and TRDN should be performed next, keeping in mind that pathogenic variants in CALM1 and TRDN are extremely rare causes of CPVT.
  • Gene-targeted deletion/duplication analysis of RYR2 can be performed next if a pathogenic variant in RYR2 or CALM1 or biallelic pathogenic variants in CASQ2 or TRDN have not been identified [rx].
A multigene panel that includes CALM1CASQ2RYR2, and TRDN and other genes of interest (see Differential Diagnosis) may also be considered. Note:
  • The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time.
  • Some multigene panels may include genes not associated with the condition discussed in this GeneReview; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype.
  • In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician.
  • Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
    For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
More comprehensive genomic testing – (when available) including exome sequencing and genome sequencing may be considered if serial single-gene testing (and/or use of a multigene panel that includes CALM1CASQ2RYR2, and TRDN) fails to confirm a diagnosis in an individual with features of CPVT. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation).
  • Magnetic resonance imaging (MRI) A cardiac MRI can provide still or moving pictures of how the blood is flowing through the heart and detect irregularities.
  • Computerized tomography (CT)CT scans combine several X-ray images to provide a more detailed cross-sectional view of the heart.
  • Coronary angiogram –  To study the flow of blood through your heart and blood vessels, your doctor may use a coronary angiogram to reveal potential blockages or abnormalities. It uses a dye and special X-rays to show the inside of your coronary arteries.
  • Chest X-ray – This test is used to take still pictures of your heart and lungs and can detect if your heart is enlarged.

Stress Test

  • Your doctor may recommend a stress test to see how your heart functions while it is working hard during exercise or when medication is given to make it beat fast. In an exercise stress test, electrodes are placed on your chest to monitor heart function while you exercise, usually by walking on a treadmill. Other heart tests may also be performed in conjunction with a stress test.

Additional Tests

  • Your doctor may order additional tests as needed to diagnose an underlying condition that is contributing to tachycardia and judge the condition of your heart.

Event Recorder

This device is similar to a Holter monitor, but it does not record all the heartbeats. There are two types:

  • One type uses a phone to transmit signals from the recorder while the person is experiencing symptoms.
  • The other type is worn all the time for a long time. These can sometimes be worn for as long as a month.

This event recorder is good for diagnosing rhythm disturbances that happen at random moments.

Electrophysiological Testing (EP studies)

  • This is an invasive, relatively painless, non-surgical test and can help determine the type of arrhythmia, its origin, and potential response to treatment. The test is carried out in an EP lab by an electrophysiologist and makes it possible to reproduce troubling arrhythmias in a controlled setting.

Tilt-Table Test

  • If an individual experiences fainting spells, dizziness, or lightheadedness, and neither the ECG nor the Holter revealed any arrhythmias, a tilt-table test might be performed. This monitors blood pressure, heart rhythm, and heart rate while they are moved from a lying to an upright position. When reflexes work correctly, they cause the heart rate and blood pressure to change when moved to an upright position. This is to make sure the brain gets an adequate supply of blood.

Treatment of Tachycardia

But if the episodes are prolonged, or recur often, your doctor may recommend treatment, including

  • Carotid sinus massage – A healthcare professional can apply gentle pressure on the neck, where the carotid artery splits into two branches.
  • Pressing gently on the eyeballs with eyes closed. Caution – This procedure should be supervised carefully by a healthcare physician.
  • Valsalva maneuver – This consists of holding your nostrils closed while blowing air through your nose.
  • Using the dive reflex – The dive reflex is the body’s response to sudden immersion in water, especially cold water.
  • Sedation
  • Cutting down on coffee or caffeinated substances
  • Cutting down on alcohol
  • Quitting tobacco use
  • Getting more rest

Pharmacologic Treatment


  • If vagal maneuvers fail – a trial of intravenous adenosine may be given at an initial dose of 6 mg and a subsequent dose of 12 mg., Its use may serve as a diagnostic and therapeutic tool because it will terminate almost all AVNRTs and AVRTs by breaking the AV-nodal dependent circuit. In patients with non–AV-nodal dependent circuits (i.e., focal atrial tachycardia and atrial flutter), intravenous use of adenosine may prove to be a valuable diagnostic tool because the transient AV block may unmask ectopic atrial P waves or flutter waves. Patients should always be monitored by ECG during adenosine administration.
  • Adenosine – may induce a wide range of transient bradycardias (including sinus arrest and asystole) as well as atrial fibrillation, SVT and ventricular tachycardia. Albeit very rare, cases of sustained ventricular tachycardia, ventricular fibrillation, and Torsades de pointes have been reported. In patients with underlying coronary disease, adenosine may lead to coronary steal syndrome and subsequent myocardial ischemia.  Adenosine should therefore always be administered with an external pacemaker or defibrillator nearby.
  • When vagal maneuvers and adenosine – fail to terminate a narrow-complex tachycardia, intravenous treatment with a nondihydropiridine calcium-channel blocker (e.g., diltiazem and verapamil) or β-blocker may be used. Calcium-channel blockers terminate 64%–98% of SVTs in hemodynamically stable patients. Administering a calcium-channel blocker intravenously over 20 minutes has been shown to reduce the rate of hypotension. There are fewer data supporting the use of β-blockers in the acute treatment of SVT; however, they are considered reasonable choices because of their safety profile.,
  • If all aforementioned pharmacologic therapies fail – synchronized cardioversion is recommended, even in hemodynamically stable patients.
  • In patients presenting in atrial fibrillation who have known Wolff–Parkinson – White or new pre-excitation pattern on ECG, the use of potent AV-nodal blockers (i.e., β-blockers, diltiazem, verapamil, and digoxin) should be avoided because these medications may potentiate conduction over the accessory pathway and lead to potentially life-threatening ventricular arrhythmias. In these cases, intravenous use of procainamide is the preferred approach in the acute setting.
  • Adenosine is rapidly metabolized in the periphery – and therefore must be given as a rapid push through a large, ideally peripheral, intravenous route. The initial dose is 6 mg intravenously (IV) (pediatric dose 0.1 mg/kg, maximum dose of 6 mg). If the initial dose is ineffective, adenosine may be dosed again at 12 mg IVP (pediatric dose 0.2 mg/kg, maximum dose 12 mg). The second dose of adenosine 12 mg IVP may be repeated one additional time if there is no effect. Each dose of adenosine needs to be flushed rapidly with 10 mL to 20 mL normal saline. Often two-person administration, with one person administering the adenosine at a proximal IV port, and a second person flushing the IV line via a distal port immediately after adenosine administration, is required to adequate flush in the adenosine.
  • Consider reducing the adenosine dose to 3 mg – IVP if the patient is currently receiving carbamazepine or dipyridamole, is the recipient of a heart transplant, or adenosine is being given through a central line.
  • If adenosine fails – second line medications include diltiazem (0.25 mg/kg IV loading dose followed by 5mg/hr to 15 mg/hr infusion), esmolol (0.5 mg/kg IV loading dose, then 0.5 mg/kg/min up to 0.2 mg/kg/min, will need to repeat bolus for every up-titration), or metoprolol (2.5 mg to 5 mg IV every two to five minutes, not to exceed 15 mg over 10 to 15 minutes).

Summary of recommendations from the 2015 guideline of the American College of Cardiology, the American Heart Association and the Heart Rhythm Society on the management of adults with supraventricular tachycardia (SVT) [

Acute treatment

  • Vagal maneuvers are recommended for acute treatment in patients with regular SVT (class I recommendation, level B-R evidence)
  • Intravenous administration of adenosine is recommended for acute treatment in patients with regular SVT (class I recommendation, level B-R evidence)
  • Synchronized cardioversion is recommended for acute treatment in patients with hemodynamically stable SVT when pharmacologic treatment is ineffective or contraindicated (class I recommendation, level B-NR evidence)
  • Intravenous administration of diltiazem or verapamil can be effective for acute treatment in patients with hemodynamically stable SVT (class IIa recommendation, level B-R evidence)
  • Intravenous use of β-blockers is reasonable for acute treatment in patients with hemodynamically stable SVT (class IIa recommendation, level C-LD evidence)

Ongoing management

  • Oral β-blocker – diltiazem or verapamil treatment is useful for ongoing management in patients with symptomatic SVT who do not have ventricular pre-excitation during sinus rhythm (class I recommendation, level B-R evidence)
  • Electrophysiologic study – with the option of radiofrequency catheter ablation is useful for the diagnosis and potential treatment of SVT (class I recommendation, level B-NR evidence)
  • Patients with SVT – should be educated on how to perform vagal maneuvers for ongoing management of SVT (class I recommendation, level C-LD evidence)

Referral for radiofrequency catheter ablation

  • Catheter ablation of the slow pathway is recommended in patients with AVNRT (class I recommendation, level B-NR evidence)
  • Catheter ablation is recommended in patients with symptomatic focal atrial tachycardia as an alternative to pharmacologic treatment (class I recommendation, level B-NR evidence)
  • Catheter ablation of the accessory pathway is recommended in patients with AVRT or pre-excited atrial fibrillation (class I recommendation, level B-NR evidence)
  • An electrophysiologic study is reasonable in asymptomatic patients with pre-excitation to stratify risk for arrhythmic events (class IIa recommendation, level B-NR evidence)
  • Catheter ablation of the cavotricuspid isthmus is useful in patients with atrial flutter that is either symptomatic or refractory to pharmacologic rate control (class I recommendation, level B-R evidence)

Note: AVNRT = atrioventricular nodal re-entrant tachycardia, AVRT = atrioventricular re-entrant tachycardia.

  • Class I = strong recommendation where benefits > risks; class IIa = moderate-strength recommendation where benefits >> risks.
  • Level B-R = moderate-quality evidence from one or more randomized controlled trials (RCTs) or meta-analyses of moderate-quality RCTs;
  • Level B-NR = moderate-quality evidence from one or more nonrandomized or observational or registry studies;
  • Level C-LD = limited data from RCTs or nonrandomized observational or registry studies with limitations of design or execution.


Complications

Complications are either related to the medications or radiofrequency ablation. Since the latter is an invasive procedure the following complications may occur:

  • Hematoma
  • Pseudoaneurysm of the artery
  • Bleeding
  • Myocardial infarction
  • Heart block and the need for a pacemaker
  • Stroke
  • Death
  • Overall, focal atrial tachycardia is a benign arrhythmia.
  • Focal atrial tachycardia typically occurs secondary to an underlying disease process or acute illness.
  • Focal atrial tachycardia is one form of atrial tachycardia. Atrial activation patterns in focal atrial tachycardia will be similar during the tachycardia, yet distinct from the normal sinus P wave. Focal atrial tachycardia can be regular or irregular if variable block exists. A “warm-up” and “cool down” pattern can occur during initiation and termination, respectively.
  • Patients can be asymptomatic or present with palpitations, chest pain, lightheadedness, dizziness, or presyncope. Focal atrial tachycardia often presents on telemetry on asymptomatic or sleeping patients.
  • Ventricular rate control is achievable with calcium channel or beta-blockers. If the patient remains persistently tachycardic or has uncontrolled symptoms, the patient may benefit from antiarrhythmic therapy with class IC or III antiarrhythmics.
  • A possible significant cardiac sequella of prolonged atrial tachycardia (or any tachycardia) is tachycardia-induced cardiomyopathy. If there are concerns for high tachycardia burden, outpatient monitoring may be necessary.

Prevention

The most effective way to prevent tachycardia is to maintain a healthy heart and reduce your risk of developing heart disease. If you already have heart disease, monitor it and follow your treatment plan to lower your tachycardia risk.

Prevent Heart Disease

Treat or eliminate risk factors that may lead to heart disease. Take the following steps:

  • Exercise and eat a healthy diet – Live a heart-healthy lifestyle by exercising regularly and eating a healthy, low-fat diet that’s rich in fruits, vegetables, and whole grains.
  • Maintain a healthy weight – Being overweight increases your risk of developing heart disease.
  • Keep blood pressure and cholesterol levels under control – Make lifestyle changes and take medications as prescribed to correct high blood pressure (hypertension) or high cholesterol.
  • Stop smoking – If you smoke and can’t quit on your own, talk to your doctor about strategies or programs to help you break a smoking habit.
  • Drink in moderation – If you choose to drink alcohol, do so in moderation. For healthy adults, that means up to one drink a day for women of all ages and men older than age 65, and up to two drinks a day for men age 65 and younger. For some conditions, it’s recommended that you completely avoid alcohol. Ask your doctor for advice specific to your condition.
  • Don’t use recreational drugs – Don’t use stimulants, such as cocaine. Talk to your doctor about an appropriate program for you if you need help ending recreational drug use.
  • Use over-the-counter medications with caution – Some cold and cough medications contain stimulants that may trigger a rapid heartbeat. Ask your doctor which medications you need to avoid.
  • Limit caffeine – If you drink caffeinated beverages, do so in moderation (no more than one to two beverages daily).
  • Control stress – Avoid unnecessary stress and learn coping techniques to handle normal stress in a healthy way.
  • Go to scheduled checkups – Have regular physical exams and report any signs or symptoms to your doctor.

Monitor and treat existing heart disease

If you already have heart disease, you can take steps to lower your risk of developing tachycardia or another arrhythmia:

  • Follow the plan – Be sure you understand your treatment plan and take all medications as prescribed.
  • Report changes immediately – If your symptoms change or get worse or you develop new symptoms, tell your doctor immediately.


References

Tachycardia

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]
Translate »